Hologic (HOLX) 10-K27 Nov 242024 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Sep. 28, 2024	Nov. 21, 2024	Mar. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Sep. 28, 2024
Current Fiscal Year End Date	--09-28
Document Transition Report	false
Entity File Number	1-36214
Entity Registrant Name	HOLOGIC, INC
Entity Central Index Key	0000859737
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2902449
Entity Address, Address Line One	250 Campus Drive
Entity Address, City or Town	Marlborough
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01752
City Area Code	508
Local Phone Number	263-2900
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HOLX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 18,056,688,950
Entity Common Stock, Shares Outstanding		226,941,217
Documents Incorporated by Reference	Portions of the registrant’s Proxy Statement for the registrant’s annual meeting of stockholders to be filed within 120 days of the end of its fiscal year ended September 28, 2024 are incorporated into Part III (Items 10, 11, 12, 13 and 14) of this Annual Report on Form 10-K where indicated.

Audit Information

Audit Information	12 Months Ended
Audit Information	Sep. 28, 2024
Audit Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Boston, Massachusetts

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Revenues:
Revenue from product and services	$ 4,030.3	$ 4,030.4	$ 4,862.8
Costs of revenues:
Amortization of acquired intangible assets	180.5	205.7	295.7
Impairment of intangible assets and equipment	39.2	179.5	17.4
Gross profit	2,227.8	2,071.5	2,997.4
Operating expenses:
Research and development	272.8	294.3	283.4
Selling and marketing	585.4	595.2	630.3
General and administrative	409.4	392.4	407.7
Amortization of acquired intangible assets	29.2	28.1	45.2
Impairment of intangible assets and equipment	5.6	44.3	27.7
Contingent consideration fair value adjustments	1.7	(14.9)	(39.5)
Loss on assets held-for-sale	0	51.7	0
Restructuring charges	41.1	12	2.4
Operating expenses	1,345.2	1,403.1	1,357.2
Income from operations	882.6	668.4	1,640.2
Interest income	108.7	120.5	12.9
Interest expense	(122.1)	(111.1)	(95.1)
Debt extinguishment loss	0	0	(0.7)
Other income (expense), net	(4.1)	(1.7)	30.9
Income before income taxes	865.1	676.1	1,588.2
Provision for income taxes	75.6	220.1	286.2
Net income	$ 789.5	$ 456	$ 1,302
Net income per common share:
Basic (in dollars per share)	$ 3.35	$ 1.85	$ 5.18
Diluted (in dollars per share)	$ 3.32	$ 1.83	$ 5.13
Weighted average number of shares outstanding:
Basic (in shares)	235,723	246,772	251,527
Diluted (in shares)	237,553	248,831	253,845
Product
Revenues:
Revenue from product and services	$ 3,255.1	$ 3,279.9	$ 4,191.2
Costs of revenues:
Cost of goods and services sold	1,206.2	1,184.3	1,166.1
Service
Revenues:
Revenue from product and services	775.2	750.5	671.6
Costs of revenues:
Cost of goods and services sold	$ 376.6	$ 389.4	$ 386.2

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 789.5	$ 456	$ 1,302
Changes in foreign currency translation adjustment	53.1	99.2	(224.1)
Gain recognized, net of taxes	1.6	0	0
Changes in pension plans, net of taxes	(0.3)	0.6	1
Gain (loss) recognized, net of tax of $(5.7) in 2024, $(2.9) in 2023, and $13.7 in 2022, for interest rate swaps	(18.3)	(9.2)	44
Other comprehensive income (loss)	36.1	90.6	(179.1)
Comprehensive income	$ 825.6	$ 546.6	$ 1,122.9

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Statement of Comprehensive Income [Abstract]
Gain (loss) recognized interest rate swaps, tax	$ (5.7)	$ (2.9)	$ 13.7

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,160.2	$ 2,722.5
Short-term investments	173.4	0
Accounts receivable, less reserves	600.4	625.6
Inventory	679.8	617.6
Prepaid expenses and other current assets	156.2	175.3
Prepaid income taxes	53.3	31.6
Assets held-for-sale - current assets	0	11.9
Total current assets	3,823.3	4,184.5
Property, plant and equipment, net	537.8	517
Intangible assets, net	844.6	888.6
Goodwill	3,443.1	3,281.3
Long-term investments	96.4	0
Other assets	410.8	267.9
Total assets	9,156	9,139.3
Current liabilities:
Current portion of long-term debt	37.5	287
Accounts payable	203.8	175.2
Accrued expenses	579.7	534.6
Deferred revenue	212.9	199.2
Finance lease liabilities (current)	3.3	3.1
Assets held-for-sale - current liabilities	0	8.2
Total current liabilities	1,037.2	1,207.3
Long-term debt, net of current portion	2,497.1	2,531.2
Finance lease liabilities (non-current)	12.2	15.3
Deferred income tax liabilities	59.4	20.2
Deferred revenue, net of current portion	13.8	13.8
Other long-term liabilities	406.3	334.6
Commitments and contingencies (Note 15 and 16)
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 301,185 and 299,940 shares issued, respectively	3	3
Additional paid-in-capital	6,244.2	6,141.2
Retained earnings	2,845.8	2,056.3
Treasury stock, at cost – 69,460 and 58,231 shares, respectively	(3,851.5)	(3,036)
Accumulated other comprehensive loss	(111.5)	(147.6)
Total stockholders’ equity	5,130	5,016.9
Total liabilities and stockholders’ equity	$ 9,156	$ 9,139.3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 28, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,623,000	1,623,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	750,000,000	750,000,000
Common stock, shares issued (in shares)	301,185,000	299,940,000
Treasury stock (in shares)	69,460,000	58,231,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Millions	Total		Accelerated Share Repurchase Agreement	Share Repurchase Program	Common Stock [Member]	Additional Paid-in-Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock, Common	Treasury Stock, Common Accelerated Share Repurchase Agreement	Treasury Stock, Common Share Repurchase Program
Balance (in shares) at Sep. 25, 2021					297,306				43,653
Balance at Sep. 25, 2021	$ 4,218.6				$ 3	$ 5,965.8	$ 298.3	$ (59.1)	$ (1,989.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)					336
Exercise of stock options	13.8					13.8
Vesting of restricted stock units, net of shares withheld for employee taxes (in shares)					561
Vesting of restricted stock units, net of shares withheld for employee taxes	(22.9)					(22.9)
Common stock issued under the employee stock purchase plan (in shares)					330
Common stock issued under the employee stock purchase plan	19.2					19.2
Stock-based compensation expense	66.7					66.7
Net income	1,302						1,302
Foreign currency translation adjustment	(224.1)							(224.1)
Adjustment to minimum pension liability, net	1							1
Repurchase of common stock (in shares)											7,748
Repurchase of common stock				$ (542.1)							$ (542.1)
Unrealized gain (loss) on interest rate swap	44							44
Balance (in shares) at Sep. 24, 2022					298,533				51,401
Balance at Sep. 24, 2022	4,876.2				$ 3	6,042.6	1,600.3	(238.2)	$ (2,531.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)					504
Exercise of stock options	21.5					21.5
Vesting of restricted stock units, net of shares withheld for employee taxes (in shares)					555
Vesting of restricted stock units, net of shares withheld for employee taxes	(24)					(24)
Common stock issued under the employee stock purchase plan (in shares)					348
Common stock issued under the employee stock purchase plan	21.5					21.5
Stock-based compensation expense	79.6					79.6
Net income	456						456
Foreign currency translation adjustment	99.2							99.2
Adjustment to minimum pension liability, net	0.6							0.6
Repurchase of common stock (in shares)											6,830
Repurchase of common stock				$ (504.5)							$ (504.5)
Unrealized gain (loss) on interest rate swap	(9.2)							(9.2)
Balance (in shares) at Sep. 30, 2023					299,940				58,231
Balance at Sep. 30, 2023	$ 5,016.9				$ 3	6,141.2	2,056.3	(147.6)	$ (3,036)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	400				423
Exercise of stock options	$ 16.9					16.9
Vesting of restricted stock units, net of shares withheld for employee taxes (in shares)					473
Vesting of restricted stock units, net of shares withheld for employee taxes	(17.4)					(17.4)
Common stock issued under the employee stock purchase plan (in shares)					349
Common stock issued under the employee stock purchase plan	21.2					21.2
Stock-based compensation expense	82.3					82.3
Net income	789.5						789.5
Foreign currency translation adjustment	53.1							53.1
Adjustment to minimum pension liability, net	(0.3)							(0.3)
Unrealized gain on available-for-sale securities	1.6							1.6
Repurchase of common stock (in shares)										6,988	4,241	[1]
Repurchase of common stock	(315.5)	[1]	$ (500)							$ (500)	$ (315.5)	[1]
Unrealized gain (loss) on interest rate swap	(18.3)							(18.3)
Balance (in shares) at Sep. 28, 2024					301,185				69,460
Balance at Sep. 28, 2024	$ 5,130				$ 3	$ 6,244.2	$ 2,845.8	$ (111.5)	$ (3,851.5)

[1]Includes excise tax on share repurchases.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)		12 Months Ended
Consolidated Statements of Cash Flows - USD ($)		Sep. 28, 2024		Sep. 30, 2023		Sep. 24, 2022
OPERATING ACTIVITIES
Net income		$ 789,500,000		$ 456,000,000		$ 1,302,000,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		99,300,000		89,600,000		89,200,000
Amortization of acquired intangible assets		209,700,000		233,800,000		340,900,000
Stock-based compensation expense		82,300,000		79,600,000		66,700,000
Deferred income taxes and other non-cash taxes		(72,100,000)		(109,100,000)		(166,200,000)
Intangible assets and equipment impairment charges		44,800,000		223,800,000		45,100,000
Loss on assets held-for-sale		0		51,700,000		0
Contingent consideration fair value adjustments		1,700,000		(14,900,000)		(39,500,000)
Debt extinguishment loss		0		0		700,000
Other adjustments and non-cash items		45,900,000		28,900,000		32,600,000
Changes in operating assets and liabilities, excluding the effect of acquisitions:
Accounts receivable		41,000,000		(1,500,000)		272,300,000
Inventory		(47,400,000)		(4,900,000)		(136,600,000)
Prepaid income taxes		(21,700,000)		17,400,000		(23,300,000)
Prepaid expenses and other assets		7,300,000		23,600,000		384,300,000
Accounts payable		22,200,000		(23,000,000)		(14,400,000)
Accrued expenses and other liabilities		73,400,000		(14,200,000)		(15,800,000)
Deferred revenue		9,300,000		14,400,000		(12,300,000)
Net cash provided by operating activities		1,285,200,000		1,051,200,000		2,125,700,000
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired		(297,300,000)		(5,000,000)		(158,600,000)
Sale of business, net of cash disposed		(31,300,000)		0		0
Purchases of available-for-sale securities		(267,700,000)		0		0
Capital expenditures		(72,400,000)		(91,800,000)		(70,600,000)
Proceeds from the Department of Defense		0		20,500,000		75,000,000
Increase in equipment under customer usage agreements		(57,800,000)		(58,400,000)		(56,600,000)
Strategic investments		(42,500,000)		(10,000,000)		0
Purchase of intellectual property		(10,000,000)		0		0
Other activity		(2,000,000)		(7,400,000)		4,500,000
Net cash used in investing activities		(781,000,000)		(152,100,000)		(206,300,000)
FINANCING ACTIVITIES
Proceeds from long-term debt, net of issuance costs		0		0		1,491,200,000
Repayment of long-term debt		(287,500,000)		(15,000,000)		(1,387,500,000)
Repayments under accounts receivable securitization agreement		0		0		(248,500,000)
Repayment of acquired long-term debt		0		0		(63,700,000)
Payment of contingent consideration		(2,600,000)		(7,600,000)		(12,200,000)
Payment of deferred acquisition consideration		0		(800,000)		0
Repurchases of common stock		(835,100,000)		(474,800,000)		(542,100,000)
Net proceeds from issuance of common stock under employee stock plans		37,800,000		43,000,000		33,500,000
Payment of minimum tax withholdings on net share settlements of equity awards		(17,400,000)		(24,000,000)		(22,900,000)
Payments under finance lease obligations		(3,800,000)		(4,000,000)		(3,800,000)
Net cash used in financing activities		(1,108,600,000)		(483,200,000)		(756,000,000)
Effect of exchange rate changes on cash and cash equivalents		8,900,000		300,000		5,800,000
Net (decrease) increase in cash and cash equivalents		(595,500,000)		416,200,000		1,169,200,000
Cash and cash equivalents, beginning of period		2,755,700,000	[1]	2,339,500,000	[1]	1,170,300,000
Cash and cash equivalents, end of period	[1]	$ 2,160,200,000		$ 2,755,700,000		$ 2,339,500,000

[1]Includes $33.2 million of cash recorded in assets held-for-sale - current assets as of September 30, 2023.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 29, 2023
Disposed of by Sale \| SSI Ultrasound Imaging Business
Cash	$ 33.2	$ 33.2

Operations

Operations	12 Months Ended
Operations	Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operations	Operations Hologic, Inc. (the “Company” or “Hologic”) develops, manufactures and supplies premium diagnostics products, medical imaging systems, and surgical products with an emphasis on women's health and well-being through early detection and treatment. The Company operates in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Sep. 28, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company assesses the terms of its strategic investments to determine if they meet the definition of a variable interest entity (VIE) and if so, whether the Company has a controlling financial interest. A controlling financial interest occurs if the Company has both the power to direct activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb the losses of or the right to receive the benefits from the VIE that could potentially be significant to the VIE. The Company’s strategic investments did not meet the controlling financial interest criteria, and therefore the Company did not consolidate any VIEs during fiscal 2024, 2023 or 2022. The Company’s fiscal year ends on the last Saturday in September. Fiscal 2024, 2023 and 2022 ended on September 28, 2024, September 30, 2023 and September 24, 2022, respectively. Fiscal 2023 was a 53-week year and fiscal 2024 and 2022 were 52-week years. Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events recorded in the consolidated financial statements as of and for the year ended September 28, 2024, except as noted below. On October 11, 2024, the Company entered into a definitive agreement to acquire Gynesonics, Inc. (“Gynesonics”) for a purchase price of approximately $350.0 million, subject to working capital and other customary adjustments. Gynesonics, located in Redwood, California, develops a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Completion of the acquisition is subject to customary closing conditions, including receipt of required regulatory approvals. Gynesonics will be included in the GYN Surgical reportable segment. On November 19, 2024, the Company executed an accelerated share repurchase agreement (ASR) with JPMorgan Chase & Co., (“JP Morgan”) pursuant to which the Company agreed to repurchase $250 million of the Company’s common stock. Refer to Note 12 for further discussion. Management’s Estimates and Uncertainties The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple performance obligation arrangements, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, accounts receivable reserves, inventory excess and obsolescence reserves, warranty reserves, certain accrued expenses, restructuring and other related charges, contingent liabilities, tax reserves, deferred tax rates and the recoverability of the Company’s net deferred tax assets and related valuation allowances, and stock-based compensation. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including dependence on third-party reimbursements to support the markets of the Company’s products, early stage of development of certain products, rapid technological changes, recoverability of long-lived assets (including intangible assets and goodwill), competition, stability of world financial markets, ability to obtain regulatory approvals, changes in the regulatory environment, limited number of suppliers, customer concentration, integration of acquisitions, substantial indebtedness, government regulations, management of international activities, protection of proprietary rights, patent and other litigation, dependence on contract manufacturers, supply chain constraints, inflation and interest rates, and dependence on key individuals. Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. Cash equivalents are highly liquid investments with insignificant interest rate risk and maturities of three months or less at the time of acquisition. Investments Investments in debt securities are classified as available-for-sale and are reported at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. The Company determines the appropriate classification of its investment in debt securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. Strategic Investments The majority of the Company’s strategic investments are in non-marketable equity securities, which are measured at cost, less any impairment, adjusted to fair value for any observable price changes in orderly transactions for identical or similar investments of the same issuer. Investments in entities for which the Company has the ability to exercise significant influence are accounted for under the equity method if the Company holds less than 50 percent of the voting stock and the entity is not a VIE in which the Company is the primary beneficiary in accordance with Accounting Standards Codification (“ASC”) Topic 323, Investments - Equity Method and Joint Ventures . The Company records these investments initially at cost and adjusts the carrying amount to reflect its proportional share of the earnings or losses of the investee. Refer to Note 6 for additional details on strategic investment balances. Concentrations of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, available-for-sale debt securities, equity investments and trade accounts receivable. The Company invests its cash, cash equivalents and available-for-sale debt securities with high credit quality financial institutions. The Company’s customers are principally located in the U.S., Europe and Asia. The Company performs ongoing credit evaluations of the financial condition of its customers and generally does not require collateral. Although the Company is directly affected by the overall financial condition of the healthcare industry, as well as global economic conditions, management does not believe significant credit risk exists as of September 28, 2024. The Company generally has not experienced any material losses related to receivables from individual customers or groups of customers in the healthcare industry. The Company maintains an allowance for doubtful accounts based on accounts past due and historical collection experience. There were no customers with a balance greater than 10% of accounts receivable as of September 28, 2024 and September 30, 2023. There were no customers that represented greater than 10% of consolidated revenues for fiscal years 2024, 2023 and 2022. Concentration of Suppliers The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations. Supplemental Cash Flow Statement Information Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Cash paid during the period for income taxes $ 137.9 $ 296.1 $ 36.2 Cash paid during the period for interest $ 117.1 $ 105.4 $ 99.7 Non-Cash Financing Activities: Fair value of contingent consideration at acquisition $ — $ 1.1 $ — Cash paid for income taxes presented above is net of tax refunds of $19.6 million, $39.3 million and $430.4 million for fiscal years 2024, 2023 and 2022, respectively. The fiscal 2024 and 2023 refunds received primarily related to tax filings and over-payments made in the ordinary course of business, while the fiscal 2022 refunds were primarily related to federal and state loss carryback claims. Inventories Inventories are valued at the lower of cost or net realizable value on a first-in, first-out basis. Work-in-process and finished goods inventories consist of materials, labor and manufacturing overhead. The valuation of inventory requires management to estimate excess and obsolete inventory. The Company employs a variety of methodologies to determine the net realizable value of its inventory. Provisions for excess and obsolete inventory are primarily based on management’s estimates of forecasted sales, usage levels and expiration dates, as applicable for certain disposable products. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of product revenues. Inventories consisted of the following: September 28, 2024 September 30, 2023 Raw materials $ 251.4 $ 238.6 Work-in-process 62.0 66.3 Finished goods 366.4 312.7 $ 679.8 $ 617.6 Property, Plant and Equipment Property, plant and equipment is recorded at cost less accumulated depreciation and impairments. The straight-line method of depreciation is used for all property and equipment. Property, plant and equipment consisted of the following: Estimated Useful Life September 28, 2024 September 30, 2023 Equipment 3–10 years $ 378.1 $ 380.0 Equipment under customer usage agreements 3–8 years 523.1 508.1 Buildings and improvements 20–35 years 247.1 230.0 Leasehold improvements Shorter of the Original Lease Term or Estimated Useful Life 44.0 44.4 Land 40.8 41.1 Furniture and fixtures 5–7 years 24.6 19.2 Finance lease right-of-use asset 8.8 8.2 1,266.5 1,231.0 Less - accumulated depreciation and amortization (728.7) (714.0) $ 537.8 $ 517.0 Equipment under customer usage agreements primarily consists of diagnostic instruments located at customer sites but owned by the Company. Generally, the customer has the right to use the equipment for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of disposables, primarily assays, tests and handpieces. The depreciation costs associated with equipment under customer usage agreements are charged to cost of product revenues over the estimated useful life of the equipment. The costs to maintain the equipment in the field are charged to cost of product revenue as incurred. In September 2020 and October 2020, the Company was awarded grants of $7.6 million and $119.3 million, respectively, from the Department of Defense Joint Acquisition Task Force (“DOD”) to expand production capacity for the Company's two SARS-CoV-2 assays. These grants were specifically to fund capital equipment and labor investments to increase manufacturing capacity to enable the Company to provide a certain amount of COVID-19 tests per month for the U.S. market. The Company accounted for the funds received under these grants as a reimbursement of the purchased capital equipment. The Company procured and paid for the capital equipment and necessary resources to build out its facility and construct the manufacturing lines to meet the requirements specified in the grant agreement. Subsequent to the Company paying for the capital equipment, the DOD reimbursed the Company upon it meeting certain requirements. However, the DOD retained title to the assets purchased under the agreement, and title was transferred to the Company upon meeting certain milestones of the manufacturing efforts and obtaining approval from the DOD that the respective milestone had been met. As of the end of fiscal 2022, the Company had completed all milestones under the agreement and was awaiting approval by the DOD. During the second quarter of fiscal 2023, the Company received the final DOD approvals and the final payment from the DOD of $20.5 million, which was recorded as a reduction of the cost basis of the purchased equipment. As of September 30, 2023, no amounts were awaiting approval and all defined milestones were completed. In fiscal 2022, the Company received $75.0 million from the DOD for reimbursement of capital equipment, which was recorded as a reduction of the cost basis of the purchased equipment. In addition, a portion of the DOD grant funded expenditures in connection with the project that did not qualify for capitalization and was recorded as a reduction to expenses, which was $7.6 million in fiscal 2022. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of its Mobidiag business and based on the fair value of the asset group recorded an impairment charge of $12.1 million related to property, plant and equipment. In addition, during the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of its SSI ultrasound imaging business and recorded an impairment charge of $5.8 million related to property, plant and equipment. Long-Lived Assets The Company reviews its long-lived assets, which includes property, plant and equipment and identifiable intangible assets (see below for discussion of intangible assets), for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with ASC 360-10-35-15, Property, Plant and Equipment—Impairment or Disposal of Long-Lived Assets (ASC 360). Recoverability of these assets is evaluated by comparing the carrying value of the assets to the undiscounted cash flows estimated to be generated by those assets over their remaining economic life. If the undiscounted cash flows are not sufficient to recover the carrying value of the assets, the assets are considered impaired. The impairment loss is measured by comparing the fair value of the assets to their carrying value. Fair value is determined by either a quoted market price, if any, or a value determined by a discounted cash flow technique. Business Combinations and Acquisition of Intangible Assets The Company accounts for the acquisition of a business in accordance with ASC 805, Business Combinations (ASC 805). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Contingent consideration not deemed to be linked to continuing employment is recorded at fair value on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using a Monte Carlo simulation. These cash flow projections are discounted with an appropriate risk adjusted rate. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured and adjusted as a component of operating expenses based on changes to the underlying assumptions. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded. The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The Company uses the income approach to determine the fair value of developed technology and in-process research and development (“IPR&D”) acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. Developed technology represents patented and unpatented technology and know-how. The value of the in-process projects is based on the project's stage of completion, the complexity of the work completed as of the acquisition date, the projected costs to complete, the contribution of core technologies and other acquired assets, the expected introduction date, the estimated cash flows to be generated upon commercial release and the estimated useful life of the technology. The Company believes that the estimated developed technology and IPR&D amounts represent the fair value at the date of acquisition and do not exceed the amount a third-party would pay for the assets. The significant assumptions used to estimate the fair value of intangible assets include discount rates and certain assumptions that form the basis of the forecasted results, specifically revenue growth rates. These significant assumptions are forward looking and could be affected by future economic and market conditions. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships and trade names. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names. Intangible Assets and Goodwill Intangible Assets Intangible assets are initially recorded at fair value and stated net of accumulated amortization and impairments. The Company amortizes its intangible assets that have finite lives using either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized. Amortization is recorded over the estimated useful lives ranging from 5 to 30 years. The Company evaluates the recoverability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of after-tax cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements . Indefinite lived intangible assets, such as IPR&D assets, are initially recorded at fair value and are required to be tested for impairment annually, or more frequently if indicators of impairment are present. The Company’s annual impairment test date is as of the first day of its fourth quarter. Intangible assets consisted of the following: September 28, 2024 September 30, 2023 Description Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,567.0 $ 3,834.0 $ 4,411.0 $ 3,649.5 In-process research and development 25.1 — 25.7 — Customer relationships 609.7 569.8 600.0 550.6 Trade names 260.3 224.5 253.6 212.8 Total acquired intangible assets $ 5,462.1 $ 4,628.3 $ 5,290.3 $ 4,412.9 Internal-use software 25.7 20.5 24.0 17.8 Capitalized software embedded in products 30.2 24.6 27.7 22.7 Total intangible assets $ 5,518.0 $ 4,673.4 $ 5,342.0 $ 4,453.4 During the second quarter of fiscal 2024, in connection with commencing its company-wide annual strategic planning process, the Company identified indicators of impairment in its BioZorb product line, which was part of the Focal acquisition. As a result, the Company performed an undiscounted cash flow analysis pursuant to ASC 360 to determine if the cash flows expected to be generated by the BioZorb product line over the remaining estimated useful life of the primary asset were sufficient to recover the carrying value of the asset group. Based on this analysis, the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. Therefore, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculated the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Based on this analysis, the fair value of the BioZorb asset group was below its carrying value and the Company recorded an impairment charge of $26.8 million during the second quarter of fiscal 2024. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: $25.9 million to developed technology and $0.9 million to trade names, which reduced the carrying value of the assets to $13.9 million and $0.5 million respectively. During the third quarter of fiscal 2024, the Federal Drug Administration classified a prior safety notice for the BioZorb Marker as a Class I recall. This was the technical classification of a prior safety notice only, not a product removal. Following this, the Company lowered its forecasts for this product line, which is an indicator of impairment. Accordingly, the Company performed an undiscounted cash flow analysis, and the cash flows were not sufficient to recover the carrying value of the asset group. The Company performed a fair value analysis and determined that the fair value of the asset group was de minimus. As a result, the Company recorded an impairment charge of $13.3 million and $0.4 million to developed technology and trade names, respectively, to fully write-off the assets. During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible asset from its Mobidiag acquisition for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the DCF model and recorded a $4.3 million impairment charge, reducing the fair value of this asset to $22.4 million. The reduction in the fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trade name intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of $7.3 million to bring the net carrying values to zero. During the third quarter of fiscal 2023, in connection with its company-wide annual budgeting and strategic planning process as well as evaluating the current operating performance of its Mobidiag business, including product design and manufacturing requirements, the Company reassessed its short-term and long-term commercial plans for this business. The Company made certain operational and strategic decisions to invest and focus more on the long-term success of this business, which resulted in the Company significantly reducing its forecasted revenues and operating results. As a result, the Company identified indicators of impairment and performed an undiscounted cash flow analysis pursuant to ASC 360 to determine if the cash flows expected to be generated by the Mobidiag business over the estimated remaining useful life of its primary assets were sufficient to recover the carrying value of the asset group. Based on this analysis the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. As a result, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which was based on a DCF analysis. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows were based on the Company's most recent strategic plan at that time and for periods beyond the strategic plan, the Company's estimates were based on assumed growth rates expected as of the measurement date. The Company believed its assumptions were consistent with the plans and estimates that a market participant would use to manage the business. The discount rate used was intended to reflect the risks inherent in future cash flow projections and was based on an estimate of the weighted average cost of capital (WACC) of market participants relative to the asset group. The Company used a discount rate of 17.0%. Based on this analysis, the fair value of the Mobidiag asset group was below its carrying value. Prior to calculating and allocating the impairment charge, the Company assessed the only in-process research and development intangible asset in this asset group for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the DCF model and recorded a $10.5 million impairment charge, reducing the fair value of this asset to $26.5 million. The reduction in fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project to focus on other projects. To record the asset group to fair value, the Company recorded an impairment charge of $186.9 million during the third quarter of fiscal 2023. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: $153.7 million to developed technology, $10.4 million to customer relationships, $10.7 million to trade names, and $12.1 million to equipment. The Company believed its assumptions used to determine the fair value of the asset group were reasonable. The Company also re-evaluated the remaining useful lives of the intangible assets and concluded no changes were necessary at that time. During the third quarter of fiscal 2023, the Company also identified indicators of impairment associated with its SSI ultrasound imaging asset group. The Company determined that the fair value of this asset group was approximately zero and the carrying value of the long-lived assets was fully impaired. As a result, the Company recorded an impairment charge of $26.4 million, of which $20.6 million was allocated to intangible assets, primarily developed technology, and $5.8 million was allocated to equipment. During the fourth quarter of fiscal 2022, the Company performed its annual impairment test of its Mobidiag IPR&D intangible asset. The Company determined the fair value of the asset utilizing a DCF model and recorded a $27.7 million impairment charge. The reduction in fair value was due to an increase in the discount rate from higher interest rates, a reduction in forecasted revenues and timing of completing the project. During the fourth quarter of fiscal 2022, the Company identified a certain product line associated with the Focal Therapeutics, Inc. acquisition that would no longer be commercially sold. As a result, the Company recorded an impairment charge to write-off a developed technology asset of $8.2 million. During the third quarter of fiscal 2022, the Company identified certain product lines associated with the Faxitron Bioptics, LLC acquisition that would no longer be commercially sold. As a result, the Company recorded an impairment charge to write-off the developed technology assets of $9.2 million. Amortization expense related to developed technology is classified as cost of product revenues—amortization of intangible assets. Amortization expense related to customer relationships and trade names is classified as a component of amortization of intangible assets within operating expenses. The estimated amortization expense at September 28, 2024 for each of the five succeeding fiscal years was as follows: Fiscal 2025 $ 199.3 Fiscal 2026 $ 169.2 Fiscal 2027 $ 82.1 Fiscal 2028 $ 79.0 Fiscal 2029 $ 72.9 Goodwill In accordance with ASC 350, Intangibles—Goodwill and Other (ASC 350), the Company tests goodwill for impairment annually at the reporting unit level and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate, operational performance of the business or key personnel, and an adverse action or assessment by a regulator. In performing the impairment test, the Company utilizes the single-step approach prescribed under Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04). This approach requires a comparison of the carrying value of each reporting unit to its estimated fair value and to the extent the carrying value exceeds the fair value a charge is recorded up to the amount of goodwill in the reporting unit. To estimate the fair value of its reporting units, the Company primarily utilizes the income approach. The income approach is based on a DCF analysis and calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows are based on the Company’s most recent budget and strategic plan and for years beyond this period, the Company’s estimates are based on assumed growth rates expected as of the measurement date. The Company believes its assumptions are consistent with the plans and estimates used to manage the underlying businesses. The discount rates used are intended to reflect the risks inherent in future cash flow projections and are based on estimates of the weighted-average cost of capital (“WACC”) of market participants. The market approach considers comparable market data based on multiples of revenue or earnings before interest, taxes, depreciation and amortization (“EBITDA”) and is primarily used as a corroborative analysis to the results of the DCF analysis. The Company believes its assumptions used to determine the fair value of its reporting units are reasonable. If different assumptions were used, particularly with respect to forecasted cash flows, terminal values, WACCs, or market multiples, different estimates of fair value may result and there could be the potential that an impairment charge could result. Actual operating results and the related cash flows of the reporting units could differ from the estimated operating results and related cash flows. The Company conducted its fiscal 2024 impairment test for its reporting units on the first day of the fourth quarter, and as noted above used DCF and market approaches to estimate the

Revenue

Revenue	12 Months Ended
Revenue	Sep. 28, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customer (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is included in its Molecular Diagnostics business. The Company's products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Business (in millions) United States Intl. Total United States Intl. Total United States Intl. Total Diagnostics: Cytology & Perinatal $ 283.3 $ 195.9 $ 479.2 $ 297.4 $ 183.2 $ 480.6 $ 300.4 $ 174.3 $ 474.7 Molecular Diagnostics 999.1 273.4 1,272.5 1,061.0 300.7 1,361.7 1,694.5 816.9 2,511.4 Blood Screening 30.3 — 30.3 37.8 — 37.8 32.4 — 32.4 Total 1,312.7 469.3 1,782.0 1,396.2 483.9 1,880.1 2,027.3 991.2 3,018.5 Breast Health: Breast Imaging 932.9 277.8 1,210.7 884.0 260.2 1,144.2 735.1 216.5 951.6 Interventional Breast Solutions 244.6 67.6 312.2 232.6 55.9 288.5 222.1 54.1 276.2 Total 1,177.5 345.4 1,522.9 1,116.6 316.1 1,432.7 957.2 270.6 1,227.8 GYN Surgical 482.5 158.8 641.3 475.3 128.9 604.2 423.8 99.1 522.9 Skeletal Health 51.4 32.7 84.1 69.9 43.5 113.4 59.6 34.0 93.6 Total $ 3,024.1 $ 1,006.2 $ 4,030.3 $ 3,058.0 $ 972.4 $ 4,030.4 $ 3,467.9 $ 1,394.9 $ 4,862.8 Years Ended Geographic Regions ( in millions ) September 28, 2024 September 30, 2023 September 24, 2022 United States $ 3,024.1 $ 3,058.0 $ 3,467.9 Europe 532.7 520.3 888.5 Asia-Pacific 259.6 255.7 359.7 Rest of World 213.9 196.4 146.7 $ 4,030.3 $ 4,030.4 $ 4,862.8 The following table provides revenue recognized by source: Years Ended Revenue by type ( in millions ) September 28, 2024 September 30, 2023 September 24, 2022 Disposables $ 2,490.2 $ 2,539.4 $ 3,603.6 Capital equipment, components and software 764.9 740.5 587.6 Service 758.2 730.5 652.4 Other 17.0 20.0 19.2 $ 4,030.3 $ 4,030.4 $ 4,862.8 The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company's performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Revenue from laboratory testing services, which are generated by the Company's Biotheranostics business, is recognized based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group. Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering physician, the payor has been identified, and insurance has been verified. The estimated timeframes for cash collection are three months for Medicare payors, six months for Medicare Advantage payors, and nine months for commercial payors. Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company's contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast Solutions surgical handpieces provide for a right of return for a limited period of time. Estimates of variable consideration and constraints are not material to the Company's financial statements. Remaining Performance Obligations As of September 28, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $861.1 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Company's Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 47.6% of this amount as revenue in 2025, 28.6% in 2026, 14.5% in 2027, 6.2% in 2028, and 3.1% thereafter. As permitted, the Company does not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company's conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company's Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities on the Consolidated Balance Sheets. The Company recognized revenue of $134.4 million and $132.7 million in the years ended September 28, 2024 and September 30, 2023, respectively, that was included in the contract liability balance at September 30, 2023 and September 24, 2022, respectively. Practical Expedients The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.

Leases

Leases	12 Months Ended
Leases	Sep. 28, 2024
Leases [Abstract]
Leases	Leases The Company accounts for leases pursuant to ASC 842 Leases (ASC 842) and recognizes lease assets and liabilities on its balance sheet. As a lessee, the Company elected to combine lease and non-lease components together for the majority of its leases, and as a result accounts for each separate lease component and the non-lease components associated with that lease component as a single lease component. As a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not have a significant amount of sales-type leases. Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. In accordance with ASC 842, for leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 11 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the Consolidated Balance Sheet as of September 28, 2024. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of September 28, 2024 was 4.92%. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 28, 2024 September 30, 2023 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 92.2 $ — $ 62.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 5.0 $ — $ 5.6 Liabilities Operating lease liabilities (current) Accrued expenses $ 24.0 $ — $ 20.4 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.3 $ — $ 3.1 Operating lease liabilities (non-current) Other long-term liabilities $ 83.9 $ — $ 47.1 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 12.2 $ — $ 15.3 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 28, 2024 As of September 30, 2023 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 5.92 4.83 4.18 5.69 Weighted average discount rate 5.0 % 4.1 % 2.9 % 4.2 % The following table provides information related to the Company’s operating and finance leases: Year Ended September 28, 2024 Year Ended September 30, 2023 Operating lease cost (a) $ 41.3 $ 29.9 Finance lease cost - amortization of right-of-use assets $ 0.7 $ 0.7 Finance lease cost - interest cost $ 0.8 $ 0.8 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.7 $ 0.9 Operating cash flows from operating leases $ 26.1 $ 28.3 Financing cash flows from finance leases $ 3.8 $ 4.0 Total cash paid for amounts included in the measurement of lease liabilities $ 30.6 $ 33.2 ROU assets arising from entering into new operating lease obligations (b) $ 60.4 $ 15.7 ROU assets arising from entering into new finance lease obligations $ — $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 28, 2024. During the first quarter of fiscal 2024, in conjunction with the strategy change to move the Mobidiag development activities and operations to the Company’s San Diego, California location, the Company recorded a lease asset impairment charge of $12.5 million. Please refer to Footnote 8 for additional details. (b) During fiscal 2024, the Company renewed two leases at the Company’s Marlborough, Massachusetts locations in the amount of $23.3 million and $8.4 million for a term of 10 years and 5 years, respectively. The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance leases as of September 28, 2024: Fiscal Year Operating Leases Finance Leases 2025 $ 28.7 $ 3.8 2026 25.1 3.8 2027 20.8 4.0 2028 14.4 3.0 2029 8.0 0.6 Thereafter 29.6 1.7 Total future minimum lease payments 126.6 16.9 Less: imputed interest (18.7) (1.4) Present value of lease liabilities $ 107.9 $ 15.5 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company’s consolidated revenue for all periods presented. In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $10.4 million as of September 28, 2024. The Company leases a portion of a building it owns and subleases some of its rented facilities and received aggregate rental income of $1.5 million, $1.1 million and $2.8 million in fiscal 2024, 2023 and 2022, respectively, which has been recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and sublease agreements at September 28, 2024 are as follows: Fiscal 2025 $ 1.2 Fiscal 2026 1.1 Fiscal 2027 1.1 Fiscal 2028 0.8 Fiscal 2029 0.4 Thereafter 0.6 Total $ 5.2
Leases	Leases The Company accounts for leases pursuant to ASC 842 Leases (ASC 842) and recognizes lease assets and liabilities on its balance sheet. As a lessee, the Company elected to combine lease and non-lease components together for the majority of its leases, and as a result accounts for each separate lease component and the non-lease components associated with that lease component as a single lease component. As a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not have a significant amount of sales-type leases. Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. In accordance with ASC 842, for leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 11 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the Consolidated Balance Sheet as of September 28, 2024. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of September 28, 2024 was 4.92%. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 28, 2024 September 30, 2023 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 92.2 $ — $ 62.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 5.0 $ — $ 5.6 Liabilities Operating lease liabilities (current) Accrued expenses $ 24.0 $ — $ 20.4 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.3 $ — $ 3.1 Operating lease liabilities (non-current) Other long-term liabilities $ 83.9 $ — $ 47.1 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 12.2 $ — $ 15.3 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 28, 2024 As of September 30, 2023 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 5.92 4.83 4.18 5.69 Weighted average discount rate 5.0 % 4.1 % 2.9 % 4.2 % The following table provides information related to the Company’s operating and finance leases: Year Ended September 28, 2024 Year Ended September 30, 2023 Operating lease cost (a) $ 41.3 $ 29.9 Finance lease cost - amortization of right-of-use assets $ 0.7 $ 0.7 Finance lease cost - interest cost $ 0.8 $ 0.8 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.7 $ 0.9 Operating cash flows from operating leases $ 26.1 $ 28.3 Financing cash flows from finance leases $ 3.8 $ 4.0 Total cash paid for amounts included in the measurement of lease liabilities $ 30.6 $ 33.2 ROU assets arising from entering into new operating lease obligations (b) $ 60.4 $ 15.7 ROU assets arising from entering into new finance lease obligations $ — $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 28, 2024. During the first quarter of fiscal 2024, in conjunction with the strategy change to move the Mobidiag development activities and operations to the Company’s San Diego, California location, the Company recorded a lease asset impairment charge of $12.5 million. Please refer to Footnote 8 for additional details. (b) During fiscal 2024, the Company renewed two leases at the Company’s Marlborough, Massachusetts locations in the amount of $23.3 million and $8.4 million for a term of 10 years and 5 years, respectively. The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance leases as of September 28, 2024: Fiscal Year Operating Leases Finance Leases 2025 $ 28.7 $ 3.8 2026 25.1 3.8 2027 20.8 4.0 2028 14.4 3.0 2029 8.0 0.6 Thereafter 29.6 1.7 Total future minimum lease payments 126.6 16.9 Less: imputed interest (18.7) (1.4) Present value of lease liabilities $ 107.9 $ 15.5 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company’s consolidated revenue for all periods presented. In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $10.4 million as of September 28, 2024. The Company leases a portion of a building it owns and subleases some of its rented facilities and received aggregate rental income of $1.5 million, $1.1 million and $2.8 million in fiscal 2024, 2023 and 2022, respectively, which has been recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and sublease agreements at September 28, 2024 are as follows: Fiscal 2025 $ 1.2 Fiscal 2026 1.1 Fiscal 2027 1.1 Fiscal 2028 0.8 Fiscal 2029 0.4 Thereafter 0.6 Total $ 5.2
Leases	Leases The Company accounts for leases pursuant to ASC 842 Leases (ASC 842) and recognizes lease assets and liabilities on its balance sheet. As a lessee, the Company elected to combine lease and non-lease components together for the majority of its leases, and as a result accounts for each separate lease component and the non-lease components associated with that lease component as a single lease component. As a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not have a significant amount of sales-type leases. Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. In accordance with ASC 842, for leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 11 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the Consolidated Balance Sheet as of September 28, 2024. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of September 28, 2024 was 4.92%. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 28, 2024 September 30, 2023 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 92.2 $ — $ 62.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 5.0 $ — $ 5.6 Liabilities Operating lease liabilities (current) Accrued expenses $ 24.0 $ — $ 20.4 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.3 $ — $ 3.1 Operating lease liabilities (non-current) Other long-term liabilities $ 83.9 $ — $ 47.1 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 12.2 $ — $ 15.3 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 28, 2024 As of September 30, 2023 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 5.92 4.83 4.18 5.69 Weighted average discount rate 5.0 % 4.1 % 2.9 % 4.2 % The following table provides information related to the Company’s operating and finance leases: Year Ended September 28, 2024 Year Ended September 30, 2023 Operating lease cost (a) $ 41.3 $ 29.9 Finance lease cost - amortization of right-of-use assets $ 0.7 $ 0.7 Finance lease cost - interest cost $ 0.8 $ 0.8 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.7 $ 0.9 Operating cash flows from operating leases $ 26.1 $ 28.3 Financing cash flows from finance leases $ 3.8 $ 4.0 Total cash paid for amounts included in the measurement of lease liabilities $ 30.6 $ 33.2 ROU assets arising from entering into new operating lease obligations (b) $ 60.4 $ 15.7 ROU assets arising from entering into new finance lease obligations $ — $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 28, 2024. During the first quarter of fiscal 2024, in conjunction with the strategy change to move the Mobidiag development activities and operations to the Company’s San Diego, California location, the Company recorded a lease asset impairment charge of $12.5 million. Please refer to Footnote 8 for additional details. (b) During fiscal 2024, the Company renewed two leases at the Company’s Marlborough, Massachusetts locations in the amount of $23.3 million and $8.4 million for a term of 10 years and 5 years, respectively. The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance leases as of September 28, 2024: Fiscal Year Operating Leases Finance Leases 2025 $ 28.7 $ 3.8 2026 25.1 3.8 2027 20.8 4.0 2028 14.4 3.0 2029 8.0 0.6 Thereafter 29.6 1.7 Total future minimum lease payments 126.6 16.9 Less: imputed interest (18.7) (1.4) Present value of lease liabilities $ 107.9 $ 15.5 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company’s consolidated revenue for all periods presented. In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $10.4 million as of September 28, 2024. The Company leases a portion of a building it owns and subleases some of its rented facilities and received aggregate rental income of $1.5 million, $1.1 million and $2.8 million in fiscal 2024, 2023 and 2022, respectively, which has been recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and sublease agreements at September 28, 2024 are as follows: Fiscal 2025 $ 1.2 Fiscal 2026 1.1 Fiscal 2027 1.1 Fiscal 2028 0.8 Fiscal 2029 0.4 Thereafter 0.6 Total $ 5.2
Leases	Leases The Company accounts for leases pursuant to ASC 842 Leases (ASC 842) and recognizes lease assets and liabilities on its balance sheet. As a lessee, the Company elected to combine lease and non-lease components together for the majority of its leases, and as a result accounts for each separate lease component and the non-lease components associated with that lease component as a single lease component. As a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not have a significant amount of sales-type leases. Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. In accordance with ASC 842, for leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 11 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the Consolidated Balance Sheet as of September 28, 2024. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of September 28, 2024 was 4.92%. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 28, 2024 September 30, 2023 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 92.2 $ — $ 62.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 5.0 $ — $ 5.6 Liabilities Operating lease liabilities (current) Accrued expenses $ 24.0 $ — $ 20.4 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.3 $ — $ 3.1 Operating lease liabilities (non-current) Other long-term liabilities $ 83.9 $ — $ 47.1 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 12.2 $ — $ 15.3 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 28, 2024 As of September 30, 2023 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 5.92 4.83 4.18 5.69 Weighted average discount rate 5.0 % 4.1 % 2.9 % 4.2 % The following table provides information related to the Company’s operating and finance leases: Year Ended September 28, 2024 Year Ended September 30, 2023 Operating lease cost (a) $ 41.3 $ 29.9 Finance lease cost - amortization of right-of-use assets $ 0.7 $ 0.7 Finance lease cost - interest cost $ 0.8 $ 0.8 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.7 $ 0.9 Operating cash flows from operating leases $ 26.1 $ 28.3 Financing cash flows from finance leases $ 3.8 $ 4.0 Total cash paid for amounts included in the measurement of lease liabilities $ 30.6 $ 33.2 ROU assets arising from entering into new operating lease obligations (b) $ 60.4 $ 15.7 ROU assets arising from entering into new finance lease obligations $ — $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 28, 2024. During the first quarter of fiscal 2024, in conjunction with the strategy change to move the Mobidiag development activities and operations to the Company’s San Diego, California location, the Company recorded a lease asset impairment charge of $12.5 million. Please refer to Footnote 8 for additional details. (b) During fiscal 2024, the Company renewed two leases at the Company’s Marlborough, Massachusetts locations in the amount of $23.3 million and $8.4 million for a term of 10 years and 5 years, respectively. The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance leases as of September 28, 2024: Fiscal Year Operating Leases Finance Leases 2025 $ 28.7 $ 3.8 2026 25.1 3.8 2027 20.8 4.0 2028 14.4 3.0 2029 8.0 0.6 Thereafter 29.6 1.7 Total future minimum lease payments 126.6 16.9 Less: imputed interest (18.7) (1.4) Present value of lease liabilities $ 107.9 $ 15.5 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company’s consolidated revenue for all periods presented. In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $10.4 million as of September 28, 2024. The Company leases a portion of a building it owns and subleases some of its rented facilities and received aggregate rental income of $1.5 million, $1.1 million and $2.8 million in fiscal 2024, 2023 and 2022, respectively, which has been recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and sublease agreements at September 28, 2024 are as follows: Fiscal 2025 $ 1.2 Fiscal 2026 1.1 Fiscal 2027 1.1 Fiscal 2028 0.8 Fiscal 2029 0.4 Thereafter 0.6 Total $ 5.2

Business Combinations

Business Combinations	12 Months Ended
Business Combinations	Sep. 28, 2024
Business Combinations [Abstract]
Business Combinations	Business Combinations Fiscal 2024 Acquisitions Endomag On July 25, 2024, the Company completed the acquisition of Endomagnetics Ltd (“Endomag”) for a purchase price of $313.9 million. Endomag, located in the U.K., develops and sells breast surgery localization and lymphatic tracing technologies. Endomag’s results of operations are reported in the Company's Breast Health reportable segment from the date of acquisition. The purchase price was allocated to Endomag's preliminary tangible and identifiable intangible assets and liabilities based on their preliminary estimated fair values as of July 25, 2024, as set forth below. Cash $ 16.2 Accounts receivable 5.5 Inventory 14.9 Other assets 7.0 Accounts payable and accrued expenses (22.6) Identifiable intangible assets: Developed technology 180.9 Trade names 7.4 Customer relationship 6.5 In-process research and development 3.0 Deferred income taxes, net (43.8) Goodwill 138.9 Purchase Price $ 313.9 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Endomag’s business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the valuation of acquired assets and liabilities. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are developed technology, trade names, customer relationship and in-process research and development project. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 15.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The developed technology assets are comprised of know-how, patents and technologies embedded in Endomag’s products and relate to currently marketed products. The developed technology assets comprise the primary product families under the Sentimag, Magseed and Magtrace technology platforms. The preliminary estimate of the weighted average life for the developed technology assets was 11 years, for customer relationships was 12 years and trade name assets was 11 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the Endomag acquisition. These benefits include expanding the Company’s breast care portfolio and utilizing Breast Health’s sales and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Fiscal 2023 Acquisitions JW Medical On July 3, 2023, the Company completed the acquisition of assets from JW Medical Corporation (“JW Medical”) for a purchase price of $6.7 million. JW Medical was a long-standing distributor of the Company’s Breast Health products in South Korea. The majority of the purchase price was allocated to a customer relationship intangible asset with a useful life of 5 years. Normedi On April 3, 2023, the Company completed the acquisition of Normedi Nordic AS (“Normedi”) for a purchase price of $7.7 million, which included $1.1 million for contingent consideration. Normedi was a long-standing distributor of the Company’s Surgical products in the Nordics region of Europe. The Company allocated $3.0 million of the purchase price to a customer relationship intangible asset with a useful life of 5 years, and the excess of the purchase price over the net assets acquired was recorded to goodwill. Fiscal 2022 Acquisitions Bolder Surgical On November 29, 2021, the Company completed the acquisition of Bolder Surgical Holdings, Inc. (“Bolder”), for a purchase price of $160.1 million. Bolder, located in Louisville, Colorado, is a developer and manufacturer of energy vessel sealing surgical devices used in both laparoscopic and open procedures. Bolder's results of operations are reported in the Company's GYN Surgical reportable segment from the date of acquisition. The purchase price was allocated to Bolder’s tangible and identifiable intangible assets and liabilities based on their estimated fair values as of November 29, 2021, as set forth below. Cash $ 1.9 Accounts receivable 1.3 Inventory 3.3 Other assets 3.0 Accounts payable and accrued expenses (3.2) Identifiable intangible assets: Developed technology 73.6 Customer relationship 21.7 Trade names 1.4 Deferred income taxes, net (11.7) Goodwill 68.8 Purchase Price $ 160.1 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Bolder’s business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, customer relationships and trade names. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 16.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The developed technology assets are comprised of know-how, patents and technologies embedded in Bolder’s products and relate to currently marketed products. The developed technology assets comprise the primary product families under the JustRight and CoolSeal technology platforms. The estimate of the weighted average life for the developed technology, customer relationship, and trade name assets was 10 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the Bolder acquisition. These benefits include expanding the Company’s surgical portfolio and utilizing GYN Surgical’s sales and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Contingent Consideration The Company’s primary contingent consideration liability was related to its acquisition of Acessa Health, Inc. (“Acessa”), which was acquired in August 2020. Acessa developed the Acessa ProVu laparoscopic radiofrequency ablation system. The Company estimated the fair value of this liability to be $81.8 million as of the acquisition date. The contingent payments were based on a multiple of annual incremental revenue growth over a three-year period ending annually in December of each of 2021, 2022, and 2023. There was no maximum earnout. Pursuant to ASC 805 , the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections of Acessa, revenue growth rates of comparable companies, implied volatility and applying a risk adjusted discount rate. Each quarter the Company was required to remeasure the fair value of the liability as assumptions change, and such adjustments were recorded in operating expenses. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820. This fair value measurement was directly impacted by the Company's estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth were higher or lower than the estimates within the fair value measurement, the Company would record additional charges or gains. During the first quarter of fiscal 2024, the third and final measurement period was completed, and the Company recorded a loss of $1.7 million to increase the contingent consideration liability to fair value based on actual revenue results in the final earn-out period. The Company made a final payment of $2.6 million during the second quarter of fiscal 2024.

Strategic Investment

Strategic Investment	12 Months Ended
Strategic Investment	Sep. 28, 2024
Equity Method Investments and Joint Ventures [Abstract]
Strategic Investment	Strategic Investments Maverix Medical On November 13, 2023, the Company entered into an agreement with KKR Comet, LLC, an affiliate of KKR & Co. Inc. (“KKR Comet”), to form a legal entity to develop and acquire innovative technologies and commercial operations within the lung cancer space. The new entity, named Maverix Medical LLC (“Maverix”), is managed by Ajax Health. As part of this strategic investment, the Company contributed $24.5 million in return for 45% ownership in the Class A Common units of Maverix, and both the Company and KKR Comet have committed to make additional capital contributions in proportion to the ownership percentages upon meeting certain objectives and as approved by the Maverix board. In accordance with ASC 810, Consolidation, and ASC 323, Investments - Equity Method and Joint Ventures, the Company determined that Maverix is a VIE however the Company is not the primary beneficiary but does have significant influence and therefore this investment should be accounted for under the equity method, which requires the Company to record its proportional share of the entity’s net income (loss). This investment is recorded within Other assets in the Consolidated Balance Sheets, and the Company’s proportionate share of Maverix’s net loss for the year ended September 28, 2024 was $3.6 million. Other

Disposition

Disposition	12 Months Ended
Disposition	Sep. 28, 2024
Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract]
Disposition	Disposition Sale of SuperSonic Imagine Ultrasound Imaging Business On September 28, 2023, the Company executed an agreement to sell its SSI ultrasound imaging business to SSH Holdings Limited for a sales price of $1.9 million in cash. Under the terms of the contract, the Company agreed to fund the SSI business with $33.2 million of cash. The sale was completed on October 3, 2023. The Company also agreed to provide certain transition services for up to one year, depending on the nature of the service. The SSI ultrasound imaging asset group met the criteria to be classified as assets held-for-sale in the fourth quarter of fiscal 2023. As a result, the Company recorded a charge of $51.7 million in the fourth quarter of fiscal 2023 to record the asset group to its fair value less costs to sell pursuant to ASC 360. The assets and liabilities of the disposed business at the date of disposition were as follows: Assets: Cash $ 33.2 Accounts receivable 4.5 Inventory 16.2 Prepaid expenses and other assets 8.6 Valuation allowance (50.6) Total assets held-for-sale $ 11.9 Liabilities: Accounts payable $ 3.1 Accrued expenses 5.1 Total liabilities held-for-sale $ 8.2 The valuation allowance of $50.6 million was recorded to appropriately reflect the assets held-for-sale classification in the Consolidated Balance Sheet in the fourth quarter of fiscal 2023 relative to the loss recorded and the net tangible assets disposed. The Company concluded that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company’s operations and financial results.

Restructuring Charges

Restructuring Charges	12 Months Ended
Restructuring Charges	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring and Divestiture Charges The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. As a result of these assessments, the Company has undertaken various restructuring actions which are described below. The following table displays charges taken related to restructuring actions in fiscal 2024, 2023 and 2022 and a rollforward of the charges to the accrued balances as of September 28, 2024: Fiscal 2024 Actions Fiscal 2023 Actions Fiscal 2022 Actions Other Total Restructuring Charges Fiscal 2022 charges: Workforce reductions $ — $ — $ 2.6 $ (0.7) $ 1.9 Facility closure costs — — 0.5 — 0.5 Fiscal 2022 restructuring charges $ — $ — $ 3.1 $ (0.7) $ 2.4 Fiscal 2023 charges: Workforce reductions $ — $ 5.5 $ 6.0 $ — $ 11.5 Other costs — — 0.5 — 0.5 Fiscal 2023 restructuring charges $ — $ 5.5 $ 6.5 $ — $ 12.0 Fiscal 2024 charges: Lease asset impairment charge $ 12.5 $ — $ — $ — $ 12.5 Accelerated depreciation expense 7.2 — — — 7.2 Workforce reductions 15.8 — 3.9 — 19.7 Other costs 1.2 — 0.5 — 1.7 Fiscal 2024 restructuring charges $ 36.7 $ — $ 4.4 $ — $ 41.1 Fiscal 2024 Actions Fiscal 2023 Actions Fiscal 2022 Actions Other Total Rollforward of Accrued Restructuring Balance as of September 25, 2021 $ — $ — $ — $ 4.1 $ 4.1 Fiscal 2022 restructuring charges $ — $ — $ 3.1 $ (0.7) $ 2.4 Severance payments and adjustments — — (0.4) (3.0) (3.4) Balance as of September 24, 2022 $ — $ — $ 2.7 $ 0.4 $ 3.1 Fiscal 2023 restructuring charges $ — $ 5.5 $ 6.5 $ — $ 12.0 Severance payments and adjustments — (3.2) (2.5) (0.4) (6.1) Balance as of September 30, 2023 $ — $ 2.3 $ 6.7 $ — $ 9.0 Fiscal 2024 restructuring charges $ 36.7 $ — $ 4.4 $ — $ 41.1 Non-cash impairment charge (12.5) — — — (12.5) Non-cash accelerated depreciation charge (7.2) — — — (7.2) Severance payments and adjustments (11.5) (2.0) (4.9) — (18.4) Balance as of September 28, 2024 $ 5.5 $ 0.3 $ 6.2 $ — $ 12.0 Fiscal 2024 Actions During the first quarter of fiscal 2024, the Company further refined its strategy for the Mobidiag business, which is within the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of certain products, closure of its facilities in Finland and France, and to move the development activities and operations to the Company’s San Diego, California location. As such, the Company determined certain fixed assets lives should be shortened and that lease assets were impaired at the affected facilities and recorded accelerated depreciation of $7.2 million and a lease asset impairment charge of $12.5 million. In connection with this plan, the Company finalized its decision to terminate the employees at these locations, totaling 190. The Company initiated discussions with the respective Works Councils at the end of the first quarter of fiscal 2024. In addition, the Company recorded the minimum statutory severance benefit for the employees located in France of $1.8 million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits (ASC 712), at this time. During the second quarter of fiscal 2024, the Company finalized its negotiations with the respective Works Councils and communicated the termination and related severance benefits to the affected employees. The Company has estimated the total severance charges, including accelerated stock compensation, will be approximately $13.9 million. The majority of the severance benefits will be recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), which requires the severance benefits to be recognized ratably over the service period to obtain such benefits. The employees will cease employment in phases. As a result, the Company recorded total severance charges of $11.9 million in fiscal 2024. This action is expected to be completed by the second quarter of fiscal 2025. During fiscal 2024, the Company made various decisions to contain costs and to terminate approximately 34 employees primarily in Breast Health and Diagnostics, within sales, marketing and research and development. The Company recorded $3.9 million for severance benefits under these actions pursuant to ASC 420. These actions were completed as of September 28, 2024. Fiscal 2023 and 2022 Actions During fiscal 2023 and 2022, the Company made various decisions to terminate approximately 128 employees across all divisions in multiple departments as well as consolidate and close certain offices in Germany and transfer warehouse distribution in the United States to a third-party facility. During fiscal 2023 and 2022, the Company recorded $9.4 million and $0.3 million, respectively, primarily for severance benefits under these actions, and $0.5 million in property closure costs in fiscal 2022. The charges were recorded pursuant to ASC 712 and ASC 420 depending on the employee and nature of the severance benefit. These actions were completed as of the end of fiscal 2023. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company's Newark, Delaware facility. The transition is expected to be completed by the third quarter of fiscal 2025. In addition, research and development, sales and services support and administrative functions have been transferred to the Newark, Delaware and Marlborough, Massachusetts facilities. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420. As a result, the Company recorded severance and benefits charges of $3.9 million, $2.1 million, and $1.6 million during fiscal 2024, 2023 and 2022, respectively. The Company estimates that total severance and benefits charges, including retention and relocation and outplacement costs, will be approximately $8.6 million.

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	12 Months Ended
Borrowings and Credit Arrangements	Sep. 28, 2024
Debt Disclosure [Abstract]
Borrowings and Credit Agreements	Borrowings and Credit Agreements The Company’s borrowings consisted of the following: September 28, September 30, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 37.5 $ 287.0 Total current debt obligations $ 37.5 $ 287.0 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,158.7 1,195.6 2028 Senior Notes 397.6 396.8 2029 Senior Notes 940.8 938.8 Total long-term debt obligations 2,497.1 2,531.2 Total debt obligations $ 2,534.6 $ 2,818.2 The debt maturity schedule for the Company’s obligations as of September 28, 2024 was as follows: 2025 2026 2027 2028 2029 2030 and Thereafter Total Term Loan $ 37.5 $ 1,160.0 $ — $ — $ — $ — $ 1,197.5 2028 Senior Notes — — — 400.0 — — 400.0 2029 Senior Notes — — — — 950.0 — 950.0 $ 37.5 $ 1,160.0 $ — $ 400.0 $ 950.0 $ — $ 2,547.5 2021 Credit Agreement On September 27, 2021, the Company and certain of its subsidiaries refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the “2018 Credit Agreement”) by entering into Refinancing Amendment No. 2 (the “2021 Credit Agreement”). Borrowings under the 2021 Credit Agreement are secured by first-priority liens on, and a first-priority security interest in, substantially all of the Company's U.S. assets and the assets of the Subsidiary Guarantors. These liens are subject to release during the term of the facilities if the Company is able to achieve certain corporate or corporate family ratings and other conditions are met. The credit facilities under the 2021 Credit Agreement (the “2021 Credit Facilities”) consist of: • A $1.5 billion secured term loan (“2021 Term Loan”) with a maturity date of September 25, 2026; and • A secured revolving credit facility (“2021 Revolver”) under which the Company may borrow up to $2.0 billion, subject to certain sublimits, with a maturity date of September 25, 2026. On August 22, 2022, the Company and its subsidiaries amended the 2021 Credit Agreement by entering into an amendment (the “Third Amendment”) related to the planned phase out of LIBOR by the U.K. Financial Conduct Authority. The interest rate applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a variant of the secured overnight financing rate (“SOFR”), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The Third Amendment converted the Eurocurrency Rate to Term SOFR plus the SOFR Adjustment of 0.10% and the LIBOR Daily Floating Rate to Daily SOFR Rate plus the SOFR Adjustment of 0.10%, effective September 23, 2022. After giving effect to the Third Amendment, borrowings under the 2021 Credit Agreement, other than Swing Line Loans, bear interest, at the Company's option, at the Base Rate, at the Term SOFR Rate, at the Alternative Currency Daily Rate, or at the Daily SOFR Rate, in each case plus the Applicable Rate. The Applicable Rate in regard to the Base Rate, the Term SOFR Rate, the Alternative Currency Daily Rate, the Alternative Currency Term Rate, and the Daily SOFR Rate is subject to change depending on the Total Net Leverage Ratio (as defined in the 2021 Credit Agreement). The borrowings of the Term Loan under the 2021 Credit Facilities bear interest at an annual rate equal to the Term SOFR Rate plus the SOFR Adjustment of 0.10% for a one-month interest period plus an Applicable Rate equal to 1.00%. As of September 28, 2024, the interest rate under the 2021 Term Loan was 5.96% per annum. The Company is also required to pay a quarterly commitment fee calculated on a daily basis equal to the Applicable Rate as of such day multiplied by the undrawn committed amount available under the 2021 Revolver (taking into account any outstanding amounts under the LC Sublimit). As of September 28, 2024, this commitment fee was 0.15% per annum for the 2021 Revolver. The Company is required to make scheduled principal payments under the 2021 Term Loan in increasing amounts, which is $9.375 million per three-month period through fiscal 2025, and increases to $18.75 million per three-month period in fiscal 2026. The remaining balance of $1.085 billion (or such lesser aggregate principal amount of the Term Loans then outstanding) on the 2021 Term Loan and any amounts outstanding under the 2021 Revolver are due at maturity. In addition, subject to the terms and conditions set forth in the 2021 Credit Agreement, the Company is required to make certain mandatory prepayments from the net proceeds of specified types of asset sales (subject to certain reinvestment rights), debt issuances (excluding permitted debt) and insurance recoveries (subject to certain reinvestment rights). Certain of the mandatory prepayments are subject to reduction or elimination if certain financial covenants are met. These mandatory prepayments are required to be applied by the Company first to the 2021 Term Loan, second to any outstanding amount under any Swing Line Loans, third to the 2021 Revolver, fourth to prepay any outstanding reimbursement obligations with respect to letters of credit and fifth to cash collateralize such letters of credit. Subject to certain limitations, the Company may voluntarily prepay any of the 2021 Credit Facilities without premium or penalty. On October 27, 2023 (the first quarter of fiscal 2024), the Company made a $250.0 million voluntary prepayment on the 2021 Term Loan. The outstanding principal balance of the 2021 Term Loan was $1.20 billion, and there were no amounts outstanding under the 2021 Revolver. The 2021 Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants restricting the ability of the Company, subject to negotiated exceptions, to incur additional indebtedness and grant additional liens on its assets, engage in mergers or acquisitions or dispose of assets, enter into sale-leaseback transactions, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the 2021 Credit Agreement requires the Borrowers to maintain certain financial ratios. The 2021 Credit Agreement also contains customary representations and warranties and events of default, including payment defaults, breach of representations and warranties, covenant defaults, cross defaults and an event of default upon a change of control of the Company. The Company evaluated the 2021 Credit Agreement for derivatives pursuant to ASC 815, Derivatives and Hedging (ASC 815), and identified embedded derivatives that required bifurcation as the features are not clearly and closely related to the host instrument. The embedded derivatives were a default provision, which could require additional interest payments, and a provision requiring contingent payments to compensate the lenders for changes in tax deductions. The Company determined that the fair value of these embedded derivatives was immaterial as of September 28, 2024. Pursuant to ASC 470, Debt (ASC 470), the accounting for the refinancing was evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the 2018 Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of $0.7 million in the first quarter of fiscal 2022 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to these creditors. For the remainder of the creditors, this transaction was accounted for as a modification. Pursuant to ASC 470, third-party costs of $7.0 million were recorded as a reduction to debt representing deferred issuance costs and fees paid directly to the lenders. Interest expense, non-cash interest expense, the weighted average interest rate, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Interest expense (1) $ 85.8 $ 92.4 $ 31.8 Non-cash interest expense $ 2.2 $ 2.3 $ 2.2 Weighted average interest rate 6.39 % 5.84 % 1.74 % Interest rate at end of period 5.96 % 6.42 % 4.18 % (1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount. Under the Company’s interest rate swap agreements, it received $16.8 million and $35.4 million in fiscal 2024 and 2023, respectively, which was recorded as a reduction to interest expense. In fiscal 2022, the Company paid $4.9 million under its interest rate swaps, which was recorded as an increase to interest expense. Senior Notes 2028 Senior Notes On January 19, 2018, the Company completed a private placement of $1.0 billion aggregate principal amount of senior notes and allocated $400 million in aggregate principal amount to its 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) at an offering price of 100% of the aggregate principal amount of the 2028 Senior Notes. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries. The 2028 Senior Notes mature on February 1, 2028 and bear interest at the rate of 4.625% per year, payable semi-annually on February 1 and August 1 of each year, commencing on August 1, 2018. The Company has the option to redeem the 2028 Senior Notes on or after: February 1, 2024 through February 1, 2025 at 101.541% of par; February 1, 2025 through February 1, 2026 at 100.770% of par; and February 1, 2026 and thereafter at 100% of par. In addition, if the Company undergoes a change of control coupled with a decline in ratings, as provided in the indenture, the Company will be required to make an offer to purchase each holder’s 2028 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date. The Company evaluated the 2028 Senior Notes for derivatives pursuant to ASC 815 and did not identify any embedded derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument. 2029 Senior Notes On September 28, 2020, the Company completed a private placement of $950 million aggregate principal amount of its 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) at an offering price of 100% of the aggregate principal amount of the 2029 Senior Notes. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries. The 2029 Senior Notes mature on February 15, 2029 and bear interest at the rate of 3.250% per year, payable semi-annually on February 15 and August 15 of each year, commencing on February 15, 2021. The Company has the option to redeem the 2029 Senior Notes on or after: September 28, 2024 through September 27, 2025 at 100.813% of par; and September 28, 2025 and thereafter at 100% of par. In addition, if the Company undergoes a change of control coupled with a decline in ratings, as provided in the indenture, the Company will be required to make an offer to purchase each holder’s 2029 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date. The Company evaluated the 2029 Senior Notes for derivatives pursuant to ASC 815 and did not identify any embedded derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument. Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Interest Rate Interest Expense (1) Non-Cash Interest Expense Interest Expense (1) Non-Cash Interest Expense Interest Expense (1) Non-Cash Interest Expense 2029 Senior Notes 3.250 % $ 32.9 $ 2.1 $ 33.5 $ 2.1 $ 32.9 $ 2.1 2028 Senior Notes 4.625 % 19.2 0.7 19.5 0.7 19.2 0.7 Total $ 52.1 $ 2.8 $ 53.0 $ 2.8 $ 52.1 $ 2.8 (1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Sep. 28, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company applies the provisions of ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value each reporting period and its nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows: • Level 1—Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2—Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3—Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in money market funds, United States Treasury securities and commercial paper that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents, and Short term and Long term investments on the Consolidated Balance Sheets, which is determined based on maturities at the time of purchase and re-evaluated at each balance sheet date. The Company also has investments in derivative instruments comprised of interest rate swaps, forward foreign currency contracts and foreign currency option contracts (including collars). These instruments were valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 2 for further discussion and information on these derivative contracts. In addition, the Company has a contingent consideration liability that is recorded at fair value and is based on Level 3 inputs. Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following: Fair Value Measurements at September 28, 2024 Fair Value Quoted Prices in Significant Significant Assets: Money market mutual funds $ 341.7 $ 341.7 $ — $ — U.S. Treasury securities 626.3 626.3 — — Commercial paper 24.9 24.9 — — Interest rate swaps 3.1 — 3.1 — Foreign currency option contracts 0.8 — 0.8 — Total $ 996.8 $ 992.9 $ 3.9 $ — Liabilities: Contingent consideration $ 1.1 $ — $ — $ 1.1 Interest rate swaps 0.2 — 0.2 — Forward foreign currency contracts 12.6 — 12.6 — Total $ 13.9 $ — $ 12.8 $ 1.1 Fair Value Measurements at September 30, 2023 Fair Value Quoted Prices in Significant Significant Assets: Interest rate swaps $ 26.9 $ — $ 26.9 $ — Forward foreign currency contracts 8.4 — 8.4 — Total $ 35.3 $ — $ 35.3 $ — Liabilities: Contingent consideration $ 2.0 $ — $ — $ 2.0 Total $ 2.0 $ — $ — $ 2.0 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the years ended September 28, 2024, September 30, 2023, and September 24, 2022 were as follows: Years Ended 2024 2023 2022 Balance at beginning of period $ 2.0 $ 23.4 $ 75.1 Contingent consideration recorded at acquisition — 1.1 — Fair value adjustments 1.7 (14.9) (39.5) Payments (2.6) (7.6) (12.2) Balance at end of period $ 1.1 $ 2.0 $ 23.4 Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, primarily comprised of property, plant and equipment, intangible assets, and goodwill. During the third quarter of fiscal 2024, the Company recorded intangible asset impairment reducing the carrying value of the assets to $13.9 million and $0.5 million, respectively. See Note 2 for further discussion. During the first quarter of fiscal 2024, the Company recorded a $12.5 million impairment charge for right-of-use lease assets related to the closure of its Mobidiag facilities in Finland and France (see Note 8 for further discussion), reducing the carrying value to zero. In addition, during the first quarter of fiscal 2024, the Company recorded a $4.3 million impairment charge for an in-process research and development project from the Mobidiag acquisition, reducing the carrying value of this asset to $22.4 million. During the fourth quarter of fiscal 2023, the Company’s SSI ultrasound imaging business met the criteria to be classified as assets held-for-sale, and the Company recorded a $51.7 million loss to record the asset group at its fair value less costs to sell. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of its Mobidiag business and based on the fair value of the asset group recorded impairment charges aggregating $186.9 million, of which $174.8 million was allocated to intangible assets and $12.1 million was allocated to property, plant and equipment. Subsequent to the impairment charges, the carrying value of the definite-lived intangible assets and property, plant and equipment was $65.8 million and $4.6 million, respectively. In addition, the Company recorded a $10.5 million impairment charge for the only in-process research and development project from the Mobidiag acquisition, and the resulting carrying value was $26.5 million. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of its SSI ultrasound imaging business and recorded impairment charges aggregating $26.4 million, of which $20.6 million was allocated to intangible assets and $5.8 million was allocated to equipment. Subsequent to the impairment charges, the carrying value of these assets was zero. During the fourth quarter of fiscal 2022, the Company recorded a $27.7 million impairment charge to record its Mobidiag IPR&D asset to fair value, which is a Level 3 measurement, and it recorded an $8.2 million impairment charge to write-off a developed technology asset from its Focal acquisition. In addition, the Company recorded an impairment charge of $4.0 million to record an equity investment at its estimated fair value. During the third quarter of fiscal 2022, the Company recorded a $9.2 million impairment charge to write off two developed technology assets from its Faxitron acquisition. During the second quarter of fiscal 2022, the Company recorded a $4.3 million impairment charge to write-off an equity method investment acquired in the Mobidiag acquisition. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, United States Treasury securities, commercial paper, accounts receivable, equity investments, interest rate swaps, forward foreign currency contracts, foreign currency option contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s United States Treasury securities, commercial paper, interest rate swaps, forward foreign currency contracts and foreign currency option contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at their cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value. The Company’s cash and cash equivalents and short and long-term investments as of September 28, 2024 were as follows: Valuation Balance Sheet Classification in millions Cost Unrealized Gains Unrealized Losses Fair Value Cash and cash equivalents Investments Cash $ 1,437.1 $ — $ — $ 1,437.1 $ 1,437.1 $ — Money market mutual funds 341.7 — — 341.7 341.7 — U.S. Treasury debt securities 624.7 1.6 — 626.3 356.5 269.8 Commercial paper 24.9 — — 24.9 24.9 — Total $ 2,428.4 $ 1.6 $ — $ 2,430.0 $ 2,160.2 $ 269.8 The Company classifies its investments in debt securities as available-for-sale and records them at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss), which was immaterial for the year ended September 28, 2024. The Company periodically assesses these securities for potential impairment losses and credit losses. The amount of credit losses, if any, will be determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. There were no impairments and credit losses related to available-for-sale securities for the year ended September 28, 2024. The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the years ended September 28, 2024 and September 30, 2023, respectively. There were no sales of available-for-sale securities during the year ended September 28, 2024. The fair value of the available-for-sale securities by contractual maturity as of September 28, 2024 and September 30, 2023 are as follows: September 28, 2024 September 30, 2023 in millions Fair Value Fair Value Due in three months or less $ 723.1 $ — Due after three months through one year 173.4 — Due after one year through five years 96.4 — Total available-for-sale securities $ 992.9 $ — Amounts outstanding under the Company’s 2021 Credit Agreement of $1.20 billion aggregate principal as of September 28, 2024 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 2028 Senior Notes and 2029 Senior Notes had fair values of approximately $393.1 million and $882.2 million, respectively, as of September 28, 2024 based on their trading prices, representing a Level 1 measurement. Refer to Note 9 for the carrying amounts of the various components of the Company's debt.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Sep. 28, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s income before income taxes consisted of the following: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Domestic $ 609.4 $ 861.4 $ 1,340.3 Foreign 255.7 (185.3) 247.9 $ 865.1 $ 676.1 $ 1,588.2 The provision (benefit) for income taxes contained the following components: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Federal: Current $ 91.6 $ 250.6 $ 298.6 Deferred (50.9) (72.1) (129.8) 40.7 178.5 168.8 State: Current 14.2 45.9 54.8 Deferred (7.5) (9.4) (9.5) 6.7 36.5 45.3 Foreign: Current 41.9 32.7 99.0 Deferred (13.7) (27.6) (26.9) 28.2 5.1 72.1 $ 75.6 $ 220.1 $ 286.2 The income tax provision differed from the tax provision computed at the U.S. federal statutory rate due to the following: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Income tax provision at federal statutory rate 21.0 % 21.0 % 21.0 % Increase (decrease) in tax resulting from: Cynosure loss on sale and carryback — — (1.2) State income taxes, net of federal benefit 2.5 4.1 2.9 U.S. tax on foreign earnings 0.5 (1.0) (2.6) Internal Restructuring — — (0.9) Tax credits (1.6) (1.1) (0.5) Unrecognized tax benefits 3.9 3.5 0.2 Compensation 1.0 0.8 0.2 Foreign rate differential (6.8) (4.8) (0.8) Change in deferred tax — — 0.4 Assets held-for-sale charge — 1.5 — Change in valuation allowance 2.7 8.2 0.4 Return to provision (1.2) (1.9) (0.7) Worthless stock deduction (12.4) — — Other (0.9) 2.3 (0.4) 8.7 % 32.6 % 18.0 % The Company’s effective tax rate for fiscal 2024 was lower than the U.S. statutory tax rate primarily due to a one-time tax benefit of $107.2 million related to a worthless stock deduction on an investment in one of the Company’s international subsidiaries recorded in the first quarter of fiscal 2024, the U.S. deduction for foreign derived intangible income, and the geographic mix of income earned by the Company’s international subsidiaries, and federal and state tax credits. The Company's effective tax rate for fiscal 2023 was higher than the U.S. statutory tax rate primarily due to the tax effect of the SSI ultrasound imaging assets held-for-sale charge, income tax reserves, the global intangible low-taxed income inclusion, and state income taxes, partially offset by the impact of the U.S. deduction for foreign derived intangible income, and the geographic mix of income earned by our international subsidiaries. The Company's effective tax rate for fiscal 2022 was lower than the U.S. statutory tax rate primarily due to the impact of the U.S. deduction for foreign derived intangible income, reserve releases resulting from statute of limitations expirations and favorable audit settlements (net of reserve additions for uncertain tax positions), the geographic mix of income earned by the Company's international subsidiaries and a tax benefit related to an internal restructuring, partially offset by state income taxes and the global intangible low-taxed income inclusion. The Company obtains tax incentives through the Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $79.8 million and $45.5 million, or $0.34 and $0.18 per share to diluted net income in fiscal years 2024 and 2023, respectively. The tax incentive for 100 percent exemption from income tax expires in fiscal year 2029, with the 50 percent exemption to expire in fiscal year 2033. The Company’s historical practice has been to renew, extend, or obtain new tax incentive grants upon expiration of existing tax incentive grants. If the Company is not able to renew, extend, or obtain new tax incentive grants, the expiration of existing tax incentive grants could have a material impact on the Company’s financial results in future periods. Incentives in fiscal years prior to 2023 were not material to the Company's consolidated financial statements. The Company’s significant deferred tax assets and liabilities were as follows: September 28, 2024 September 30, 2023 Deferred tax assets Net operating loss and other tax carryforwards $ 137.1 $ 125.8 Capitalized research and development 96.8 70.1 Non-deductible accruals 41.0 32.7 Non-deductible reserves 37.8 42.8 Stock-based compensation 21.9 19.8 Nonqualified deferred compensation plan 15.9 13.5 Lease liability 26.2 14.0 Other temporary differences 21.0 5.9 397.7 324.6 Less: valuation allowance (143.1) (114.7) $ 254.6 $ 209.9 Deferred tax liabilities Depreciation and amortization $ (161.8) $ (160.3) Right of use asset (23.4) (13.2) $ (185.2) $ (173.5) $ 69.4 $ 36.4 Under ASC 740, Accounting for Income Taxes (ASC 740), the Company can only recognize the future benefit of deferred tax assets to the extent that it is “more likely than not” that these assets will be realized. After considering all available positive and negative evidence, the Company establishes a valuation allowance against specifically identified deferred tax assets because it is more-likely-than-not that these assets will not be realized. In making this determination, the Company considers numerous factors including historical profitability, estimated future taxable income and the character of such income. The valuation allowance increased $28.4 million in fiscal 2024 from fiscal 2023 primarily due to valuation allowances recorded against net operating loss carryforwards of certain foreign subsidiaries. As of September 28, 2024, the Company had $22.5 million, $172.1 million, and $275.2 million in gross federal, state, and foreign net operating losses, respectively, $4.6 million and $2.1 million in federal and state credit carryforwards, respectively, and $438.9 million and $134.2 million in gross state and foreign capital loss carryforwards, respectively. These losses, credits, and capital loss carryforwards expire between 2025 and 2044, except for $97.5 million in losses, $4.2 million in credits, and $134.2 million in capital loss carryforwards that have unlimited carryforward periods. The state and foreign net operating losses include $107.7 million and $208.6 million, respectively, and the state capital loss carryforwards include $438.9 million, that the Company expects will expire unutilized. The Company has determined that unremitted foreign earnings are not considered indefinitely reinvested to the extent foreign earnings can be distributed without a significant tax cost. As such, the Company records foreign withholding tax liabilities related to the future repatriation of such earnings. The Company continues to indefinitely reinvest all other outside basis differences to the extent reversal would incur a significant tax liability. It is not practicable for the Company to calculate the unrecognized deferred tax liability related to such incremental tax costs on those outside basis differences. The Company’s gross unrecognized tax benefits increased $16.7 million from fiscal 2023 to 2024 and was primarily due to intercompany transfer pricing for ordinary business operations and increases to prior year positions, which were partially offset by reserve releases resulting from statute of limitations expirations and audit settlements. The $8.9 million increase in gross unrecognized tax benefits from fiscal 2022 to 2023 was primarily due to intercompany transfer pricing for ordinary business operations and other current year positions, partially offset by reserve releases resulting from statute of limitations expirations and audit settlements. In the next twelve months it is reasonably possible that the Company will reduce its gross unrecognized tax benefits excluding interest by up to $8.3 million due to expiring statutes of limitations. The timing of the ultimate resolution of the Company’s examinations with relevant taxing authorities, which can include formal administrative and legal proceedings, and could have a significant impact on the reversal of unrecognized tax benefits, is difficult to predict. As a result, the Company is not able to provide a reasonably reliable estimate of the timing for reversals of unrecognized income tax benefits that are under examination. The Company’s unrecognized income tax benefits activity for fiscal 2024, 2023 and 2022 was as follows: 2024 2023 2022 Balance at beginning of fiscal year $ 256.5 $ 247.6 $ 212.8 Tax positions related to current year: Additions 7.8 6.8 45.9 Tax positions related to prior years: Additions related to change in estimate 11.8 4.5 21.5 Reductions (2.1) — (6.6) Lapses in statutes of limitations and settlements (0.8) (2.4) (26.0) Balance as of the end of the fiscal year $ 273.2 $ 256.5 $ 247.6 As of fiscal 2024, 2023, and 2022 there were $213.9 million, $240.5 million, and $231.6 million of unrecognized tax benefits that if recognized would affect the annual effective tax rate. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as a component of income tax expense. During fiscal years 2024, 2023, and 2022, the Company recognized $20.3 million, $15.8 million, and $0.7 million in gross interest. The Company had gross accrued interest of $50.4 million and $30.1 million as of September 28, 2024 and September 30, 2023, respectively, and accrued penalties were not significant. The Company and its subsidiaries are subject to examination by U.S. federal, state, and foreign tax authorities. The Company is currently undergoing several income tax audits including examinations by the U.S. Internal Revenue Service (fiscal years 2017-2020), U.K. HM Revenue and Customs (fiscal years 2016-2022) and various state tax authorities. Excluding jurisdictions under audit, the Company’s income tax returns are generally no longer subject to examination prior to fiscal year 2019. Other Tax Accounting Pronouncements ASU 2016-16 removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. In accordance with ASU 2016-16, the Company recorded a $77.2 million increase to current income tax expense, and a $90.8 million decrease to deferred tax expense related to an internal restructuring for the year ended September 24, 2022. The net result was an increase to net income of $13.6 million, or $0.05 to diluted net income per share for the year ended September 24, 2022. Non-Income Tax Matters The Company is subject to tax examinations for value added, sales-based, payroll and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates and records loss contingencies pursuant to ASC 450, Contingencies (ASC 450). In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.

Stockholders' Equity and Stock-

Stockholders' Equity and Stock-Based Compensation	12 Months Ended
Stockholders' Equity and Stock-Based Compensation	Sep. 28, 2024
Share-Based Payment Arrangement [Abstract]
Stockholders' Equity and Stock-Based Compensation	Stockholders' Equity and Stock-Based Compensation Stock Repurchase Program On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to $1.0 billion of the Company’s outstanding common stock, effective as of the close of trading September 23, 2022. This repurchase program replaced the previous $1.0 billion authorization. During fiscal 2024 and 2023, the Company repurchased 4.2 million and 6.8 million shares of its common stock for total consideration of $308.3 million and $501.6 million, respectively, excluding the 1% excise tax on share repurchases of $7.2 million and $2.9 million, respectively. As of September 28, 2024, $190.3 million remained available under this authorization. Subsequent to September 28, 2024, the Company repurchased 2.7 million shares for a total consideration of $217.2 million. On November 6, 2023, the Board of Directors authorized the Company to repurchase up to $500 million of the Company’s outstanding shares pursuant to an accelerated share repurchase (ASR) agreement. On November 15, 2023, the Company executed the ASR agreement with Goldman Sachs & Co. (“Goldman Sachs”) pursuant to which the Company agreed to repurchase $500 million of the Company’s common stock. In connection with the launch of the ASR, on November 17, 2023, the Company paid Goldman Sachs an aggregate of $500 million and received approximately 5.6 million shares of the Company’s common stock, representing 80% of the transaction value based on the Company’s closing share price on November 14, 2023. On February 27, 2024, the ASR agreement was completed, and the Company received an additional 1.4 million shares for the final settlement. This final settlement was based on the total transaction value and the volume-weighted average share price of the Company’s common stock during the term of the agreement. On September 12, 2024, the Board of Directors authorized a new stock repurchase program, with a five-year term, to repurchase up to $1.5 billion of the Company’s outstanding stock. This new stock repurchase authorization is in addition to the Company’s prior stock repurchase authorization. As of September 28, 2024, $1.5 billion remained unused under this program. On November 19, 2024, the Company executed an ASR agreement with JPMorgan Chase & Co., (“JP Morgan”) pursuant to which the Company agreed to repurchase $250.0 million of the Company’s common stock. In connection with the launch of the ASR, on November 20, 2024, the Company paid JP Morgan an aggregate of $250.0 million and received approximately 2.5 million shares of the Company’s common stock, representing 80% of the transaction value based on the Company’s closing share price on November 18, 2024. The final number of shares to be received under the ASR agreement will be determined upon completion of the transaction and will be based on the total transaction value and the volume-weighted average share price of our common stock during the term of the transaction. Final settlement of the transaction is expected to be completed in the second quarter of fiscal 2025. Stock-Based Compensation Equity Compensation Plans The Company has one share-based compensation plan pursuant to which awards are currently being issued—the 2008 amended and restated Equity Incentive Plan (“2008 Equity Plan”). The purpose of the 2008 Equity Plan is to provide stock options, restricted stock units and other equity interests in the Company to employees, officers, directors, consultants and advisors of the Company and any other person who is determined by the Board of Directors to have made (or is expected to make) contributions to the Company. The 2008 Equity Plan is administered by the Board of Directors of the Company. On December 8, 2022, the Board of Directors approved an additional 6.5 million shares of common stock available under the 2008 Equity Plan increasing the total shares reserved for issuance under the plan to 38 million. As of September 28, 2024, the Company had 7.5 million shares available for future grant under the 2008 Equity Plan. The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations in fiscal 2024, 2023 and 2022: 2024 2023 2022 Cost of revenues $ 10.7 $ 10.5 $ 9.1 Research and development 10.3 10.5 8.8 Selling and marketing 13.4 12.0 10.5 General and administrative 47.8 46.6 38.3 Restructuring 0.1 — — $ 82.3 $ 79.6 $ 66.7 Grant-Date Fair Value The Company uses a binomial model to determine the fair value of its stock options. The Company considers a number of factors to determine the fair value of options including the assistance of an outside valuation adviser. Information pertaining to stock options granted during fiscal 2024, 2023 and 2022 and related assumptions are noted in the following table: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Options granted (in millions) 0.6 0.5 0.7 Weighted-average exercise price $ 72.34 $ 74.66 $ 71.07 Weighted-average grant date fair value $ 25.07 $ 25.95 $ 21.01 Assumptions: Risk-free interest rates 4.4 % 4.3 % 1.1 % Expected life (in years) 4.8 4.8 4.8 Expected volatility 33.4 % 33.9 % 34.2 % Dividend yield — — — The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. In projecting expected stock price volatility, the Company uses a combination of historical stock price volatility and implied volatility from observable market prices of similar equity instruments. The Company estimated the expected life of stock options based on historical experience using employee exercise and option expiration data. Stock-Based Compensation Expense Attribution The Company uses the straight-line attribution method to recognize stock-based compensation expense for stock options and restricted stock units (“RSUs”), unless the employee meets the plan retirement provision of reaching a certain age and years of service criteria in which case the expense is accelerated to match the required service period to receive such benefit. The vesting term of stock options is generally four years with annual vesting of 25% per year on the anniversary of the grant date, and RSUs generally vest over three years with annual vesting at 33% per year on the anniversary of the grant date. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. Under ASC 718, the Company's accounting policy is to estimate forfeitures at the time awards are granted and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Based on an analysis of historical forfeitures, the Company has determined a specific forfeiture rate for certain employee groups and has applied forfeiture rates ranging from 0% to 6.0% as of September 28, 2024 depending on the specific employee group. This analysis is re-evaluated annually and the forfeiture rate adjusted as necessary. Ultimately, the actual stock-based compensation expense recognized will only be for those stock options and RSUs that vest. Stock-based compensation expense related to stock options was $14.0 million, $14.2 million, and $12.0 million in fiscal 2024, 2023 and 2022, respectively. Stock compensation expense related to stock units, including RSUs, performance stock units (“PSUs”), free cash flow performance stock units (“FCFs”) and market stock units (“MSUs”) was $61.1 million, $58.5 million, and $48.2 million in fiscal 2024, 2023 and 2022, respectively. The related tax benefit recorded in the Consolidated Statements of Income was $11.4 million, $10.7 million and $8.6 million in fiscal 2024, 2023 and 2022, respectively. At September 28, 2024, there was $10.0 million and $45.0 million of unrecognized compensation expense related to stock options and stock units, respectively, to be recognized over a weighted average period of 2.2 years and 1.7 years, respectively. Share Based Payment Activity The following table summarizes all stock option activity under the Company’s stock option plans for the year ended September 28, 2024: Number Weighted- Weighted- Aggregate Options outstanding at September 30, 2023 4.2 $ 51.63 5.6 $ 77.6 Granted 0.6 72.34 Canceled/ forfeited (0.1) 73.09 Exercised (0.4) 39.89 15.5 Options outstanding at September 28, 2024 4.3 $ 55.32 5.3 $ 108.8 Options exercisable at September 28, 2024 3.1 $ 48.57 4.2 $ 98.5 Options vested and expected to vest at September 28, 2024 (1) 4.2 $ 55.21 5.3 $ 108.6 (1) This represents the number of vested stock options as of September 28, 2024 plus the unvested outstanding options at September 28, 2024 expected to vest in the future, adjusted for estimated forfeitures. During fiscal 2023 and 2022, the total intrinsic value of options exercised (i.e., the difference between the market price on the date of exercise and the price paid by the employee to exercise the options) was $18.4 million and $11.1 million, respectively. A summary of the Company’s RSU, PSU, FCF and MSU activity during the year ended September 28, 2024 is presented below: Non-vested Shares Number of Weighted-Average Non-vested at September 30, 2023 1.6 $ 73.33 Granted 0.9 73.10 Vested (0.7) 70.87 Forfeited (0.1) 72.42 Non-vested at September 28, 2024 1.7 $ 73.84 The number of RSUs vested includes shares withheld on behalf of employees to satisfy minimum statutory tax withholding requirements. The Company pays the minimum statutory tax withholding requirement on behalf of its employees. During fiscal 2024, 2023 and 2022 the total fair value of RSUs vested was $51.5 million, $48.4 million and $43.8 million, respectively. The Company granted 0.7 million, 0.7 million and 0.7 million RSUs during fiscal 2024, 2023 and 2022, respectively. In addition, included in the above chart, the Company also granted 0.1 million, 0.1 million and 0.1 million PSUs during fiscal 2024, 2023, and 2022, respectively, to members of the Company's senior management team, which includes additional shares issued upon achieving metrics within the performance criteria. Each recipient of the PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of the three year performance period provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted $0.1 million, $0.1 million and $0.1 million of FCF PSUs based on a three-year cumulative free cash flow measure (FCF) to its senior management team in fiscal 2024, 2023 and 2022, respectively. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of the three year or one-year measurement periods. The PSUs and FCF PSUs were valued at $71.94, $74.35 and $71.16 per share based on the ending stock price on the date of grant in fiscal 2024, 2023 and 2022, respectively. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million, 0.1 million and 0.1 million MSUs during fiscal 2024, 2023 and 2022, respectively, to its senior management team. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of the three year performance period based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $88.06, $97.91 and $75.43 per share using the Monte Carlo simulation model in fiscal 2024, 2023 and 2022, respectively. These awards cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period regardless of the measurement criteria being met. Employee Stock Purchase Plan The Hologic, Inc. Amended and Restated 2012 Employee Stock Purchase Plan (“2012 ESPP”) provides for the granting of up to 8.5 million shares of the Company’s common stock to eligible employees. The 2012 ESPP plan period is semi-annual and allows participants to purchase the Company’s common stock at 85% of the lower of (i) the market price per share of the common stock on the first day of the offering period or (ii) the market price per share of the common stock on the purchase date. Stock-based compensation expense in fiscal 2024, 2023 and 2022 was $7.2 million, $6.9 million and $6.5 million, respectively. The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the following weighted average assumptions: September 28, 2024 September 30, 2023 September 24, 2022 Assumptions: Risk-free interest rates 5.29 % 4.10 % 0.96 % Expected life (in years) 0.5 0.5 0.5 Expected volatility 33.4 % 34.0 % 34.0 % Dividend yield — — —

401(k) Plan

401(k) Plan	12 Months Ended
401(k) Plan	Sep. 28, 2024
Retirement Benefits [Abstract]
401(k) Plan	401(k) Plan The Company's U.S. employees have access to a qualified 401(k) defined contribution plan. The Company made contributions of $23.3 million, $23.9 million and $21.8 million for fiscal 2024, 2023 and 2022, respectively.

Deferred Compensation Plan

Deferred Compensation Plan	12 Months Ended
Deferred Compensation Plan	Sep. 28, 2024
Compensation Related Costs [Abstract]
Deferred Compensation Plan	Deferred Compensation Plans Nonqualified Deferred Compensation Plan The Company has a Nonqualified Deferred Compensation Plan (“DCP”) which provides non-qualified retirement benefits to a select group of executive officers, senior management and highly compensated employees of the Company. Eligible employees may elect to contribute up to 75% of their annual base salary and 100% of their annual bonus to the DCP and such employee contributions are 100% vested. In addition, the Company may elect to make annual discretionary contributions on behalf of participants in the DCP. Each Company contribution is subject to a three-year vesting schedule, such that each contribution vests one third annually. Employee contributions are recorded within accrued expenses. Upon enrollment into the DCP, employees make investment elections for both their voluntary contributions and discretionary contributions, if any, made by the Company. Earnings and losses on contributions based on these investment elections are recorded as a component of compensation expense in the period earned. Annually, the Compensation Committee of the Board of Directors has approved a discretionary cash contribution to the DCP for each year. Discretionary contributions by the Company to the DCP are held in a Rabbi Trust. The Company records compensation expense for the DCP discretionary contributions ratably over the three-year vesting period of each annual contribution, unless the participant meets the plan retirement provision of reaching a certain age and years of service criteria in which case the expense is accelerated to match the required service period to receive such benefit. Under the DCP, the Company recorded compensation expense related to Company contributions of $3.5 million, $3.9 million and $4.0 million in fiscal 2024, 2023 and 2022, respectively. The full amount of the discretionary contribution, net of forfeitures, along with employee deferrals is recorded within accrued expenses and totaled $82.4 million and $65.4 million at September 28, 2024 and September 30, 2023, respectively. The Company has purchased Company-owned group life insurance contracts, in which both voluntary and discretionary Company DCP contributions are invested, to partially fund payment of the Company’s obligation to the DCP participants. The total amount invested at September 28, 2024 and September 30, 2023 was $71.0 million and $56.1 million, respectively. The values of these life insurance contracts are recorded in other long-term assets. Changes in the cash surrender value of life insurance contracts, which were not significant in fiscal 2024, 2023 and 2022, are recorded within other income (expense), net. Deferred Equity Plan Effective September 17, 2015, the Company adopted the Hologic, Inc. Deferred Equity Plan (the “DEP”). The DEP is designed to allow executives and non-employee Directors to accumulate Company stock in a tax-efficient manner to meet their long-term equity accumulation goals and shareholder ownership guidelines. Under the DEP, eligible participants may elect to defer the settlement of stock units granted under the 2008 Equity Plan until separation from service or separation from service plus a fixed number of years. Participants may defer settlement by vesting tranche. Although the equity will vest on schedule, if deferral of settlement is elected, no shares are issued until the settlement date. The settlement date is the earlier of death, disability, change in control of the Company or separation from service plus the number of years of deferral elected by the participant. While these shares upon vesting are not distributed to the individuals and are not outstanding, these shares are included in basic weighted average shares outstanding used to calculate earnings per share.

Non-cancelable Purchase Commitm

Non-cancelable Purchase Commitments	12 Months Ended
Non-cancelable Purchase Commitments	Sep. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable Purchase Commitments	Non-cancelable Purchase Commitments The Company has certain non-cancelable purchase obligations primarily related to inventory purchases and diagnostics instruments, primarily Panther systems, and to a lesser extent other operating expense commitments. These obligations are not recorded in the Consolidated Balance Sheets. For reasons of quality assurance, sole source availability or cost effectiveness, certain key components and raw materials and instruments are available only from a sole supplier and the Company has certain long-term supply contracts to assure continuity of supply. At September 28, 2024, non-cancelable purchase commitments were as follows: Fiscal 2025 475.9 Fiscal 2026 7.3 Fiscal 2027 3.4 Fiscal 2028 0.9 Fiscal 2029 0.5 Thereafter 0.7 Total $ 488.7

Litigation and Related Matters

Litigation and Related Matters	12 Months Ended
Litigation and Related Matters	Sep. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
Litigation and Related Matters	Litigation and Related Matters On November 4, 2022, a product liability complaint was filed against the Company in Massachusetts state court by a group of plaintiffs who claim they sustained injuries caused by the BioZorb 3D Bioabsorbable Marker, and additional complaints were subsequently filed alleging similar claims. The BioZorb device is an implantable three-dimensional marker that helps clinicians overcome certain challenges presented by breast conserving cancer surgery (lumpectomy). The complaints allege that the plaintiffs suffered side effects that were not disclosed in the BioZorb instructions for use and make various additional claims related to the design, manufacture and marketing of the device. Complaints have been filed on behalf of approximately 100 plaintiffs, one pending in Massachusetts state court, and the remainder in United States District Court for the District of Massachusetts. Discovery is ongoing. While the Company believes it has valid defenses and plans to vigorously defend its position, litigation can be costly and unpredictable, and at this early stage the Company cannot reasonably assess the outcome of this matter.

Business Segments and Geographi

Business Segments and Geographic Information	12 Months Ended
Business Segments and Geographic Information	Sep. 28, 2024
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic Information The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess performance. The Company’s chief operating decision maker is its chief executive officer, and the Company’s reportable segments have been identified based on the types of products manufactured and the end markets to which the products are sold. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of disposable products and supplies, primarily used for diagnostic testing and surgical procedures. The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense and goodwill and intangible asset impairment charges, transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues. Segment information for fiscal 2024, 2023, and 2022 was as follows: Years Ended September 28, September 30, September 24, Total revenues: Diagnostics $ 1,782.0 $ 1,880.1 $ 3,018.5 Breast Health 1,522.9 1,432.7 1,227.8 GYN Surgical 641.3 604.2 522.9 Skeletal Health 84.1 113.4 93.6 $ 4,030.3 $ 4,030.4 $ 4,862.8 Operating income (loss): Diagnostics $ 303.1 $ 193.9 $ 1,359.4 Breast Health 394.5 273.0 183.2 GYN Surgical 185.5 188.9 104.9 Skeletal Health (0.5) 12.6 (7.3) $ 882.6 $ 668.4 $ 1,640.2 Depreciation and amortization: Diagnostics $ 218.8 $ 224.7 $ 274.0 Breast Health 41.6 50.0 58.8 GYN Surgical 48.1 48.0 96.6 Skeletal Health 0.5 0.7 0.7 $ 309.0 $ 323.4 $ 430.1 Capital expenditures: Diagnostics $ 80.2 $ 85.2 $ 96.8 Breast Health 30.9 41.1 14.6 GYN Surgical 16.6 17.0 12.8 Skeletal Health 1.4 0.8 0.3 Corporate 1.1 6.1 2.7 $ 130.2 $ 150.2 $ 127.2 Identifiable assets: Diagnostics $ 2,431.3 $ 2,596.4 $ 2,881.7 Breast Health 1,588.9 1,170.1 1,245.8 GYN Surgical 1,419.9 1,455.4 1,461.5 Skeletal Health 48.3 33.7 27.5 Corporate 3,667.6 3,883.7 3,454.7 $ 9,156.0 $ 9,139.3 $ 9,071.2 The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy, and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of world” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Years Ended September 28, September 30, September 24, United States 75.0 % 75.9 % 71.3 % Europe 13.2 % 12.9 % 18.3 % Asia-Pacific 6.5 % 6.3 % 7.4 % Rest of world 5.3 % 4.9 % 3.0 % 100.0 % 100.0 % 100.0 % The Company’s property, plant and equipment were geographically located as follows: September 28, 2024 September 30, 2023 September 24, 2022 United States $ 379.7 $ 367.6 $ 332.4 Europe 70.6 67.0 72.1 Costa Rica 40.0 36.0 32.1 United Kingdom 32.0 32.4 31.7 Rest of world 15.5 14.0 13.3 $ 537.8 $ 517.0 $ 481.6

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	12 Months Ended
Accrued Expenses and Other Long-Term Liabilities	Sep. 28, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	Accrued Expenses and Other Long-Term Liabilities Accrued expenses and other long-term liabilities consisted of the following: September 28, 2024 September 30, 2023 Accrued Expenses Compensation and employee benefits $ 289.0 $ 280.1 Income and other taxes 69.4 62.3 Operating leases 24.0 20.4 Other 197.3 171.8 $ 579.7 $ 534.6 September 28, 2024 September 30, 2023 Other Long-Term Liabilities Reserve for income tax uncertainties $ 311.8 $ 274.3 Operating leases 83.9 47.1 Other 10.6 13.2 $ 406.3 $ 334.6

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Pay vs Performance Disclosure
Net income	$ 789.5	$ 456	$ 1,302

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
Insider Trading Arrangements	Sep. 28, 2024	Sep. 28, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted		false
Non-Rule 10b5-1 Arrangement Adopted		false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 28, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Subsequent Events Consideration	Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events recorded in the consolidated financial statements as of and for the year ended September 28, 2024, except as noted below. On October 11, 2024, the Company entered into a definitive agreement to acquire Gynesonics, Inc. (“Gynesonics”) for a purchase price of approximately $350.0 million, subject to working capital and other customary adjustments. Gynesonics, located in Redwood, California, develops a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Completion of the acquisition is subject to customary closing conditions, including receipt of required regulatory approvals. Gynesonics will be included in the GYN Surgical reportable segment. On November 19, 2024, the Company executed an accelerated share repurchase agreement (ASR) with JPMorgan Chase & Co., (“JP Morgan”) pursuant to which the Company agreed to repurchase $250 million of the Company’s common stock. Refer to Note 12 for further discussion.
Management's Estimates	Management’s Estimates and Uncertainties The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple performance obligation arrangements, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, accounts receivable reserves, inventory excess and obsolescence reserves, warranty reserves, certain accrued expenses, restructuring and other related charges, contingent liabilities, tax reserves, deferred tax rates and the recoverability of the Company’s net deferred tax assets and related valuation allowances, and stock-based compensation. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including dependence on third-party reimbursements to support the markets of the Company’s products, early stage of development of certain products, rapid technological changes, recoverability of long-lived assets (including intangible assets and goodwill), competition, stability of world financial markets, ability to obtain regulatory approvals, changes in the regulatory environment, limited number of suppliers, customer concentration, integration of acquisitions, substantial indebtedness, government regulations, management of international activities, protection of proprietary rights, patent and other litigation, dependence on contract manufacturers, supply chain constraints, inflation and interest rates, and dependence on key individuals.
Cash Equivalents	Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. Cash equivalents are highly liquid investments with insignificant interest rate risk and maturities of three months or less at the time of acquisition.
Investments and Strategic Investments	Investments Investments in debt securities are classified as available-for-sale and are reported at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. The Company determines the appropriate classification of its investment in debt securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. Strategic Investments The majority of the Company’s strategic investments are in non-marketable equity securities, which are measured at cost, less any impairment, adjusted to fair value for any observable price changes in orderly transactions for identical or similar investments of the same issuer. Investments in entities for which the Company has the ability to exercise significant influence are accounted for under the equity method if the Company holds less than 50 percent of the voting stock and the entity is not a VIE in which the Company is the primary beneficiary in accordance with Accounting Standards Codification (“ASC”) Topic 323, Investments - Equity Method and Joint Ventures . The Company records these investments initially at cost and adjusts the carrying amount to reflect its proportional share of the earnings or losses of the investee. Refer to Note 6 for additional details on strategic investment balances.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, available-for-sale debt securities, equity investments and trade accounts receivable. The Company invests its cash, cash equivalents and available-for-sale debt securities with high credit quality financial institutions. The Company’s customers are principally located in the U.S., Europe and Asia. The Company performs ongoing credit evaluations of the financial condition of its customers and generally does not require collateral. Although the Company is directly affected by the overall financial condition of the healthcare industry, as well as global economic conditions, management does not believe significant credit risk exists as of September 28, 2024. The Company generally has not experienced any material losses related to receivables from individual customers or groups of customers in the healthcare industry. The Company maintains an allowance for doubtful accounts based on accounts past due and historical collection experience.
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value on a first-in, first-out basis. Work-in-process and finished goods inventories consist of materials, labor and manufacturing overhead. The valuation of inventory requires management to estimate excess and obsolete inventory. The Company employs a variety of methodologies to determine the net realizable value of its inventory. Provisions for excess and obsolete inventory are primarily based on management’s estimates of forecasted sales, usage levels and expiration dates, as applicable for certain disposable products. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of product revenues. Inventories consisted of the following: September 28, 2024 September 30, 2023 Raw materials $ 251.4 $ 238.6 Work-in-process 62.0 66.3 Finished goods 366.4 312.7 $ 679.8 $ 617.6
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment is recorded at cost less accumulated depreciation and impairments. The straight-line method of depreciation is used for all property and equipment. Property, plant and equipment consisted of the following: Estimated Useful Life September 28, 2024 September 30, 2023 Equipment 3–10 years $ 378.1 $ 380.0 Equipment under customer usage agreements 3–8 years 523.1 508.1 Buildings and improvements 20–35 years 247.1 230.0 Leasehold improvements Shorter of the Original Lease Term or Estimated Useful Life 44.0 44.4 Land 40.8 41.1 Furniture and fixtures 5–7 years 24.6 19.2 Finance lease right-of-use asset 8.8 8.2 1,266.5 1,231.0 Less - accumulated depreciation and amortization (728.7) (714.0) $ 537.8 $ 517.0 Equipment under customer usage agreements primarily consists of diagnostic instruments located at customer sites but owned by the Company. Generally, the customer has the right to use the equipment for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of disposables, primarily assays, tests and handpieces. The depreciation costs associated with equipment under customer usage agreements are charged to cost of product revenues over the estimated useful life of the equipment. The costs to maintain the equipment in the field are charged to cost of product revenue as incurred. In September 2020 and October 2020, the Company was awarded grants of $7.6 million and $119.3 million, respectively, from the Department of Defense Joint Acquisition Task Force (“DOD”) to expand production capacity for the Company's two SARS-CoV-2 assays. These grants were specifically to fund capital equipment and labor investments to increase manufacturing capacity to enable the Company to provide a certain amount of COVID-19 tests per month for the U.S. market. The Company accounted for the funds received under these grants as a reimbursement of the purchased capital equipment. The Company procured and paid for the capital equipment and necessary resources to build out its facility and construct the manufacturing lines to meet the requirements specified in the grant agreement. Subsequent to the Company paying for the capital equipment, the DOD reimbursed the Company upon it meeting certain requirements. However, the DOD retained title to the assets purchased under the agreement, and title was transferred to the Company upon meeting certain milestones of the manufacturing efforts and obtaining approval from the DOD that the respective milestone had been met. As of the end of fiscal 2022, the Company had completed all milestones under the agreement and was awaiting approval by the DOD. During the second quarter of fiscal 2023, the Company received the final DOD approvals and the final payment from the DOD of $20.5 million, which was recorded as a reduction of the cost basis of the purchased equipment. As of September 30, 2023, no amounts were awaiting approval and all defined milestones were completed. In fiscal 2022, the Company received $75.0 million from the DOD for reimbursement of capital equipment, which was recorded as a reduction of the cost basis of the purchased equipment. In addition, a portion of the DOD grant funded expenditures in connection with the project that did not qualify for capitalization and was recorded as a reduction to expenses, which was $7.6 million in fiscal 2022. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of its Mobidiag business and based on the fair value of the asset group recorded an impairment charge of $12.1 million related to property, plant and equipment. In addition, during the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of its SSI ultrasound imaging business and recorded an impairment charge of $5.8 million related to property, plant and equipment.
Long-Lived Assets	Long-Lived Assets The Company reviews its long-lived assets, which includes property, plant and equipment and identifiable intangible assets (see below for discussion of intangible assets), for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with ASC 360-10-35-15, Property, Plant and Equipment—Impairment or Disposal of Long-Lived Assets
Business Combinations and Acquisition of Intangible Assets	Business Combinations and Acquisition of Intangible Assets The Company accounts for the acquisition of a business in accordance with ASC 805, Business Combinations (ASC 805). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Contingent consideration not deemed to be linked to continuing employment is recorded at fair value on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using a Monte Carlo simulation. These cash flow projections are discounted with an appropriate risk adjusted rate. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured and adjusted as a component of operating expenses based on changes to the underlying assumptions. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded. The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The Company uses the income approach to determine the fair value of developed technology and in-process research and development (“IPR&D”) acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. Developed technology represents patented and unpatented technology and know-how. The value of the in-process projects is based on the project's stage of completion, the complexity of the work completed as of the acquisition date, the projected costs to complete, the contribution of core technologies and other acquired assets, the expected introduction date, the estimated cash flows to be generated upon commercial release and the estimated useful life of the technology. The Company believes that the estimated developed technology and IPR&D amounts represent the fair value at the date of acquisition and do not exceed the amount a third-party would pay for the assets. The significant assumptions used to estimate the fair value of intangible assets include discount rates and certain assumptions that form the basis of the forecasted results, specifically revenue growth rates. These significant assumptions are forward looking and could be affected by future economic and market conditions.
Intangible Assets and Goodwill	Intangible Assets and Goodwill Intangible Assets Intangible assets are initially recorded at fair value and stated net of accumulated amortization and impairments. The Company amortizes its intangible assets that have finite lives using either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized. Amortization is recorded over the estimated useful lives ranging from 5 to 30 years. The Company evaluates the recoverability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of after-tax cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements . Indefinite lived intangible assets, such as IPR&D assets, are initially recorded at fair value and are required to be tested for impairment annually, or more frequently if indicators of impairment are present. The Company’s annual impairment test date is as of the first day of its fourth quarter. Intangible assets consisted of the following: September 28, 2024 September 30, 2023 Description Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,567.0 $ 3,834.0 $ 4,411.0 $ 3,649.5 In-process research and development 25.1 — 25.7 — Customer relationships 609.7 569.8 600.0 550.6 Trade names 260.3 224.5 253.6 212.8 Total acquired intangible assets $ 5,462.1 $ 4,628.3 $ 5,290.3 $ 4,412.9 Internal-use software 25.7 20.5 24.0 17.8 Capitalized software embedded in products 30.2 24.6 27.7 22.7 Total intangible assets $ 5,518.0 $ 4,673.4 $ 5,342.0 $ 4,453.4 During the second quarter of fiscal 2024, in connection with commencing its company-wide annual strategic planning process, the Company identified indicators of impairment in its BioZorb product line, which was part of the Focal acquisition. As a result, the Company performed an undiscounted cash flow analysis pursuant to ASC 360 to determine if the cash flows expected to be generated by the BioZorb product line over the remaining estimated useful life of the primary asset were sufficient to recover the carrying value of the asset group. Based on this analysis, the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. Therefore, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculated the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Based on this analysis, the fair value of the BioZorb asset group was below its carrying value and the Company recorded an impairment charge of $26.8 million during the second quarter of fiscal 2024. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: $25.9 million to developed technology and $0.9 million to trade names, which reduced the carrying value of the assets to $13.9 million and $0.5 million respectively. During the third quarter of fiscal 2024, the Federal Drug Administration classified a prior safety notice for the BioZorb Marker as a Class I recall. This was the technical classification of a prior safety notice only, not a product removal. Following this, the Company lowered its forecasts for this product line, which is an indicator of impairment. Accordingly, the Company performed an undiscounted cash flow analysis, and the cash flows were not sufficient to recover the carrying value of the asset group. The Company performed a fair value analysis and determined that the fair value of the asset group was de minimus. As a result, the Company recorded an impairment charge of $13.3 million and $0.4 million to developed technology and trade names, respectively, to fully write-off the assets. During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible asset from its Mobidiag acquisition for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the DCF model and recorded a $4.3 million impairment charge, reducing the fair value of this asset to $22.4 million. The reduction in the fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trade name intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of $7.3 million to bring the net carrying values to zero. During the third quarter of fiscal 2023, in connection with its company-wide annual budgeting and strategic planning process as well as evaluating the current operating performance of its Mobidiag business, including product design and manufacturing requirements, the Company reassessed its short-term and long-term commercial plans for this business. The Company made certain operational and strategic decisions to invest and focus more on the long-term success of this business, which resulted in the Company significantly reducing its forecasted revenues and operating results. As a result, the Company identified indicators of impairment and performed an undiscounted cash flow analysis pursuant to ASC 360 to determine if the cash flows expected to be generated by the Mobidiag business over the estimated remaining useful life of its primary assets were sufficient to recover the carrying value of the asset group. Based on this analysis the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. As a result, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which was based on a DCF analysis. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows were based on the Company's most recent strategic plan at that time and for periods beyond the strategic plan, the Company's estimates were based on assumed growth rates expected as of the measurement date. The Company believed its assumptions were consistent with the plans and estimates that a market participant would use to manage the business. The discount rate used was intended to reflect the risks inherent in future cash flow projections and was based on an estimate of the weighted average cost of capital (WACC) of market participants relative to the asset group. The Company used a discount rate of 17.0%. Based on this analysis, the fair value of the Mobidiag asset group was below its carrying value. Prior to calculating and allocating the impairment charge, the Company assessed the only in-process research and development intangible asset in this asset group for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the DCF model and recorded a $10.5 million impairment charge, reducing the fair value of this asset to $26.5 million. The reduction in fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project to focus on other projects. To record the asset group to fair value, the Company recorded an impairment charge of $186.9 million during the third quarter of fiscal 2023. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: $153.7 million to developed technology, $10.4 million to customer relationships, $10.7 million to trade names, and $12.1 million to equipment. The Company believed its assumptions used to determine the fair value of the asset group were reasonable. The Company also re-evaluated the remaining useful lives of the intangible assets and concluded no changes were necessary at that time. During the third quarter of fiscal 2023, the Company also identified indicators of impairment associated with its SSI ultrasound imaging asset group. The Company determined that the fair value of this asset group was approximately zero and the carrying value of the long-lived assets was fully impaired. As a result, the Company recorded an impairment charge of $26.4 million, of which $20.6 million was allocated to intangible assets, primarily developed technology, and $5.8 million was allocated to equipment. During the fourth quarter of fiscal 2022, the Company performed its annual impairment test of its Mobidiag IPR&D intangible asset. The Company determined the fair value of the asset utilizing a DCF model and recorded a $27.7 million impairment charge. The reduction in fair value was due to an increase in the discount rate from higher interest rates, a reduction in forecasted revenues and timing of completing the project. During the fourth quarter of fiscal 2022, the Company identified a certain product line associated with the Focal Therapeutics, Inc. acquisition that would no longer be commercially sold. As a result, the Company recorded an impairment charge to write-off a developed technology asset of $8.2 million. During the third quarter of fiscal 2022, the Company identified certain product lines associated with the Faxitron Bioptics, LLC acquisition that would no longer be commercially sold. As a result, the Company recorded an impairment charge to write-off the developed technology assets of $9.2 million. Amortization expense related to developed technology is classified as cost of product revenues—amortization of intangible assets. Amortization expense related to customer relationships and trade names is classified as a component of amortization of intangible assets within operating expenses. The estimated amortization expense at September 28, 2024 for each of the five succeeding fiscal years was as follows: Fiscal 2025 $ 199.3 Fiscal 2026 $ 169.2 Fiscal 2027 $ 82.1 Fiscal 2028 $ 79.0 Fiscal 2029 $ 72.9 Goodwill In accordance with ASC 350, Intangibles—Goodwill and Other (ASC 350), the Company tests goodwill for impairment annually at the reporting unit level and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate, operational performance of the business or key personnel, and an adverse action or assessment by a regulator. In performing the impairment test, the Company utilizes the single-step approach prescribed under Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04). This approach requires a comparison of the carrying value of each reporting unit to its estimated fair value and to the extent the carrying value exceeds the fair value a charge is recorded up to the amount of goodwill in the reporting unit. To estimate the fair value of its reporting units, the Company primarily utilizes the income approach. The income approach is based on a DCF analysis and calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows are based on the Company’s most recent budget and strategic plan and for years beyond this period, the Company’s estimates are based on assumed growth rates expected as of the measurement date. The Company believes its assumptions are consistent with the plans and estimates used to manage the underlying businesses. The discount rates used are intended to reflect the risks inherent in future cash flow projections and are based on estimates of the weighted-average cost of capital (“WACC”) of market participants. The market approach considers comparable market data based on multiples of revenue or earnings before interest, taxes, depreciation and amortization (“EBITDA”) and is primarily used as a corroborative analysis to the results of the DCF analysis. The Company believes its assumptions used to determine the fair value of its reporting units are reasonable. If different assumptions were used, particularly with respect to forecasted cash flows, terminal values, WACCs, or market multiples, different estimates of fair value may result and there could be the potential that an impairment charge could result. Actual operating results and the related cash flows of the reporting units could differ from the estimated operating results and related cash flows. The Company conducted its fiscal 2024 impairment test for its reporting units on the first day of the fourth quarter, and as noted above used DCF and market approaches to estimate the fair value of its reporting units as of June 30, 2024, and ultimately used the fair value determined by the DCF approach in making its impairment test conclusions. As a result of completing this analysis, all of the Company's reporting units had fair values exceeding their carrying values. At September 28, 2024, the Company believes that its reporting units, with goodwill aggregating $3.4 billion, were not at risk of failing the goodwill impairment test based on its current forecasts and qualitative assessment. The Company conducted its fiscal 2023 and 2022 impairment tests for its reporting units on the first day of the fourth quarter of its respective fiscal year, and as noted above used DCF and market approaches to estimate the fair value of its reporting units as of the measurement date, and ultimately used the fair value determined by the DCF approach in making its impairment test conclusions. As a result of completing these analyses, all of the Company's reporting units had fair values exceeding their carrying values. A rollforward of goodwill activity by reportable segment from September 30, 2023 to September 28, 2024 is as follows: Diagnostics Breast Health GYN Surgical Skeletal Health Total Balance at September 30, 2023 $ 1,351.6 $ 787.8 $ 1,133.9 $ 8.0 $ 3,281.3 Endomag acquisition — 138.9 — — 138.9 Foreign currency and other adjustments 14.2 7.9 0.8 — 22.9 Balance at September 28, 2024 $ 1,365.8 $ 934.6 $ 1,134.7 $ 8.0 $ 3,443.1
Other Assets	Other Assets Other assets consisted of the following: September 28, 2024 September 30, 2023 Other Assets Tax receivable $ 37.5 $ 33.0 Operating lease right of use assets 92.2 62.7 Life insurance contracts 71.0 56.1 Deferred tax assets 128.8 56.6 Strategic investments 54.3 15.5 Other 27.0 44.0 $ 410.8 $ 267.9
Research and Software Development Costs	Research and Software Development Costs Costs incurred for the research and development of the Company’s products are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future by the Company for use in research and development activities are deferred. The deferred costs are expensed as the related goods are delivered or the services are performed. The Company accounts for the development costs of software embedded in the Company’s products in accordance with ASC 985, Software. Costs incurred in the research, design and development of software embedded in products to be sold to customers are charged to expense until technological feasibility of the ultimate product to be sold is established. The Company’s policy is that technological feasibility is achieved when a working model, with the key features and functions of the product, is available for customer testing. Software development costs incurred after the establishment of technological feasibility and until the product is available for general release are capitalized, provided recoverability is reasonably assured. Capitalized software development costs are amortized over their estimated useful life and recorded within cost of revenues - product.
Foreign Currency Translation	Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, Foreign Currency Matters. The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s foreign subsidiaries is determined based on the guidance in ASC 830. The majority of the Company's foreign subsidiaries' functional currency is the applicable local currency, although certain of the Company's foreign subsidiaries' functional currency is the U.S. dollar based on the nature of their operations or functions. Assets and liabilities of subsidiaries whose functional currency is the local currency are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in other income (expense), net, in the Consolidated Statements of Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss), which is a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in other income (expense), net, in the Consolidated Statements of Income. During fiscal years 2024, 2023 and 2022, the Company recorded net foreign exchange (losses) gains of $(21.0) million, $(7.9) million, and $48.5 million, respectively.
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income (Loss) Other comprehensive income (loss) includes certain transactions that have generally been reported in the statement of stockholders’ equity. The following tables summarize the components and changes in accumulated balances of other comprehensive loss for the periods presented: Year Ended September 28, 2024 Year Ended September 30, 2023 Foreign Currency Translation Pension Plan Available-for-sale debt securities Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plan Hedged Interest Rate Swaps Total Beginning Balance $ (168.0) $ 0.3 $ — $ 20.1 $ (147.6) $ (267.2) $ (0.3) $ 29.3 $ (238.2) Other comprehensive income (loss) before reclassifications 53.1 (0.3) 1.6 (18.3) 36.1 99.2 0.6 (9.2) 90.6 Ending Balance $ (114.9) $ — $ 1.6 $ 1.8 $ (111.5) $ (168.0) $ 0.3 $ 20.1 $ (147.6)
Derivatives	Derivatives Interest Rate Risk - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (“AOCI”) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement; see Note 9) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was $1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on $1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is $500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $500 million of principal. The changes in the fair value of the swaps are recorded in AOCI and net of taxes were a loss of $18.3 million, a loss of $9.2 million and a gain of $44.0 million, respectively, for fiscal years 2024, 2023, and 2022, respectively. The fair value of these derivative instruments was in an asset position of $2.9 million as of September 28, 2024. Forward Foreign Currency Contracts, Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts (including collars) to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the U.K. Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The Company uses collars and forward contracts as part of its foreign currency hedging strategy to manage the risk associated with fluctuations in foreign currency exchange rates. Collars, which are a combination of a put and call option, limit the range of possible positive or negative returns on an underlying exposure to a specific range. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the years ended September 28, 2024, September 30, 2023, and September 24, 2022 were as follows: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 3.9 $ 1.3 $ 68.5 Foreign currency option contracts — (4.0) — $ 3.9 $ (2.7) $ 68.5 Amount of unrealized (loss) gain recognized in income Forward foreign currency contracts $ (20.9) $ (7.5) $ 14.7 Foreign currency option contracts 0.8 (5.5) 5.5 $ (20.1) $ (13.0) $ 20.2 Amount of gain (loss) recognized in income Total $ (16.2) $ (15.7) $ 88.7 As of September 28, 2024, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and are used to hedge forecasted transactions denominated in the Euro, U.K. pound, Australian dollar, Canadian dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of $378.5 million. Financial Instrument Presentation The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of September 28, 2024: Balance Sheet Location September 28, 2024 September 30, 2023 Assets: Derivative instrument designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets $ 3.1 $ 16.2 Interest rate swap contracts Other assets — 10.7 $ 3.1 $ 26.9 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ — $ 8.4 Foreign currency option contracts Prepaid expenses and other current assets 0.8 — $ 0.8 $ 8.4 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Other long-term liabilities 0.2 — Total $ 0.2 $ — Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 12.6 $ — The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Amount of (loss) gain recognized in other comprehensive income (loss), net of taxes: Interest rate swap $ (18.3) $ (9.2) $ 44.0 Total $ (18.3) $ (9.2) $ 44.0
Accounts Receivable and Reserves	Trade Receivables and Allowance for Credit Losses The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity from new macroeconomic events, such as pandemics and inflation, must be taken into consideration. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses for fiscal 2024, 2023 and 2022: Balance at Charged to Write- Balance at Period Ended: September 28, 2024 $ 38.5 $ 5.7 $ (2.8) $ 41.4 September 30, 2023 $ 37.7 $ 3.7 $ (2.9) $ 38.5 September 24, 2022 $ 40.5 $ 4.2 $ (7.0) $ 37.7
Cost of Service and Other Revenues	Cost of Service and Other Revenues Cost of service and other revenues primarily represents payroll and related costs associated with the Company’s professional services, employees, consultants, infrastructure costs and overhead allocations, including depreciation, rent and materials consumed in providing the service.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for share-based payments in accordance with ASC 718, Stock Compensation (ASC 718) .
Net Income Per Share	Net Income Per Share Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average number of common shares and the dilutive effect of potential future issuances of common stock from outstanding stock options and restricted stock units for the period outstanding determined by applying the treasury stock method. In accordance with ASC 718, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of in-the-money stock options and restricted stock units. This results in the assumed buyback of additional shares, thereby reducing the dilutive impact of equity awards.
Product Warranties	Product Warranties The Company generally offers a one-year warranty for its products. The Company provides for the estimated cost of product warranties at the time product revenue is recognized. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. Product warranty activity for fiscal 2024 and 2023 was as follows: Balance at Provisions Acquired Settlements/ Balance at End Period ended: September 28, 2024 $ 8.3 $ 9.0 $ 0.1 $ (7.5) $ 9.9 September 30, 2023 $ 8.0 $ 6.8 $ 0.8 $ (7.3) $ 8.3
Advertising Costs	Advertising Costs Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising. Advertising costs, which include trade shows and conventions, were approximately $22.6 million, $31.4 million and $78.1 million for fiscal 2024, 2023 and 2022, respectively, and were included in selling and marketing expense in the Consolidated Statements of Income. The higher advertising costs in fiscal 2022 was primarily due to the Company's agreement to be a sponsor of the Women's Tennis Association and related structure of the arrangement and the production and airing of its Super Bowl commercial in February 2022.
Recently Issued Accounting Pronouncements	New Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures . The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in Update 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its consolidated financial position and results of operations. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures . The FASB issued this Update to enhance income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its consolidated financial position and results of operations. In March 2024, the SEC issued its final climate disclosure rule, which requires the disclosure of Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics in annual reports and registration statements, when material. Disclosure requirements were to begin phasing in for fiscal years beginning on or after January 1, 2025, however on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. The Company is monitoring SEC developments and evaluating the impact of the new rule to its financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 28, 2024
Accounting Policies [Abstract]
Supplemental Cash Flow Statement Information	Supplemental Cash Flow Statement Information Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Cash paid during the period for income taxes $ 137.9 $ 296.1 $ 36.2 Cash paid during the period for interest $ 117.1 $ 105.4 $ 99.7 Non-Cash Financing Activities: Fair value of contingent consideration at acquisition $ — $ 1.1 $ — Cash paid for income taxes presented above is net of tax refunds of $19.6 million, $39.3 million and $430.4 million for fiscal years 2024, 2023 and 2022, respectively. The fiscal 2024 and 2023 refunds received primarily related to tax filings and over-payments made in the ordinary course of business, while the fiscal 2022 refunds were primarily related to federal and state loss carryback claims.
Schedule of Inventories	Inventories consisted of the following: September 28, 2024 September 30, 2023 Raw materials $ 251.4 $ 238.6 Work-in-process 62.0 66.3 Finished goods 366.4 312.7 $ 679.8 $ 617.6
Schedule of Property, Plant and Equipment	Property, plant and equipment consisted of the following: Estimated Useful Life September 28, 2024 September 30, 2023 Equipment 3–10 years $ 378.1 $ 380.0 Equipment under customer usage agreements 3–8 years 523.1 508.1 Buildings and improvements 20–35 years 247.1 230.0 Leasehold improvements Shorter of the Original Lease Term or Estimated Useful Life 44.0 44.4 Land 40.8 41.1 Furniture and fixtures 5–7 years 24.6 19.2 Finance lease right-of-use asset 8.8 8.2 1,266.5 1,231.0 Less - accumulated depreciation and amortization (728.7) (714.0) $ 537.8 $ 517.0
Schedule of Intangible Assets	Intangible assets consisted of the following: September 28, 2024 September 30, 2023 Description Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,567.0 $ 3,834.0 $ 4,411.0 $ 3,649.5 In-process research and development 25.1 — 25.7 — Customer relationships 609.7 569.8 600.0 550.6 Trade names 260.3 224.5 253.6 212.8 Total acquired intangible assets $ 5,462.1 $ 4,628.3 $ 5,290.3 $ 4,412.9 Internal-use software 25.7 20.5 24.0 17.8 Capitalized software embedded in products 30.2 24.6 27.7 22.7 Total intangible assets $ 5,518.0 $ 4,673.4 $ 5,342.0 $ 4,453.4
Schedule of Estimated Amortization Expense	The estimated amortization expense at September 28, 2024 for each of the five succeeding fiscal years was as follows: Fiscal 2025 $ 199.3 Fiscal 2026 $ 169.2 Fiscal 2027 $ 82.1 Fiscal 2028 $ 79.0 Fiscal 2029 $ 72.9
Rollforward of Goodwill Activity by Reportable Segment	A rollforward of goodwill activity by reportable segment from September 30, 2023 to September 28, 2024 is as follows: Diagnostics Breast Health GYN Surgical Skeletal Health Total Balance at September 30, 2023 $ 1,351.6 $ 787.8 $ 1,133.9 $ 8.0 $ 3,281.3 Endomag acquisition — 138.9 — — 138.9 Foreign currency and other adjustments 14.2 7.9 0.8 — 22.9 Balance at September 28, 2024 $ 1,365.8 $ 934.6 $ 1,134.7 $ 8.0 $ 3,443.1
Schedule of Other Assets	Other assets consisted of the following: September 28, 2024 September 30, 2023 Other Assets Tax receivable $ 37.5 $ 33.0 Operating lease right of use assets 92.2 62.7 Life insurance contracts 71.0 56.1 Deferred tax assets 128.8 56.6 Strategic investments 54.3 15.5 Other 27.0 44.0 $ 410.8 $ 267.9
Changes in accumulated balances of other comprehensive income	The following tables summarize the components and changes in accumulated balances of other comprehensive loss for the periods presented: Year Ended September 28, 2024 Year Ended September 30, 2023 Foreign Currency Translation Pension Plan Available-for-sale debt securities Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plan Hedged Interest Rate Swaps Total Beginning Balance $ (168.0) $ 0.3 $ — $ 20.1 $ (147.6) $ (267.2) $ (0.3) $ 29.3 $ (238.2) Other comprehensive income (loss) before reclassifications 53.1 (0.3) 1.6 (18.3) 36.1 99.2 0.6 (9.2) 90.6 Ending Balance $ (114.9) $ — $ 1.6 $ 1.8 $ (111.5) $ (168.0) $ 0.3 $ 20.1 $ (147.6)
Schedule of Accumulated Other Comprehensive Income (Loss) Related to Derivatives	Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the years ended September 28, 2024, September 30, 2023, and September 24, 2022 were as follows: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 3.9 $ 1.3 $ 68.5 Foreign currency option contracts — (4.0) — $ 3.9 $ (2.7) $ 68.5 Amount of unrealized (loss) gain recognized in income Forward foreign currency contracts $ (20.9) $ (7.5) $ 14.7 Foreign currency option contracts 0.8 (5.5) 5.5 $ (20.1) $ (13.0) $ 20.2 Amount of gain (loss) recognized in income Total $ (16.2) $ (15.7) $ 88.7
Schedule of Derivative Instruments on the Consolidated Balance Sheets	The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of September 28, 2024: Balance Sheet Location September 28, 2024 September 30, 2023 Assets: Derivative instrument designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets $ 3.1 $ 16.2 Interest rate swap contracts Other assets — 10.7 $ 3.1 $ 26.9 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ — $ 8.4 Foreign currency option contracts Prepaid expenses and other current assets 0.8 — $ 0.8 $ 8.4 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Other long-term liabilities 0.2 — Total $ 0.2 $ — Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 12.6 $ —
Schedule of Unrealized Loss Recognized in AOCI	The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Amount of (loss) gain recognized in other comprehensive income (loss), net of taxes: Interest rate swap $ (18.3) $ (9.2) $ 44.0 Total $ (18.3) $ (9.2) $ 44.0
Accounts Receivable Reserve Activity	The following is a rollforward of the allowance for credit losses for fiscal 2024, 2023 and 2022: Balance at Charged to Write- Balance at Period Ended: September 28, 2024 $ 38.5 $ 5.7 $ (2.8) $ 41.4 September 30, 2023 $ 37.7 $ 3.7 $ (2.9) $ 38.5 September 24, 2022 $ 40.5 $ 4.2 $ (7.0) $ 37.7
Schedule of Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts for fiscal 2024, 2023, and 2022 was as follows: September 28, 2024 September 30, 2023 September 24, 2022 Basic weighted average common shares outstanding 235,723 246,772 251,527 Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units 1,830 2,059 2,318 Diluted weighted average common shares outstanding 237,553 248,831 253,845 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 1,171 981 1,049
Schedule of Product Warranty Activity	Product warranty activity for fiscal 2024 and 2023 was as follows: Balance at Provisions Acquired Settlements/ Balance at End Period ended: September 28, 2024 $ 8.3 $ 9.0 $ 0.1 $ (7.5) $ 9.9 September 30, 2023 $ 8.0 $ 6.8 $ 0.8 $ (7.3) $ 8.3

Revenue (Tables)

Revenue (Tables)	12 Months Ended
Revenue (Tables)	Sep. 28, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Business (in millions) United States Intl. Total United States Intl. Total United States Intl. Total Diagnostics: Cytology & Perinatal $ 283.3 $ 195.9 $ 479.2 $ 297.4 $ 183.2 $ 480.6 $ 300.4 $ 174.3 $ 474.7 Molecular Diagnostics 999.1 273.4 1,272.5 1,061.0 300.7 1,361.7 1,694.5 816.9 2,511.4 Blood Screening 30.3 — 30.3 37.8 — 37.8 32.4 — 32.4 Total 1,312.7 469.3 1,782.0 1,396.2 483.9 1,880.1 2,027.3 991.2 3,018.5 Breast Health: Breast Imaging 932.9 277.8 1,210.7 884.0 260.2 1,144.2 735.1 216.5 951.6 Interventional Breast Solutions 244.6 67.6 312.2 232.6 55.9 288.5 222.1 54.1 276.2 Total 1,177.5 345.4 1,522.9 1,116.6 316.1 1,432.7 957.2 270.6 1,227.8 GYN Surgical 482.5 158.8 641.3 475.3 128.9 604.2 423.8 99.1 522.9 Skeletal Health 51.4 32.7 84.1 69.9 43.5 113.4 59.6 34.0 93.6 Total $ 3,024.1 $ 1,006.2 $ 4,030.3 $ 3,058.0 $ 972.4 $ 4,030.4 $ 3,467.9 $ 1,394.9 $ 4,862.8 Years Ended Geographic Regions ( in millions ) September 28, 2024 September 30, 2023 September 24, 2022 United States $ 3,024.1 $ 3,058.0 $ 3,467.9 Europe 532.7 520.3 888.5 Asia-Pacific 259.6 255.7 359.7 Rest of World 213.9 196.4 146.7 $ 4,030.3 $ 4,030.4 $ 4,862.8 The following table provides revenue recognized by source: Years Ended Revenue by type ( in millions ) September 28, 2024 September 30, 2023 September 24, 2022 Disposables $ 2,490.2 $ 2,539.4 $ 3,603.6 Capital equipment, components and software 764.9 740.5 587.6 Service 758.2 730.5 652.4 Other 17.0 20.0 19.2 $ 4,030.3 $ 4,030.4 $ 4,862.8

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Sep. 28, 2024
Leases [Abstract]
Assets And Liabilities, Lessee	The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 28, 2024 September 30, 2023 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 92.2 $ — $ 62.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 5.0 $ — $ 5.6 Liabilities Operating lease liabilities (current) Accrued expenses $ 24.0 $ — $ 20.4 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.3 $ — $ 3.1 Operating lease liabilities (non-current) Other long-term liabilities $ 83.9 $ — $ 47.1 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 12.2 $ — $ 15.3 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 28, 2024 As of September 30, 2023 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 5.92 4.83 4.18 5.69 Weighted average discount rate 5.0 % 4.1 % 2.9 % 4.2 %
Lease, Cost	The following table provides information related to the Company’s operating and finance leases: Year Ended September 28, 2024 Year Ended September 30, 2023 Operating lease cost (a) $ 41.3 $ 29.9 Finance lease cost - amortization of right-of-use assets $ 0.7 $ 0.7 Finance lease cost - interest cost $ 0.8 $ 0.8 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.7 $ 0.9 Operating cash flows from operating leases $ 26.1 $ 28.3 Financing cash flows from finance leases $ 3.8 $ 4.0 Total cash paid for amounts included in the measurement of lease liabilities $ 30.6 $ 33.2 ROU assets arising from entering into new operating lease obligations (b) $ 60.4 $ 15.7 ROU assets arising from entering into new finance lease obligations $ — $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 28, 2024. During the first quarter of fiscal 2024, in conjunction with the strategy change to move the Mobidiag development activities and operations to the Company’s San Diego, California location, the Company recorded a lease asset impairment charge of $12.5 million. Please refer to Footnote 8 for additional details. (b) During fiscal 2024, the Company renewed two leases at the Company’s Marlborough, Massachusetts locations in the amount of $23.3 million and $8.4 million for a term of 10 years and 5 years, respectively.
Finance Lease, Liability, Maturity	The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance leases as of September 28, 2024: Fiscal Year Operating Leases Finance Leases 2025 $ 28.7 $ 3.8 2026 25.1 3.8 2027 20.8 4.0 2028 14.4 3.0 2029 8.0 0.6 Thereafter 29.6 1.7 Total future minimum lease payments 126.6 16.9 Less: imputed interest (18.7) (1.4) Present value of lease liabilities $ 107.9 $ 15.5
Lessee, Operating Lease, Liability, Maturity	The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance leases as of September 28, 2024: Fiscal Year Operating Leases Finance Leases 2025 $ 28.7 $ 3.8 2026 25.1 3.8 2027 20.8 4.0 2028 14.4 3.0 2029 8.0 0.6 Thereafter 29.6 1.7 Total future minimum lease payments 126.6 16.9 Less: imputed interest (18.7) (1.4) Present value of lease liabilities $ 107.9 $ 15.5
Operating Lease, Lease Income	The future minimum annual rental income payments under these lease and sublease agreements at September 28, 2024 are as follows: Fiscal 2025 $ 1.2 Fiscal 2026 1.1 Fiscal 2027 1.1 Fiscal 2028 0.8 Fiscal 2029 0.4 Thereafter 0.6 Total $ 5.2

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
Business Combinations (Tables)	Sep. 28, 2024
Business Combinations [Abstract]
Schedule of Purchase Price Allocation	The purchase price was allocated to Endomag's preliminary tangible and identifiable intangible assets and liabilities based on their preliminary estimated fair values as of July 25, 2024, as set forth below. Cash $ 16.2 Accounts receivable 5.5 Inventory 14.9 Other assets 7.0 Accounts payable and accrued expenses (22.6) Identifiable intangible assets: Developed technology 180.9 Trade names 7.4 Customer relationship 6.5 In-process research and development 3.0 Deferred income taxes, net (43.8) Goodwill 138.9 Purchase Price $ 313.9 The purchase price was allocated to Bolder’s tangible and identifiable intangible assets and liabilities based on their estimated fair values as of November 29, 2021, as set forth below. Cash $ 1.9 Accounts receivable 1.3 Inventory 3.3 Other assets 3.0 Accounts payable and accrued expenses (3.2) Identifiable intangible assets: Developed technology 73.6 Customer relationship 21.7 Trade names 1.4 Deferred income taxes, net (11.7) Goodwill 68.8 Purchase Price $ 160.1

Disposition (Tables)

Disposition (Tables)	12 Months Ended
Disposition (Tables)	Sep. 28, 2024
Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract]
Disposal Groups, Including Discontinued Operations	The assets and liabilities of the disposed business at the date of disposition were as follows: Assets: Cash $ 33.2 Accounts receivable 4.5 Inventory 16.2 Prepaid expenses and other assets 8.6 Valuation allowance (50.6) Total assets held-for-sale $ 11.9 Liabilities: Accounts payable $ 3.1 Accrued expenses 5.1 Total liabilities held-for-sale $ 8.2

Restructuring Charges (Tables)

Restructuring Charges (Tables)	12 Months Ended
Restructuring Charges (Tables)	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
Charges Taken Related to Restructuring Actions	The following table displays charges taken related to restructuring actions in fiscal 2024, 2023 and 2022 and a rollforward of the charges to the accrued balances as of September 28, 2024: Fiscal 2024 Actions Fiscal 2023 Actions Fiscal 2022 Actions Other Total Restructuring Charges Fiscal 2022 charges: Workforce reductions $ — $ — $ 2.6 $ (0.7) $ 1.9 Facility closure costs — — 0.5 — 0.5 Fiscal 2022 restructuring charges $ — $ — $ 3.1 $ (0.7) $ 2.4 Fiscal 2023 charges: Workforce reductions $ — $ 5.5 $ 6.0 $ — $ 11.5 Other costs — — 0.5 — 0.5 Fiscal 2023 restructuring charges $ — $ 5.5 $ 6.5 $ — $ 12.0 Fiscal 2024 charges: Lease asset impairment charge $ 12.5 $ — $ — $ — $ 12.5 Accelerated depreciation expense 7.2 — — — 7.2 Workforce reductions 15.8 — 3.9 — 19.7 Other costs 1.2 — 0.5 — 1.7 Fiscal 2024 restructuring charges $ 36.7 $ — $ 4.4 $ — $ 41.1
Charges Taken Related to Accrued Restructuring Actions	Fiscal 2024 Actions Fiscal 2023 Actions Fiscal 2022 Actions Other Total Rollforward of Accrued Restructuring Balance as of September 25, 2021 $ — $ — $ — $ 4.1 $ 4.1 Fiscal 2022 restructuring charges $ — $ — $ 3.1 $ (0.7) $ 2.4 Severance payments and adjustments — — (0.4) (3.0) (3.4) Balance as of September 24, 2022 $ — $ — $ 2.7 $ 0.4 $ 3.1 Fiscal 2023 restructuring charges $ — $ 5.5 $ 6.5 $ — $ 12.0 Severance payments and adjustments — (3.2) (2.5) (0.4) (6.1) Balance as of September 30, 2023 $ — $ 2.3 $ 6.7 $ — $ 9.0 Fiscal 2024 restructuring charges $ 36.7 $ — $ 4.4 $ — $ 41.1 Non-cash impairment charge (12.5) — — — (12.5) Non-cash accelerated depreciation charge (7.2) — — — (7.2) Severance payments and adjustments (11.5) (2.0) (4.9) — (18.4) Balance as of September 28, 2024 $ 5.5 $ 0.3 $ 6.2 $ — $ 12.0

Borrowings and Credit Arrange_2

Borrowings and Credit Arrangements (Tables)	12 Months Ended
Borrowings and Credit Arrangements (Tables)	Sep. 28, 2024
Debt Disclosure [Abstract]
Company's Borrowings and Interest Expense	The Company’s borrowings consisted of the following: September 28, September 30, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 37.5 $ 287.0 Total current debt obligations $ 37.5 $ 287.0 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,158.7 1,195.6 2028 Senior Notes 397.6 396.8 2029 Senior Notes 940.8 938.8 Total long-term debt obligations 2,497.1 2,531.2 Total debt obligations $ 2,534.6 $ 2,818.2 Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Interest Rate Interest Expense (1) Non-Cash Interest Expense Interest Expense (1) Non-Cash Interest Expense Interest Expense (1) Non-Cash Interest Expense 2029 Senior Notes 3.250 % $ 32.9 $ 2.1 $ 33.5 $ 2.1 $ 32.9 $ 2.1 2028 Senior Notes 4.625 % 19.2 0.7 19.5 0.7 19.2 0.7 Total $ 52.1 $ 2.8 $ 53.0 $ 2.8 $ 52.1 $ 2.8 (1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount.
Schedule Of Long Term Debt By Maturity Table	The debt maturity schedule for the Company’s obligations as of September 28, 2024 was as follows: 2025 2026 2027 2028 2029 2030 and Thereafter Total Term Loan $ 37.5 $ 1,160.0 $ — $ — $ — $ — $ 1,197.5 2028 Senior Notes — — — 400.0 — — 400.0 2029 Senior Notes — — — — 950.0 — 950.0 $ 37.5 $ 1,160.0 $ — $ 400.0 $ 950.0 $ — $ 2,547.5
Interest Income and Interest Expense Disclosure	Interest expense, non-cash interest expense, the weighted average interest rate, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Interest expense (1) $ 85.8 $ 92.4 $ 31.8 Non-cash interest expense $ 2.2 $ 2.3 $ 2.2 Weighted average interest rate 6.39 % 5.84 % 1.74 % Interest rate at end of period 5.96 % 6.42 % 4.18 % (1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Sep. 28, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following: Fair Value Measurements at September 28, 2024 Fair Value Quoted Prices in Significant Significant Assets: Money market mutual funds $ 341.7 $ 341.7 $ — $ — U.S. Treasury securities 626.3 626.3 — — Commercial paper 24.9 24.9 — — Interest rate swaps 3.1 — 3.1 — Foreign currency option contracts 0.8 — 0.8 — Total $ 996.8 $ 992.9 $ 3.9 $ — Liabilities: Contingent consideration $ 1.1 $ — $ — $ 1.1 Interest rate swaps 0.2 — 0.2 — Forward foreign currency contracts 12.6 — 12.6 — Total $ 13.9 $ — $ 12.8 $ 1.1 Fair Value Measurements at September 30, 2023 Fair Value Quoted Prices in Significant Significant Assets: Interest rate swaps $ 26.9 $ — $ 26.9 $ — Forward foreign currency contracts 8.4 — 8.4 — Total $ 35.3 $ — $ 35.3 $ — Liabilities: Contingent consideration $ 2.0 $ — $ — $ 2.0 Total $ 2.0 $ — $ — $ 2.0 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the years ended September 28, 2024, September 30, 2023, and September 24, 2022 were as follows: Years Ended 2024 2023 2022 Balance at beginning of period $ 2.0 $ 23.4 $ 75.1 Contingent consideration recorded at acquisition — 1.1 — Fair value adjustments 1.7 (14.9) (39.5) Payments (2.6) (7.6) (12.2) Balance at end of period $ 1.1 $ 2.0 $ 23.4
Schedule of Cash and Cash Equivalents	The Company’s cash and cash equivalents and short and long-term investments as of September 28, 2024 were as follows: Valuation Balance Sheet Classification in millions Cost Unrealized Gains Unrealized Losses Fair Value Cash and cash equivalents Investments Cash $ 1,437.1 $ — $ — $ 1,437.1 $ 1,437.1 $ — Money market mutual funds 341.7 — — 341.7 341.7 — U.S. Treasury debt securities 624.7 1.6 — 626.3 356.5 269.8 Commercial paper 24.9 — — 24.9 24.9 — Total $ 2,428.4 $ 1.6 $ — $ 2,430.0 $ 2,160.2 $ 269.8
Debt Securities, Available-for-Sale, Schedule of Maturity	The fair value of the available-for-sale securities by contractual maturity as of September 28, 2024 and September 30, 2023 are as follows: September 28, 2024 September 30, 2023 in millions Fair Value Fair Value Due in three months or less $ 723.1 $ — Due after three months through one year 173.4 — Due after one year through five years 96.4 — Total available-for-sale securities $ 992.9 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Sep. 28, 2024
Income Tax Disclosure [Abstract]
Income (Loss) Before Income Taxes	The Company’s income before income taxes consisted of the following: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Domestic $ 609.4 $ 861.4 $ 1,340.3 Foreign 255.7 (185.3) 247.9 $ 865.1 $ 676.1 $ 1,588.2
Provision for Income Taxes	The provision (benefit) for income taxes contained the following components: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Federal: Current $ 91.6 $ 250.6 $ 298.6 Deferred (50.9) (72.1) (129.8) 40.7 178.5 168.8 State: Current 14.2 45.9 54.8 Deferred (7.5) (9.4) (9.5) 6.7 36.5 45.3 Foreign: Current 41.9 32.7 99.0 Deferred (13.7) (27.6) (26.9) 28.2 5.1 72.1 $ 75.6 $ 220.1 $ 286.2
Reconciliation of Income Tax (Benefit) at U.S. Federal Statutory Rate to Company's Effective Tax Rate	The income tax provision differed from the tax provision computed at the U.S. federal statutory rate due to the following: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Income tax provision at federal statutory rate 21.0 % 21.0 % 21.0 % Increase (decrease) in tax resulting from: Cynosure loss on sale and carryback — — (1.2) State income taxes, net of federal benefit 2.5 4.1 2.9 U.S. tax on foreign earnings 0.5 (1.0) (2.6) Internal Restructuring — — (0.9) Tax credits (1.6) (1.1) (0.5) Unrecognized tax benefits 3.9 3.5 0.2 Compensation 1.0 0.8 0.2 Foreign rate differential (6.8) (4.8) (0.8) Change in deferred tax — — 0.4 Assets held-for-sale charge — 1.5 — Change in valuation allowance 2.7 8.2 0.4 Return to provision (1.2) (1.9) (0.7) Worthless stock deduction (12.4) — — Other (0.9) 2.3 (0.4) 8.7 % 32.6 % 18.0 %
Significant Components of the Company's Deferred Tax Assets and Liabilities	The Company’s significant deferred tax assets and liabilities were as follows: September 28, 2024 September 30, 2023 Deferred tax assets Net operating loss and other tax carryforwards $ 137.1 $ 125.8 Capitalized research and development 96.8 70.1 Non-deductible accruals 41.0 32.7 Non-deductible reserves 37.8 42.8 Stock-based compensation 21.9 19.8 Nonqualified deferred compensation plan 15.9 13.5 Lease liability 26.2 14.0 Other temporary differences 21.0 5.9 397.7 324.6 Less: valuation allowance (143.1) (114.7) $ 254.6 $ 209.9 Deferred tax liabilities Depreciation and amortization $ (161.8) $ (160.3) Right of use asset (23.4) (13.2) $ (185.2) $ (173.5) $ 69.4 $ 36.4
Activity of the Company's Unrecognized Income Tax Benefits	The Company’s unrecognized income tax benefits activity for fiscal 2024, 2023 and 2022 was as follows: 2024 2023 2022 Balance at beginning of fiscal year $ 256.5 $ 247.6 $ 212.8 Tax positions related to current year: Additions 7.8 6.8 45.9 Tax positions related to prior years: Additions related to change in estimate 11.8 4.5 21.5 Reductions (2.1) — (6.6) Lapses in statutes of limitations and settlements (0.8) (2.4) (26.0) Balance as of the end of the fiscal year $ 273.2 $ 256.5 $ 247.6

Stockholders' Equity and Stoc_2

Stockholders' Equity and Stock-Based Compensation (Tables)	12 Months Ended
Stockholders' Equity and Stock-Based Compensation (Tables)	Sep. 28, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Expense in Consolidated Statement of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations in fiscal 2024, 2023 and 2022: 2024 2023 2022 Cost of revenues $ 10.7 $ 10.5 $ 9.1 Research and development 10.3 10.5 8.8 Selling and marketing 13.4 12.0 10.5 General and administrative 47.8 46.6 38.3 Restructuring 0.1 — — $ 82.3 $ 79.6 $ 66.7
Information Pertaining to Stock Options Granted and Related Assumptions	Information pertaining to stock options granted during fiscal 2024, 2023 and 2022 and related assumptions are noted in the following table: Years Ended September 28, 2024 September 30, 2023 September 24, 2022 Options granted (in millions) 0.6 0.5 0.7 Weighted-average exercise price $ 72.34 $ 74.66 $ 71.07 Weighted-average grant date fair value $ 25.07 $ 25.95 $ 21.01 Assumptions: Risk-free interest rates 4.4 % 4.3 % 1.1 % Expected life (in years) 4.8 4.8 4.8 Expected volatility 33.4 % 33.9 % 34.2 % Dividend yield — — —
Stock Option Activity	The following table summarizes all stock option activity under the Company’s stock option plans for the year ended September 28, 2024: Number Weighted- Weighted- Aggregate Options outstanding at September 30, 2023 4.2 $ 51.63 5.6 $ 77.6 Granted 0.6 72.34 Canceled/ forfeited (0.1) 73.09 Exercised (0.4) 39.89 15.5 Options outstanding at September 28, 2024 4.3 $ 55.32 5.3 $ 108.8 Options exercisable at September 28, 2024 3.1 $ 48.57 4.2 $ 98.5 Options vested and expected to vest at September 28, 2024 (1) 4.2 $ 55.21 5.3 $ 108.6 (1) This represents the number of vested stock options as of September 28, 2024 plus the unvested outstanding options at September 28, 2024 expected to vest in the future, adjusted for estimated forfeitures.
Restricted Stock Unit Activity	A summary of the Company’s RSU, PSU, FCF and MSU activity during the year ended September 28, 2024 is presented below: Non-vested Shares Number of Weighted-Average Non-vested at September 30, 2023 1.6 $ 73.33 Granted 0.9 73.10 Vested (0.7) 70.87 Forfeited (0.1) 72.42 Non-vested at September 28, 2024 1.7 $ 73.84
Black-Scholes Model Weighted Average Assumptions Used to Estimate Fair Value of Shares to Be Issued as of Grant Date	The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the following weighted average assumptions: September 28, 2024 September 30, 2023 September 24, 2022 Assumptions: Risk-free interest rates 5.29 % 4.10 % 0.96 % Expected life (in years) 0.5 0.5 0.5 Expected volatility 33.4 % 34.0 % 34.0 % Dividend yield — — —

Non-cancelable Purchase Commi_2

Non-cancelable Purchase Commitments (Tables)	12 Months Ended
Non-cancelable Purchase Commitments (Tables)	Sep. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
Unrecorded Unconditional Purchase Obligations Disclosure	At September 28, 2024, non-cancelable purchase commitments were as follows: Fiscal 2025 475.9 Fiscal 2026 7.3 Fiscal 2027 3.4 Fiscal 2028 0.9 Fiscal 2029 0.5 Thereafter 0.7 Total $ 488.7

Business Segments and Geograp_2

Business Segments and Geographic Information (Tables)	12 Months Ended
Business Segments and Geographic Information (Tables)	Sep. 28, 2024
Segment Reporting [Abstract]
Segment Information	Segment information for fiscal 2024, 2023, and 2022 was as follows: Years Ended September 28, September 30, September 24, Total revenues: Diagnostics $ 1,782.0 $ 1,880.1 $ 3,018.5 Breast Health 1,522.9 1,432.7 1,227.8 GYN Surgical 641.3 604.2 522.9 Skeletal Health 84.1 113.4 93.6 $ 4,030.3 $ 4,030.4 $ 4,862.8 Operating income (loss): Diagnostics $ 303.1 $ 193.9 $ 1,359.4 Breast Health 394.5 273.0 183.2 GYN Surgical 185.5 188.9 104.9 Skeletal Health (0.5) 12.6 (7.3) $ 882.6 $ 668.4 $ 1,640.2 Depreciation and amortization: Diagnostics $ 218.8 $ 224.7 $ 274.0 Breast Health 41.6 50.0 58.8 GYN Surgical 48.1 48.0 96.6 Skeletal Health 0.5 0.7 0.7 $ 309.0 $ 323.4 $ 430.1 Capital expenditures: Diagnostics $ 80.2 $ 85.2 $ 96.8 Breast Health 30.9 41.1 14.6 GYN Surgical 16.6 17.0 12.8 Skeletal Health 1.4 0.8 0.3 Corporate 1.1 6.1 2.7 $ 130.2 $ 150.2 $ 127.2 Identifiable assets: Diagnostics $ 2,431.3 $ 2,596.4 $ 2,881.7 Breast Health 1,588.9 1,170.1 1,245.8 GYN Surgical 1,419.9 1,455.4 1,461.5 Skeletal Health 48.3 33.7 27.5 Corporate 3,667.6 3,883.7 3,454.7 $ 9,156.0 $ 9,139.3 $ 9,071.2
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Years Ended September 28, September 30, September 24, United States 75.0 % 75.9 % 71.3 % Europe 13.2 % 12.9 % 18.3 % Asia-Pacific 6.5 % 6.3 % 7.4 % Rest of world 5.3 % 4.9 % 3.0 % 100.0 % 100.0 % 100.0 %
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The Company’s property, plant and equipment were geographically located as follows: September 28, 2024 September 30, 2023 September 24, 2022 United States $ 379.7 $ 367.6 $ 332.4 Europe 70.6 67.0 72.1 Costa Rica 40.0 36.0 32.1 United Kingdom 32.0 32.4 31.7 Rest of world 15.5 14.0 13.3 $ 537.8 $ 517.0 $ 481.6

Accrued Expenses and Other Lo_2

Accrued Expenses and Other Long-Term Liabilities (Tables)	12 Months Ended
Accrued Expenses and Other Long-Term Liabilities (Tables)	Sep. 28, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and other long-term liabilities consisted of the following: September 28, 2024 September 30, 2023 Accrued Expenses Compensation and employee benefits $ 289.0 $ 280.1 Income and other taxes 69.4 62.3 Operating leases 24.0 20.4 Other 197.3 171.8 $ 579.7 $ 534.6
Schedule of Other Long-Term Liabilities	September 28, 2024 September 30, 2023 Other Long-Term Liabilities Reserve for income tax uncertainties $ 311.8 $ 274.3 Operating leases 83.9 47.1 Other 10.6 13.2 $ 406.3 $ 334.6

Operations (Details)

Operations (Details)	12 Months Ended
Operations (Details)	Sep. 28, 2024 Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	4

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Subsequent Events Consideration (Details) - USD ($)	Oct. 11, 2024	Nov. 19, 2024	Sep. 22, 2022	Dec. 09, 2020
Subsequent Event [Line Items]
Authorized value of common shares to be repurchased			$ 1,000,000,000	$ 1,000,000,000
Subsequent Event
Subsequent Event [Line Items]
Authorized value of common shares to be repurchased		$ 250,000,000
Subsequent Event \| Gynesonics
Subsequent Event [Line Items]
Total purchase price	$ 350,000,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - Customer Concentration Risk - Customer	3 Months Ended	12 Months Ended
	Sep. 24, 2022	Sep. 28, 2024	Sep. 30, 2023
Concentration Risk [Line Items]
Number of customers with balance greater than specified percentage		0
Accounts receivable \| Minimum
Concentration Risk [Line Items]
Concentration risk, percentage		10%
Total revenues \| Minimum
Concentration Risk [Line Items]
Concentration risk, percentage	10%	10%	10%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Supplemental Cash Flow Statement Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Accounting Policies [Abstract]
Cash paid during the period for income taxes	$ 137.9	$ 296.1	$ 36.2
Cash paid during the period for interest	117.1	105.4	99.7
Contingent consideration recorded at acquisition	0	1.1	0
Proceeds from income tax refunds	$ 19.6	$ 39.3	$ 430.4

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
Raw materials	$ 251.4	$ 238.6
Work-in-process	62	66.3
Finished goods	366.4	312.7
Inventories	$ 679.8	$ 617.6

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jul. 01, 2023	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 1,266.5	$ 1,231
Less - accumulated depreciation and amortization		(728.7)	(714)
Property, plant and equipment, net		537.8	517	$ 481.6
Impairment of intangible assets and equipment	$ 186.9	5.6	44.3	$ 27.7
Mobidiag \| Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Impairment of intangible assets and equipment	12.1
Ultrasound Imaging Assets \| Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Impairment of intangible assets and equipment	$ 5.8
Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 378.1	380
Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life		3 years
Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life		10 years
Equipment under customer usage agreements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 523.1	508.1
Equipment under customer usage agreements \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life		3 years
Equipment under customer usage agreements \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life		8 years
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 247.1	230
Buildings and improvements \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life		20 years
Buildings and improvements \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life		35 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 44	44.4
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		40.8	41.1
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 24.6	19.2
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life		5 years
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life		7 years
Finance lease right-of-use asset
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 8.8	$ 8.2

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Property, Plant and Equipment Narrative (Details) - USD ($)			3 Months Ended	12 Months Ended
	Oct. 15, 2020	Sep. 28, 2020	Apr. 01, 2023	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Accounting Policies [Abstract]
Grants received from Department of Defense	$ 119,300,000	$ 7,600,000
Proceeds from the Department of Defense			$ 20,500,000	$ 0	$ 20,500,000	$ 75,000,000
Department of Defense funds received						75,000,000
Department of Defense funds received, not capitalized						$ 7,600,000

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Intangible Assets (Details)	3 Months Ended						12 Months Ended
	Jun. 29, 2024 USD ($)	Mar. 30, 2024 USD ($)	Dec. 30, 2023 USD ($)	Jul. 01, 2023 USD ($)	Sep. 24, 2022 USD ($)	Jun. 25, 2022 USD ($)	Sep. 28, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 24, 2022 USD ($)
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				$ 174,800,000
Impairment of intangible assets and equipment				186,900,000			$ 5,600,000	$ 44,300,000	$ 27,700,000
Ultrasound Imaging Assets
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				26,400,000
Ultrasound Imaging Assets, Equipment
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				5,800,000
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				10,500,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life							5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life							30 years
Developed technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		$ 13,900,000					$ 0
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		500,000					0
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, fair value				$ 26,500,000
In-process research and development \| Valuation Technique, Discounted Cash Flow
Finite-Lived Intangible Assets [Line Items]
Measurement input				0.170
Ultrasound Imaging Assets, Developed Technology
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				$ 20,600,000
Mobidiag
Finite-Lived Intangible Assets [Line Items]
Accelerated amortization			$ 7,300,000
Mobidiag \| In-process research and development
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment			4,300,000
Intangible assets, current			22,400,000				$ 22,400,000
Impairment of intangible assets and equipment			4,300,000
Mobidiag \| Customer relationship
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net			0
Mobidiag \| Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net			$ 0
Mobidiag Oy
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				186,900,000
Mobidiag Oy \| Equipment
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				12,100,000
Mobidiag Oy \| Trade names
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				10,700,000
Mobidiag Oy \| Customer relationship
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				10,400,000
Mobidiag Oy \| Developed Technology
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment				$ 153,700,000	$ 27,700,000
Focal Therapeutics
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment		26,800,000
Focal Therapeutics \| Developed technology
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment	$ 13,300,000	25,900,000
Finite-lived intangible assets, net		13,900,000
Focal Therapeutics \| Trade names
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment	$ 400,000	900,000
Finite-lived intangible assets, net		$ 500,000
Focal Therapeutics \| Developed Technology
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment					$ 8,200,000
Faxitron \| Developed Technology
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets and equipment						$ 9,200,000

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,518	$ 5,342
Accumulated Amortization	4,673.4	4,453.4
Total acquired intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,462.1	5,290.3
Accumulated Amortization	4,628.3	4,412.9
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,567	4,411
Accumulated Amortization	3,834	3,649.5
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	25.1	25.7
Accumulated Amortization	0	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	609.7	600
Accumulated Amortization	569.8	550.6
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	260.3	253.6
Accumulated Amortization	224.5	212.8
Internal-use software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	25.7	24
Accumulated Amortization	20.5	17.8
Capitalized software embedded in products
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	30.2	27.7
Accumulated Amortization	$ 24.6	$ 22.7

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Schedule of Estimated Amortization Expense (Details) $ in Millions	Sep. 28, 2024 USD ($)
Accounting Policies [Abstract]
Fiscal 2025	$ 199.3
Fiscal 2026	169.2
Fiscal 2027	82.1
Fiscal 2028	79
Fiscal 2029	$ 72.9

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Rollforward of Goodwill Activity by Reportable Segments (Details) $ in Millions	12 Months Ended
	Sep. 28, 2024 USD ($)
Goodwill [Roll Forward]
Balance at September 30, 2023	$ 3,281.3
Foreign currency and other adjustments	22.9
Balance at September 28, 2024	3,443.1
Endomagnetics Ltd
Goodwill [Roll Forward]
Endomag acquisition	138.9
Diagnostics
Goodwill [Roll Forward]
Balance at September 30, 2023	1,351.6
Foreign currency and other adjustments	14.2
Balance at September 28, 2024	1,365.8
Diagnostics \| Endomagnetics Ltd
Goodwill [Roll Forward]
Endomag acquisition	0
Breast Health
Goodwill [Roll Forward]
Balance at September 30, 2023	787.8
Foreign currency and other adjustments	7.9
Balance at September 28, 2024	934.6
Breast Health \| Endomagnetics Ltd
Goodwill [Roll Forward]
Endomag acquisition	138.9
GYN Surgical
Goodwill [Roll Forward]
Balance at September 30, 2023	1,133.9
Foreign currency and other adjustments	0.8
Balance at September 28, 2024	1,134.7
GYN Surgical \| Endomagnetics Ltd
Goodwill [Roll Forward]
Endomag acquisition	0
Skeletal Health
Goodwill [Roll Forward]
Balance at September 30, 2023	8
Foreign currency and other adjustments	0
Balance at September 28, 2024	8
Skeletal Health \| Endomagnetics Ltd
Goodwill [Roll Forward]
Endomag acquisition	$ 0

Summary of Significant Accou_14

Summary of Significant Accounting Policies - Schedule of Other Assets (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
Tax receivable	$ 37.5	$ 33
Operating lease right of use assets	92.2	62.7
Life insurance contracts	71	56.1
Deferred tax assets	128.8	56.6
Strategic investments	54.3	15.5
Other	27	44
Other assets	$ 410.8	$ 267.9

Summary of Significant Accou_15

Summary of Significant Accounting Policies - Foreign Currency Transaction (Details) - USD ($)	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Accounting Policies [Abstract]
Conversion gains and losses on foreign investments	$ (21,000,000)	$ (7,900,000)	$ 48,500,000

Summary of Significant Accou_16

Summary of Significant Accounting Policies - Changes in Accumulated Balances of Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Foreign Currency Translation, Beginning Balance	$ (168)	$ (267.2)
Pension Plan, Beginning Balance	0.3	(0.3)
Available-for-sale debt securities, Beginning Balance	0
Hedged Interest Rate Swaps, Beginning Balance	20.1	29.3
Total, Beginning Balance	(147.6)	(238.2)
Other comprehensive income (loss) before reclassifications, Foreign Currency Translation	53.1	99.2	$ (224.1)
Other comprehensive income (loss) before reclassifications, Pension Plan	(0.3)	0.6	1
Other comprehensive income (loss) before reclassifications, Available-for-sale debt securities	1.6
Other comprehensive income (loss) before reclassifications, Hedged Interest Rate Swaps	(18.3)	(9.2)
Other comprehensive income (loss) before reclassifications, Total	36.1	90.6
Foreign Currency Translation, Ending Balance	(114.9)	(168)	(267.2)
Pension Plan, Ending Balance	0	0.3	(0.3)
Available-for-sale debt securities, Ending Balance	1.6	0
Hedged Interest Rate Swaps, Ending Balance	1.8	20.1	29.3
Total, Ending Balance	$ (111.5)	$ (147.6)	$ (238.2)

Summary of Significant Accou_17

Summary of Significant Accounting Policies - Derivatives (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022	Mar. 23, 2023
Derivative [Line Items]
Notional amount	$ 1,000
Variable interest rate	123%
Gain (loss) recognized in other comprehensive loss	$ (18.3)	$ (9.2)	$ 44
Notional amount	378.5
Interest Rate Swap
Derivative [Line Items]
Notional amount	1,000
Gain (loss) recognized in other comprehensive loss	(18.3)	$ (9.2)	$ 44
Interest Rate Swap, 2023
Derivative [Line Items]
Variable interest rate				3.46%
Notional amount				$ 500
Assets at fair value	$ 2.9
Interest Rate Swap, 2024
Derivative [Line Items]
Variable interest rate				2.98%
Notional amount				$ 500
Forward foreign currency contracts
Derivative [Line Items]
Derivative contract period, or less	1 year

Summary of Significant Accou_18

Summary of Significant Accounting Policies - Schedule of Derivative Instruments in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	$ 3.9	$ (2.7)	$ 68.5
Amount of unrealized (loss) gain recognized in income	(20.1)	(13)	20.2
Amount of gain (loss) recognized in income	(16.2)	(15.7)	88.7
Forward foreign currency contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	3.9	1.3	68.5
Amount of unrealized (loss) gain recognized in income	(20.9)	(7.5)	14.7
Foreign currency option contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	0	(4)	0
Amount of unrealized (loss) gain recognized in income	$ 0.8	$ (5.5)	$ 5.5

Summary of Significant Accou_19

Summary of Significant Accounting Policies - Schedule of Derivative Instruments on the Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Assets:	$ 996.8	$ 35.3
Liabilities:	13.9	2
Derivative instrument designated as a cash flow hedge:
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Liabilities:	0.2	0
Derivative instrument designated as a cash flow hedge: \| Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Assets:	3.1	26.9
Derivative instrument designated as a cash flow hedge: \| Interest Rate Swap \| Prepaid Expenses and Other Current Assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Assets:	3.1	16.2
Derivative instrument designated as a cash flow hedge: \| Interest Rate Swap \| Other assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Assets:	0	10.7
Derivative instrument designated as a cash flow hedge: \| Interest Rate Swap \| Other long-term liabilities
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Liabilities:	0.2	0
Derivatives not designated as hedging instruments:
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Assets:	0.8	8.4
Derivatives not designated as hedging instruments: \| Forward foreign currency contracts \| Prepaid Expenses and Other Current Assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Assets:	0	8.4
Derivatives not designated as hedging instruments: \| Forward foreign currency contracts \| Other long-term liabilities
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Liabilities:	12.6	0
Derivatives not designated as hedging instruments: \| Foreign currency option contracts \| Prepaid Expenses and Other Current Assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Assets:	$ 0.8	$ 0

Summary of Significant Accou_20

Summary of Significant Accounting Policies - Schedule of Unrealized Loss Recognized in AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Derivative [Line Items]
Amount of (loss) gain recognized in other comprehensive income (loss), net of taxes:	$ (18.3)	$ (9.2)	$ 44
Interest Rate Swap
Derivative [Line Items]
Amount of (loss) gain recognized in other comprehensive income (loss), net of taxes:	$ (18.3)	$ (9.2)	$ 44

Summary of Significant Accou_21

Summary of Significant Accounting Policies - Accounts Receivable Reserve Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance at Beginning of Period	$ 38.5	$ 37.7	$ 40.5
Charged to Costs and Expenses	5.7	3.7	4.2
Write- offs and Payments	(2.8)	(2.9)	(7)
Balance at End of Period	$ 41.4	$ 38.5	$ 37.7

Summary of Significant Accou_22

Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Share Amounts (Details) - shares shares in Thousands	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding (in shares)	235,723	246,772	251,527
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units (in shares)	1,830	2,059	2,318
Diluted weighted average common shares outstanding (in shares)	237,553	248,831	253,845
Outstanding stock options and restricted stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	1,171	981	1,049

Summary of Significant Accou_23

Summary of Significant Accounting Policies - Product Warranty (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
Product Warranty Term	1 year
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at Beginning of Period	$ 8.3	$ 8
Provisions	9	6.8
Acquired	0.1	0.8
Settlements/ Adjustments	(7.5)	(7.3)
Balance at End of Period	$ 9.9	$ 8.3

Summary of Significant Accou_24

Summary of Significant Accounting Policies - Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Accounting Policies [Abstract]
Advertising cost	$ 22.6	$ 31.4	$ 78.1

Revenue - Business Revenue (Det

Revenue - Business Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Disaggregation of Revenue [Line Items]
Total revenues:	$ 4,030.3	$ 4,030.4	$ 4,862.8
United States
Disaggregation of Revenue [Line Items]
Total revenues:	3,024.1	3,058	3,467.9
International
Disaggregation of Revenue [Line Items]
Total revenues:	1,006.2	972.4	1,394.9
Diagnostics
Disaggregation of Revenue [Line Items]
Total revenues:	1,782	1,880.1	3,018.5
Diagnostics \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	1,312.7	1,396.2	2,027.3
Diagnostics \| International
Disaggregation of Revenue [Line Items]
Total revenues:	469.3	483.9	991.2
Diagnostics \| Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Total revenues:	479.2	480.6	474.7
Diagnostics \| Cytology & Perinatal \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	283.3	297.4	300.4
Diagnostics \| Cytology & Perinatal \| International
Disaggregation of Revenue [Line Items]
Total revenues:	195.9	183.2	174.3
Diagnostics \| Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Total revenues:	1,272.5	1,361.7	2,511.4
Diagnostics \| Molecular Diagnostics \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	999.1	1,061	1,694.5
Diagnostics \| Molecular Diagnostics \| International
Disaggregation of Revenue [Line Items]
Total revenues:	273.4	300.7	816.9
Diagnostics \| Blood Screening
Disaggregation of Revenue [Line Items]
Total revenues:	30.3	37.8	32.4
Diagnostics \| Blood Screening \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	30.3	37.8	32.4
Diagnostics \| Blood Screening \| International
Disaggregation of Revenue [Line Items]
Total revenues:	0	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Total revenues:	1,522.9	1,432.7	1,227.8
Breast Health \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	1,177.5	1,116.6	957.2
Breast Health \| International
Disaggregation of Revenue [Line Items]
Total revenues:	345.4	316.1	270.6
Breast Health \| Breast Imaging
Disaggregation of Revenue [Line Items]
Total revenues:	1,210.7	1,144.2	951.6
Breast Health \| Breast Imaging \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	932.9	884	735.1
Breast Health \| Breast Imaging \| International
Disaggregation of Revenue [Line Items]
Total revenues:	277.8	260.2	216.5
Breast Health \| Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Total revenues:	312.2	288.5	276.2
Breast Health \| Interventional Breast Solutions \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	244.6	232.6	222.1
Breast Health \| Interventional Breast Solutions \| International
Disaggregation of Revenue [Line Items]
Total revenues:	67.6	55.9	54.1
GYN Surgical
Disaggregation of Revenue [Line Items]
Total revenues:	641.3	604.2	522.9
GYN Surgical \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	482.5	475.3	423.8
GYN Surgical \| International
Disaggregation of Revenue [Line Items]
Total revenues:	158.8	128.9	99.1
Skeletal Health
Disaggregation of Revenue [Line Items]
Total revenues:	84.1	113.4	93.6
Skeletal Health \| United States
Disaggregation of Revenue [Line Items]
Total revenues:	51.4	69.9	59.6
Skeletal Health \| International
Disaggregation of Revenue [Line Items]
Total revenues:	$ 32.7	$ 43.5	$ 34

Revenue - Geographical Revenue

Revenue - Geographical Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Disaggregation of Revenue [Line Items]
Total revenues:	$ 4,030.3	$ 4,030.4	$ 4,862.8
United States
Disaggregation of Revenue [Line Items]
Total revenues:	3,024.1	3,058	3,467.9
Europe
Disaggregation of Revenue [Line Items]
Total revenues:	532.7	520.3	888.5
Asia-Pacific
Disaggregation of Revenue [Line Items]
Total revenues:	259.6	255.7	359.7
Rest of World
Disaggregation of Revenue [Line Items]
Total revenues:	$ 213.9	$ 196.4	$ 146.7

Revenue - Revenue by Type (Deta

Revenue - Revenue by Type (Details) - USD ($) $ in Millions	12 Months Ended
Revenue - Revenue by Type (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Disaggregation of Revenue [Line Items]
Total revenues:	$ 4,030.3	$ 4,030.4	$ 4,862.8
Disposables
Disaggregation of Revenue [Line Items]
Total revenues:	2,490.2	2,539.4	3,603.6
Capital equipment, components and software
Disaggregation of Revenue [Line Items]
Total revenues:	764.9	740.5	587.6
Service
Disaggregation of Revenue [Line Items]
Total revenues:	758.2	730.5	652.4
Other
Disaggregation of Revenue [Line Items]
Total revenues:	$ 17	$ 20	$ 19.2

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Revenue - Narrative (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Estimated remaining performance obligation	$ 861.1
Revenue recognized that was included in contract liability at prior year end	$ 134.4	$ 132.7

Revenue - Remaining Performance

Revenue - Remaining Performance Obligations (Details)	Sep. 28, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-09-27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	47.60%
Remaining performance obligation over time	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-09-27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	28.60%
Remaining performance obligation over time	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-09-27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	14.50%
Remaining performance obligation over time	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-09-27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	6.20%
Remaining performance obligation over time	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-09-27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	3.10%
Remaining performance obligation over time	1 year

Leases - Narrative (Details)

Leases - Narrative (Details)	3 Months Ended	12 Months Ended
Leases - Narrative (Details)	Sep. 28, 2024 USD ($)	Sep. 28, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 24, 2022 USD ($)	Sep. 26, 2020 USD ($)
Lessee, Lease, Description [Line Items]
Period with option to terminate lease		1 year
Extension period		10 years
Weighted average discount rate		0.0492
Lease revenue as a percentage of total	0.03
Right-of-use asset obtained in exchange for finance lease liability		$ 0	$ 0
Lease receivable	$ 10,400,000	10,400,000
Sublease Income		$ 1,500,000	$ 1,100,000	$ 2,800,000
Cynosure
Lessee, Lease, Description [Line Items]
Right-of-use asset obtained in exchange for finance lease liability					$ 10,200,000
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating and finance lease, remaining lease term		1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating and finance lease, remaining lease term		11 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Leases [Abstract]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Operating lease right of use assets	$ 92.2	$ 62.7
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Finance lease right-of-use assets (non-current)	$ 5	$ 5.6
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued expenses	Accrued expenses
Operating lease liabilities (current)	$ 24	$ 20.4
Finance lease liabilities (current)	$ 3.3	$ 3.1
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities	Other long-term liabilities
Operating lease liabilities (non-current)	$ 83.9	$ 47.1
Finance lease liabilities (non-current)	$ 12.2	$ 15.3
Operating leases, weighted average remaining lease term	5 years 11 months 1 day	4 years 2 months 4 days
Finance leases, weighted average remaining lease term	4 years 9 months 29 days	5 years 8 months 8 days
Operating leases, weighted average discount rate	5%	2.90%
Finance leases, weighted average discount rate	4.10%	4.20%

Leases - Operating and Finance

Leases - Operating and Finance Leases (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2023 USD ($)	Sep. 28, 2024 USD ($) Lease	Sep. 30, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease cost		$ 41.3	$ 29.9
Finance lease cost - amortization of right-of-use assets		0.7	0.7
Finance lease cost - interest cost		0.8	0.8
Operating cash flows from finance leases		0.7	0.9
Operating cash flows from operating leases		26.1	28.3
Financing cash flows from finance leases		3.8	4
Total cash paid for amounts included in the measurement of lease liabilities		30.6	33.2
ROU assets arising from entering into new operating lease obligations		60.4	15.7
Right-of-use asset obtained in exchange for finance lease liability		$ 0	$ 0
MASSACHUSETTS
Lessee, Lease, Description [Line Items]
Number of leases renewed \| Lease		2
MASSACHUSETTS \| Lease One
Lessee, Lease, Description [Line Items]
Operating lease cost		$ 23.3
Term of contract		10 years
MASSACHUSETTS \| Lease Two
Lessee, Lease, Description [Line Items]
Operating lease cost		$ 8.4
Term of contract		5 years
Mobidiag
Lessee, Lease, Description [Line Items]
Other asset impairment charges	$ 12.5

Leases - Lease Liability Maturi

Leases - Lease Liability Maturity Schedule (Details) $ in Millions	Sep. 28, 2024 USD ($)
Operating Leases
2025	$ 28.7
2026	25.1
2027	20.8
2028	14.4
2029	8
Thereafter	29.6
Total future minimum lease payments	126.6
Less: imputed interest	(18.7)
Present value of lease liabilities	107.9
Finance Leases
2025	3.8
2026	3.8
2027	4
2028	3
2029	0.6
Thereafter	1.7
Total future minimum lease payments	16.9
Less: imputed interest	(1.4)
Present value of lease liabilities	$ 15.5

Leases - Future Minimum Annual

Leases - Future Minimum Annual Sub Lease Rental Income (Details) $ in Millions	Sep. 28, 2024 USD ($)
Leases [Abstract]
Fiscal 2025	$ 1.2
Fiscal 2026	1.1
Fiscal 2027	1.1
Fiscal 2028	0.8
Fiscal 2029	0.4
Thereafter	0.6
Total	$ 5.2

Business Combinations - Narrati

Business Combinations - Narrative (Details) - USD ($)						3 Months Ended		12 Months Ended
Business Combinations - Narrative (Details) - USD ($)	Jul. 25, 2024	Jul. 03, 2023	Apr. 03, 2023	Nov. 29, 2021	Aug. 23, 2020	Mar. 30, 2024	Dec. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Business Acquisition [Line Items]
Contingent consideration fair value adjustments								$ (1,700,000)	$ 14,900,000	$ 39,500,000
Contingent consideration – fair value adjustments								(1,700,000)	14,900,000	39,500,000
Payment of contingent consideration								$ 2,600,000	7,600,000	12,200,000
Endomagnetics Ltd
Business Acquisition [Line Items]
Total purchase price	$ 313,900,000
Measurement input	15%
Goodwill, tax deductible amount	$ 0
Endomagnetics Ltd \| Developed technology
Business Acquisition [Line Items]
Weighted average amortization period	11 years
Intangible assets acquired	$ 180,900,000
Endomagnetics Ltd \| Customer relationship
Business Acquisition [Line Items]
Weighted average amortization period	12 years
Intangible assets acquired	$ 6,500,000
Endomagnetics Ltd \| Trade names
Business Acquisition [Line Items]
Weighted average amortization period	11 years
Intangible assets acquired	$ 7,400,000
JW Medical
Business Acquisition [Line Items]
Total purchase price		$ 6,700,000
JW Medical \| Customer relationship
Business Acquisition [Line Items]
Weighted average amortization period		5 years
Normedi
Business Acquisition [Line Items]
Total purchase price			$ 7,700,000
Contingent consideration			$ 1,100,000
Normedi \| Customer relationship
Business Acquisition [Line Items]
Weighted average amortization period			5 years
Intangible assets acquired			$ 3,000,000
Bolder Surgical
Business Acquisition [Line Items]
Total purchase price				$ 160,100,000
Fair value, discount rate				16%
Bolder Surgical \| Developed technology
Business Acquisition [Line Items]
Weighted average amortization period				10 years
Intangible assets acquired				$ 73,600,000
Bolder Surgical \| Customer relationship
Business Acquisition [Line Items]
Weighted average amortization period				10 years
Intangible assets acquired				$ 21,700,000
Bolder Surgical \| Trade names
Business Acquisition [Line Items]
Weighted average amortization period				10 years
Intangible assets acquired				$ 1,400,000
Acessa Health
Business Acquisition [Line Items]
Contingent consideration					$ 81,800,000
Annual incremental revenue growth period					3 years
Contingent consideration fair value adjustments							$ 1,700,000
Contingent consideration – fair value adjustments									(14,900,000)	(39,500,000)
Payment of contingent consideration						$ 2,600,000			$ 7,600,000	$ 12,200,000

Business Combinations - Purchas

Business Combinations - Purchase Price Allocation (Details) - USD ($) $ in Millions	Sep. 28, 2024	Jul. 25, 2024	Sep. 30, 2023	Nov. 29, 2021
Business Acquisition [Line Items]
Goodwill	$ 3,443.1		$ 3,281.3
Endomagnetics Ltd
Business Acquisition [Line Items]
Cash		$ 16.2
Accounts receivable		5.5
Inventory		14.9
Other assets		7
Accounts payable and accrued expenses		(22.6)
Deferred income taxes, net		(43.8)
Goodwill		138.9
Purchase Price		313.9
Endomagnetics Ltd \| Developed technology
Business Acquisition [Line Items]
Identifiable intangible assets:		180.9
Endomagnetics Ltd \| Trade names
Business Acquisition [Line Items]
Identifiable intangible assets:		7.4
Endomagnetics Ltd \| Customer relationship
Business Acquisition [Line Items]
Identifiable intangible assets:		6.5
Endomagnetics Ltd \| In-process research and development
Business Acquisition [Line Items]
Identifiable intangible assets:		$ 3
Bolder Surgical
Business Acquisition [Line Items]
Cash				$ 1.9
Accounts receivable				1.3
Inventory				3.3
Other assets				3
Accounts payable and accrued expenses				(3.2)
Deferred income taxes, net				(11.7)
Goodwill				68.8
Purchase Price				160.1
Bolder Surgical \| Developed technology
Business Acquisition [Line Items]
Identifiable intangible assets:				73.6
Bolder Surgical \| Trade names
Business Acquisition [Line Items]
Identifiable intangible assets:				1.4
Bolder Surgical \| Customer relationship
Business Acquisition [Line Items]
Identifiable intangible assets:				$ 21.7

Strategic Investment (Details)

Strategic Investment (Details) - USD ($)	12 Months Ended
Strategic Investment (Details) - USD ($)	Sep. 28, 2024	Sep. 24, 2022	Nov. 13, 2023	Sep. 30, 2023
Schedule of Equity Method Investments [Line Items]
Other than temporary impairment		$ 4,000,000
Investments in equity securities without readily determinable fair values	$ 25,300,000			$ 15,500,000
Maverix Medical LLC
Schedule of Equity Method Investments [Line Items]
Equity method investments			$ 24,500,000
Ownership percentage			45%
Income (loss) from equity method investments	$ 3,600,000

Disposition - Additional Inform

Disposition - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2023	Jul. 01, 2023	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of intangible assets and equipment			$ 186.9	$ 5.6	$ 44.3	$ 27.7
Disposed of by Sale \| SSI Ultrasound Imaging Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales price	$ 1.9
Cash divested from deconsolidation	33.2
Impairment of intangible assets and equipment		$ 51.7
Valuation allowance	$ 50.6	$ 50.6			$ 50.6

Disposition - Schedule of Dispo

Disposition - Schedule of Disposition Related Income Statement Information (Details) - Disposed of by Sale - SSI Ultrasound Imaging Business - USD ($) $ in Millions	Sep. 30, 2023	Sep. 29, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash	$ 33.2	$ 33.2
Accounts receivable		4.5
Inventory		16.2
Prepaid expenses and other assets		8.6
Valuation allowance	$ (50.6)	(50.6)
Total assets held-for-sale		11.9
Accounts payable		3.1
Accrued expenses		5.1
Total liabilities held-for-sale		$ 8.2

Restructuring Charges - Charges

Restructuring Charges - Charges Taken Related to Restructuring Actions (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 41.1	$ 12	$ 2.4
Restructuring Charges \| Fiscal 2022 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			1.9
Facility closure costs			0.5
Restructuring charges			2.4
Restructuring Charges \| Fiscal 2023 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		11.5
Other costs		0.5
Restructuring charges		12
Restructuring Charges \| Fiscal 2024 restructuring charges
Restructuring Cost and Reserve [Line Items]
Lease asset impairment charge	12.5
Accelerated depreciation expense	7.2
Workforce reductions	19.7
Other costs	1.7
Restructuring charges	41.1
Restructuring Charges \| Fiscal 2024 Actions \| Fiscal 2022 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			0
Facility closure costs			0
Restructuring charges			0
Restructuring Charges \| Fiscal 2024 Actions \| Fiscal 2023 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		0
Other costs		0
Restructuring charges		0
Restructuring Charges \| Fiscal 2024 Actions \| Fiscal 2024 restructuring charges
Restructuring Cost and Reserve [Line Items]
Lease asset impairment charge	12.5
Accelerated depreciation expense	7.2
Workforce reductions	15.8
Other costs	1.2
Restructuring charges	36.7
Restructuring Charges \| Fiscal 2023 Actions \| Fiscal 2022 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			0
Facility closure costs			0
Restructuring charges			0
Restructuring Charges \| Fiscal 2023 Actions \| Fiscal 2023 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		5.5
Other costs		0
Restructuring charges		5.5
Restructuring Charges \| Fiscal 2023 Actions \| Fiscal 2024 restructuring charges
Restructuring Cost and Reserve [Line Items]
Lease asset impairment charge	0
Accelerated depreciation expense	0
Workforce reductions	0
Other costs	0
Restructuring charges	0
Restructuring Charges \| Fiscal 2022 Actions \| Fiscal 2022 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			2.6
Facility closure costs			0.5
Restructuring charges			3.1
Restructuring Charges \| Fiscal 2022 Actions \| Fiscal 2023 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		6
Other costs		0.5
Restructuring charges		6.5
Restructuring Charges \| Fiscal 2022 Actions \| Fiscal 2024 restructuring charges
Restructuring Cost and Reserve [Line Items]
Lease asset impairment charge	0
Accelerated depreciation expense	0
Workforce reductions	3.9
Other costs	0.5
Restructuring charges	4.4
Restructuring Charges \| Other \| Fiscal 2022 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			(0.7)
Facility closure costs			0
Restructuring charges			$ (0.7)
Restructuring Charges \| Other \| Fiscal 2023 restructuring charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		0
Other costs		0
Restructuring charges		$ 0
Restructuring Charges \| Other \| Fiscal 2024 restructuring charges
Restructuring Cost and Reserve [Line Items]
Lease asset impairment charge	0
Accelerated depreciation expense	0
Workforce reductions	0
Other costs	0
Restructuring charges	$ 0

Restructuring Charges - Charg_2

Restructuring Charges - Charges Taken Related to Accrued Restructuring Actions (Details) - Restructuring Charges - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Fiscal 2022 restructuring charges
Restructuring Reserve [Roll Forward]
Balance			$ 4.1
Fiscal restructuring charges			2.4
Severance payments and adjustments			(3.4)
Fiscal 2023 restructuring charges
Restructuring Reserve [Roll Forward]
Balance	$ 9	$ 3.1
Fiscal restructuring charges		12
Severance payments and adjustments		(6.1)
Balance		9	3.1
Fiscal 2024 restructuring charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	41.1
Non-cash impairment charge	(12.5)
Non-cash accelerated depreciation charge	(7.2)
Severance payments and adjustments	(18.4)
Balance	12
Fiscal 2024 Actions \| Fiscal 2022 restructuring charges
Restructuring Reserve [Roll Forward]
Balance			0
Fiscal restructuring charges			0
Severance payments and adjustments			0
Fiscal 2024 Actions \| Fiscal 2023 restructuring charges
Restructuring Reserve [Roll Forward]
Balance	0	0
Fiscal restructuring charges		0
Severance payments and adjustments		0
Balance		0	0
Fiscal 2024 Actions \| Fiscal 2024 restructuring charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	36.7
Non-cash impairment charge	(12.5)
Non-cash accelerated depreciation charge	(7.2)
Severance payments and adjustments	(11.5)
Balance	5.5
Fiscal 2023 Actions \| Fiscal 2022 restructuring charges
Restructuring Reserve [Roll Forward]
Balance			0
Fiscal restructuring charges			0
Severance payments and adjustments			0
Fiscal 2023 Actions \| Fiscal 2023 restructuring charges
Restructuring Reserve [Roll Forward]
Balance	2.3	0
Fiscal restructuring charges		5.5
Severance payments and adjustments		(3.2)
Balance		2.3	0
Fiscal 2023 Actions \| Fiscal 2024 restructuring charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	0
Non-cash impairment charge	0
Non-cash accelerated depreciation charge	0
Severance payments and adjustments	(2)
Balance	0.3
Fiscal 2022 Actions \| Fiscal 2022 restructuring charges
Restructuring Reserve [Roll Forward]
Balance			0
Fiscal restructuring charges			3.1
Severance payments and adjustments			(0.4)
Fiscal 2022 Actions \| Fiscal 2023 restructuring charges
Restructuring Reserve [Roll Forward]
Balance	6.7	2.7
Fiscal restructuring charges		6.5
Severance payments and adjustments		(2.5)
Balance		6.7	2.7
Fiscal 2022 Actions \| Fiscal 2024 restructuring charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	4.4
Non-cash impairment charge	0
Non-cash accelerated depreciation charge	0
Severance payments and adjustments	(4.9)
Balance	6.2
Other \| Fiscal 2022 restructuring charges
Restructuring Reserve [Roll Forward]
Balance			4.1
Fiscal restructuring charges			(0.7)
Severance payments and adjustments			(3)
Other \| Fiscal 2023 restructuring charges
Restructuring Reserve [Roll Forward]
Balance	0	0.4
Fiscal restructuring charges		0
Severance payments and adjustments		(0.4)
Balance		$ 0	$ 0.4
Other \| Fiscal 2024 restructuring charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	0
Non-cash impairment charge	0
Non-cash accelerated depreciation charge	0
Severance payments and adjustments	0
Balance	$ 0

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Details) $ in Millions	3 Months Ended	12 Months Ended			24 Months Ended
	Dec. 30, 2023 USD ($) location	Sep. 28, 2024 USD ($) position	Sep. 30, 2023 USD ($)	Sep. 24, 2022 USD ($)	Sep. 30, 2023 position
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 41.1	$ 12	$ 2.4
Various Locations
Restructuring Cost and Reserve [Line Items]
Severance charges		$ 3.9	9.4	0.3
Number of positions eliminated \| position		34			128
Various Locations \| Facility Closing
Restructuring Cost and Reserve [Line Items]
Restructuring charges				0.5
Danbury, Connecticut
Restructuring Cost and Reserve [Line Items]
Severance charges		$ 3.9	$ 2.1	$ 1.6
Expected cost		8.6
Mobidiag
Restructuring Cost and Reserve [Line Items]
Accelerated depreciation	$ 7.2
Other asset impairment charges	$ 12.5
Number of locations eliminated \| location	190
Severance charges	$ 1.8	11.9
Expected cost		$ 13.9

Borrowings and Credit Arrange_3

Borrowings and Credit Arrangements - Company's Borrowings (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	$ 37.5	$ 287
Long term debt obligations excluding convertible notes	2,497.1	2,531.2
Total debt obligations	2,534.6	2,818.2
Term Loan
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	37.5	287
Long term debt obligations excluding convertible notes	1,158.7	1,195.6
2028 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations excluding convertible notes	397.6	396.8
2029 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations excluding convertible notes	$ 940.8	$ 938.8

Borrowings and Credit Arrange_4

Borrowings and Credit Arrangements - Debt Maturity Schedule for Components of Company's Obligations (Details) $ in Millions	Sep. 28, 2024 USD ($)
Debt Instrument [Line Items]
2025	$ 37.5
2026	1,160
2027	0
2028	400
2029	950
2030 and Thereafter	0
Total	2,547.5
Term Loan
Debt Instrument [Line Items]
2025	37.5
2026	1,160
2027	0
2028	0
2029	0
2030 and Thereafter	0
Total	1,197.5
2028 Senior Notes
Debt Instrument [Line Items]
2025	0
2026	0
2027	0
2028	400
2029	0
2030 and Thereafter	0
Total	400
2029 Senior Notes
Debt Instrument [Line Items]
2025	0
2026	0
2027	0
2028	0
2029	950
2030 and Thereafter	0
Total	$ 950

Borrowings and Credit Arrange_5

Borrowings and Credit Arrangements - Additional Information (Details) - USD ($)							3 Months Ended	12 Months Ended
	Sep. 28, 2025	Oct. 27, 2023	Aug. 22, 2022	Sep. 27, 2021	Sep. 28, 2020	Jan. 19, 2018	Dec. 31, 2022	Sep. 27, 2025	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Debt Instrument [Line Items]
Debt extinguishment loss									$ 0	$ 0	$ 700,000
Current debt obligations, net of debt discount									37,500,000	287,000,000
Long term debt obligations excluding convertible notes									2,497,100,000	2,531,200,000
Interest Rate Swap
Debt Instrument [Line Items]
Notional amount									1,000,000,000
Secured Term Loan \| 2021 Term Loan
Debt Instrument [Line Items]
Debt instrument face amount				$ 1,500,000,000
Long term debt obligations excluding convertible notes									$ 1,200,000,000
Effective percentage									5.96%
Repayments of debt		$ 250,000,000
Secured Term Loan \| 2021 Term Loan \| Interest Rate Swap
Debt Instrument [Line Items]
Interest expense, debt, increase (decrease)									$ 16,800,000	35,400,000	$ 4,900,000
Secured Term Loan \| 2021 Term Loan \| Eurocurrency Rate
Debt Instrument [Line Items]
Periodic payment, principal per quarter				1,085,000,000
Commitment fee, percentage									0.15%
Secured Term Loan \| 2021 Term Loan \| Eurocurrency Rate \| Minimum
Debt Instrument [Line Items]
Periodic payment, principal per quarter				9,375,000
Secured Term Loan \| 2021 Term Loan \| Eurocurrency Rate \| Maximum
Debt Instrument [Line Items]
Periodic payment, principal per quarter				18,750,000
Secured Term Loan \| 2021 Term Loan \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Basis spread on variable rate			0.10%
Interest rate (percent)			1%
Revolver \| 2021 Revolver
Debt Instrument [Line Items]
Line of credit borrowing capacity				$ 2,000,000,000
Revolver \| 2021 Revolver \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Eurocurrency convert			0.10%
Basis spread on variable rate			0.10%
Senior Notes \| 2029 Senior Notes
Debt Instrument [Line Items]
Interest rate (percent)					3.25%				3.25%
Redemption price, percentage					100%				101%
Senior notes principal amount					$ 950,000,000
Senior Notes \| 2029 Senior Notes \| Forecast
Debt Instrument [Line Items]
Redemption price, percentage	100%							100.813%
Senior Notes \| 2028 Senior Notes
Debt Instrument [Line Items]
Debt instrument face amount						$ 400,000,000
Interest rate (percent)						4.625%			4.625%
Proceeds from issuance of senior long-term debt						$ 1,000,000,000
Offering price, percent of face value									100%
Percentage of redemption price, fourth period									101.541%
Percentage of redemption price, fifth period									100.77%
Percentage redemption price, sixth period									100%
Percentage price of principal amount for repurchase of senior notes									101%
Term Loan
Debt Instrument [Line Items]
Current debt obligations, net of debt discount									$ 37,500,000	287,000,000
Long term debt obligations excluding convertible notes									$ 1,158,700,000	$ 1,195,600,000
Term Loan \| 2021 Credit Agreement
Debt Instrument [Line Items]
Debt extinguishment loss							$ 700,000
Debt issuance costs							$ 7,000,000

Borrowings and Credit Arrange_6

Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - Credit Agreement 2021 - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Line of Credit Facility [Line Items]
Interest expense	$ 85.8	$ 92.4	$ 31.8
Non-cash interest expense	$ 2.2	$ 2.3	$ 2.2
Weighted average interest rate	6.39%	5.84%	1.74%
Interest rate at end of period	5.96%	6.42%	4.18%

Borrowings and Credit Arrange_7

Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - Senior Notes - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022	Sep. 28, 2020	Jan. 19, 2018
Debt Instrument [Line Items]
Interest expense	$ 52.1	$ 53	$ 52.1
Non-cash interest expense	$ 2.8	2.8	2.8
2029 Senior Notes
Debt Instrument [Line Items]
Interest rate (percent)	3.25%			3.25%
Interest expense	$ 32.9	33.5	32.9
Non-cash interest expense	$ 2.1	2.1	2.1
2028 Senior Notes
Debt Instrument [Line Items]
Interest rate (percent)	4.625%				4.625%
Interest expense	$ 19.2	19.5	19.2
Non-cash interest expense	$ 0.7	$ 0.7	$ 0.7

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Assets:
Fair Value	$ 992.9	$ 0
Total	996.8	35.3
Liabilities:
Contingent consideration	1.1	2
Total	13.9	2
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Total	992.9	0
Liabilities:
Contingent consideration	0	0
Total	0	0
Significant Other Observable Inputs (Level 2)
Assets:
Total	3.9	35.3
Liabilities:
Contingent consideration	0	0
Total	12.8	0
Significant Unobservable Inputs (Level 3)
Assets:
Total	0	0
Liabilities:
Contingent consideration	1.1	2
Total	1.1	2
Interest Rate Swap
Assets:
Interest rate caps - derivative	3.1	26.9
Liabilities:
Interest rate swaps	0.2
Interest Rate Swap \| Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Interest rate caps - derivative	0	0
Liabilities:
Interest rate swaps	0
Interest Rate Swap \| Significant Other Observable Inputs (Level 2)
Assets:
Interest rate caps - derivative	3.1	26.9
Liabilities:
Interest rate swaps	0.2
Interest Rate Swap \| Significant Unobservable Inputs (Level 3)
Assets:
Interest rate caps - derivative	0	0
Liabilities:
Interest rate swaps	0
Forward foreign currency contracts
Assets:
Foreign currency option contracts	0.8	8.4
Liabilities:
Forward foreign currency contracts	12.6
Forward foreign currency contracts \| Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Foreign currency option contracts	0	0
Liabilities:
Forward foreign currency contracts	0
Forward foreign currency contracts \| Significant Other Observable Inputs (Level 2)
Assets:
Foreign currency option contracts	0.8	8.4
Liabilities:
Forward foreign currency contracts	12.6
Forward foreign currency contracts \| Significant Unobservable Inputs (Level 3)
Assets:
Foreign currency option contracts	0	$ 0
Liabilities:
Forward foreign currency contracts	0
Money Market Funds
Assets:
Cash and cash equivalents	341.7
Money Market Funds \| Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Cash and cash equivalents	341.7
Money Market Funds \| Significant Other Observable Inputs (Level 2)
Assets:
Cash and cash equivalents	0
Money Market Funds \| Significant Unobservable Inputs (Level 3)
Assets:
Cash and cash equivalents	0
US Treasury Securities
Assets:
Fair Value	626.3
US Treasury Securities \| Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Fair Value	626.3
US Treasury Securities \| Significant Other Observable Inputs (Level 2)
Assets:
Fair Value	0
US Treasury Securities \| Significant Unobservable Inputs (Level 3)
Assets:
Fair Value	0
Commercial Paper
Assets:
Cash and cash equivalents	24.9
Commercial Paper \| Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Cash and cash equivalents	24.9
Commercial Paper \| Significant Other Observable Inputs (Level 2)
Assets:
Cash and cash equivalents	0
Commercial Paper \| Significant Unobservable Inputs (Level 3)
Assets:
Cash and cash equivalents	$ 0

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value Assets and Liabilities Measured Using Unobservable Inputs (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Fair Value Disclosures [Abstract]
Beginning balance	$ 2	$ 23.4	$ 75.1
Contingent consideration recorded at acquisition	0	1.1	0
Fair value adjustments	1.7	(14.9)	(39.5)
Payments	(2.6)	(7.6)	(12.2)
Ending balance	$ 1.1	$ 2	$ 23.4

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)

3 Months Ended

12 Months Ended

Jun. 29, 2024

Mar. 30, 2024

Dec. 30, 2023

Sep. 30, 2023

Jul. 01, 2023

Sep. 24, 2022

Jun. 25, 2022

Mar. 26, 2022

Sep. 28, 2024

Sep. 30, 2023

Sep. 24, 2022

Jul. 02, 2023

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]

Impairment of intangible assets and equipment

$ 186,900,000

$ 5,600,000

$ 44,300,000

$ 27,700,000

Loss on assets held-for-sale

$ 51,700,000

51,700,000

Property, plant and equipment, net

$ 517,000,000

$ 481,600,000

$ 537,800,000

$ 517,000,000

$ 481,600,000

Impairment of intangible assets and equipment

174,800,000

Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]

Impairment of intangible assets and equipment

In-process research and development

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

10,500,000

Mobidiag | In-process research and development

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

$ 4,300,000

Impairment of intangible assets and equipment

4,300,000

Intangible assets, current

22,400,000

$ 22,400,000

Ultrasound Imaging Assets

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

26,400,000

Ultrasound Imaging Assets, Developed Technology

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

20,600,000

Ultrasound Imaging Assets, Equipment

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

5,800,000

In-process research and development

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

10,500,000

27,700,000

Developed technology

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

8,200,000

$ 9,200,000

Equity Securities, Investment Summary

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

$ 4,000,000

$ 4,300,000

Finite-Lived Intangible Assets

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Finite-lived intangible assets, net

65,800,000

$ 0

Property, Plant and Equipment

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

12,100,000

Property, plant and equipment, net

4,600,000

Indefinite-Lived Intangible Assets

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Indefinite-lived intangible assets

$ 26,500,000

Right-of-Use Asset | Mobidiag

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Impairment of intangible assets and equipment

$ 12,500,000

Credit Agreement

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Borrowed principal under credit agreement

1,200,000,000

2028 Senior Notes

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Fair value of debt instrument

393,100,000

2029 Senior Notes

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Fair value of debt instrument

882,200,000

Developed technology

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Intangible asset impairment charges

$ 13,300,000

$ 25,900,000

Finite-lived intangible assets, net

13,900,000

Trade names

Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]

Intangible asset impairment charges

$ 400,000

900,000

Finite-lived intangible assets, net

$ 500,000

$ 0

Fair Value Measurements - Cash

Fair Value Measurements - Cash and Cash Equivalents (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	$ 2,160.2	$ 2,722.5
Cost	173.4	0
Total	2,428.4
Unrealized Gains	1.6
Unrealized Losses	0
Fair Value	992.9	$ 0
Total	2,430
Investments	269.8
Cash
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	1,437.1
Fair Value	1,437.1
Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	341.7
Cost	341.7
Unrealized Gains	0
Unrealized Losses	0
Fair Value	341.7
Fair Value	341.7
Investments	0
US Treasury Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	356.5
Cost	624.7
Investments, Unrealized Gain	1.6
Investments, Unrealized Loss	0
Fair Value	626.3
Investments	269.8
Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	24.9
Unrealized Gains	0
Unrealized Losses	0
Fair Value	24.9
Investments	$ 0

Fair Value Measurements - Avail

Fair Value Measurements - Available for Sale Debt Securities (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Due in three months or less	$ 723.1	$ 0
Due after three months through one year	173.4	0
Due after one year through five years	96.4	0
Total available-for-sale securities	$ 992.9	$ 0

Income Taxes - Income (Loss) Be

Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Income Tax Disclosure [Abstract]
Domestic	$ 609.4	$ 861.4	$ 1,340.3
Foreign	255.7	(185.3)	247.9
Income before income taxes	$ 865.1	$ 676.1	$ 1,588.2

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Federal:
Current	$ 91.6	$ 250.6	$ 298.6
Deferred	(50.9)	(72.1)	(129.8)
Federal, Total	40.7	178.5	168.8
State:
Current	14.2	45.9	54.8
Deferred	(7.5)	(9.4)	(9.5)
State, Total	6.7	36.5	45.3
Foreign:
Current	41.9	32.7	99
Deferred	(13.7)	(27.6)	(26.9)
Foreign, Total	28.2	5.1	72.1
Provision for income taxes	$ 75.6	$ 220.1	$ 286.2

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax (Benefit) at U.S. Federal Statutory Rate to Company's Effective Tax Rate (Details)	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Increase (decrease) in tax resulting from:
Income tax provision at federal statutory rate	21%	21%	21%
Cynosure loss on sale and carryback	0%	0%	(1.20%)
State income taxes, net of federal benefit	2.50%	4.10%	2.90%
U.S. tax on foreign earnings	0.50%	(1.00%)	(2.60%)
Internal Restructuring	0%	0%	(0.90%)
Tax credits	(1.60%)	(1.10%)	(0.50%)
Unrecognized tax benefits	3.90%	3.50%	0.20%
Compensation	1%	0.80%	0.20%
Foreign rate differential	(6.80%)	(4.80%)	(0.80%)
Change in deferred tax	0%	0%	0.40%
Assets held-for-sale charge	0%	1.50%	0%
Change in valuation allowance	2.70%	8.20%	0.40%
Return to provision	(1.20%)	(1.90%)	(0.70%)
Worthless stock deduction	(12.40%)	0%	0%
Other	(0.90%)	2.30%	(0.40%)
Effective income tax rate	8.70%	32.60%	18%

Income Taxes - Significant Comp

Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) - USD ($)	Sep. 28, 2024	Sep. 30, 2023
Deferred tax assets
Net operating loss and other tax carryforwards	$ 137,100,000	$ 125,800,000
Capitalized research and development	96,800,000	70,100,000
Non-deductible accruals	41,000,000	32,700,000
Non-deductible reserves	37,800,000	42,800,000
Stock-based compensation	21,900,000	19,800,000
Nonqualified deferred compensation plan	15,900,000	13,500,000
Lease liability	26,200,000	14,000,000
Other temporary differences	21,000,000	5,900,000
Deferred tax assets, gross	397,700,000	324,600,000
Less: valuation allowance	(143,100,000)	(114,700,000)
Deferred tax assets, net	254,600,000	209,900,000
Deferred tax liabilities
Depreciation and amortization	(161,800,000)	(160,300,000)
Right of use asset	(23,400,000)	(13,200,000)
Deferred tax liabilities, net	(185,200,000)	(173,500,000)
Deferred Tax Assets, Net	$ 69,400,000	$ 36,400,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022	Sep. 25, 2021
Income Taxes [Line Items]
Income tax benefit		$ (75.6)	$ (220.1)	$ (286.2)
Diluted (in dollars per share)		$ 3.32	$ 1.83	$ 5.13
Valuation allowance, increase (decrease)		$ (28.4)
Net operating losses		134.2
State net operating loss expected to be expired unutilized		107.7
Foreign net operating loss expected to be expired unutilized		208.6
Unrecognized tax benefit that would impact effective tax rate		213.9	$ 240.5	$ 231.6
Interest on income taxes		20.3	15.8	0.7
Interest accrued on unrecognized tax benefits		50.4	30.1
Increase to income tax expense adoption of ASU 2016-16			77.2
Decrease in deferred tax liabilities due to ASU 2016-16			90.8
Increase to Net Income resulted from adoption of ASU 2016-16			$ 13.6
Increase to Earnings per Share resulted from adoption of ASU 2016-16			$ 0.05
state loss carryforward expected to unutilize		438.9
Gross state loss carryforwards		438.9
Gross foreign loss carryforwards		134.2
Unrecognized Tax Benefits		273.2	$ 256.5	$ 247.6	$ 212.8
Change in gross unrecognized tax benefits		16.7	8.9
Net Operating Losses Carryforwards
Income Taxes [Line Items]
Amount with unlimited carry forward periods		97.5
Tax Credit Carryforward
Income Taxes [Line Items]
Amount with unlimited carry forward periods		4.2
Maximum
Income Taxes [Line Items]
Decrease in unrecognized tax benefits is reasonably possible		8.3
Domestic Tax Authority
Income Taxes [Line Items]
Net operating losses		22.5
Credit carry forwards		4.6
State and Local Jurisdiction
Income Taxes [Line Items]
Net operating losses		172.1
Credit carry forwards		2.1
Foreign Tax Authority
Income Taxes [Line Items]
Income tax benefit	$ 107.2
Net operating losses		275.2
Foreign Tax Authority \| Costa Rica
Income Taxes [Line Items]
Income tax savings		$ 79.8	$ 45.5
Diluted (in dollars per share)		$ 0.34	$ 0.18

Income Taxes - Activity of Comp

Income Taxes - Activity of Company's Unrecognized Income Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Income Tax Disclosure [Abstract]
Balance at beginning of fiscal year	$ 256.5	$ 247.6	$ 212.8
Tax positions related to current year:
Additions	7.8	6.8	45.9
Tax positions related to prior years:
Additions related to change in estimate	11.8	4.5	21.5
Reductions	(2.1)	0	(6.6)
Lapses in statutes of limitations and settlements	(0.8)	(2.4)	(26)
Balance as of the end of the fiscal year	$ 273.2	$ 256.5	$ 247.6

Stockholders' Equity and Stoc_3

Stockholders' Equity and Stock-Based Compensation - Additional Information (Details) - USD ($)

1 Months Ended

2 Months Ended

12 Months Ended

Nov. 20, 2024

Nov. 18, 2024

Sep. 12, 2024

Feb. 27, 2024

Nov. 17, 2023

Dec. 08, 2022

Dec. 31, 2013

Mar. 31, 2012

Nov. 21, 2023

Sep. 28, 2024

Sep. 30, 2023

Sep. 24, 2022

Nov. 19, 2024

Nov. 15, 2023

Nov. 06, 2023

Sep. 22, 2022

Dec. 09, 2020

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Authorized value of common shares to be repurchased

$ 1,000,000,000

Shares repurchased (in shares)

2,700,000

4,200,000

6,800,000

Common stock repurchases

$ 217,200,000

$ 308,300,000

$ 501,600,000

excise tax on share repurchase percentage

Share repurchase tax

$ 7,200,000

2,900,000

Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased

190,300,000

Accelerated share repurchase agreement

$ 500,000,000

Accelerated Share Repurchases, Settlement (Payment) or Receipt

$ 500,000,000

Percentage of share repurchase program

80%

Stock-based compensation, period of vest term granted to employees, years

3 years

Tax benefit related to stock based compensation

$ 11,400,000

10,700,000

$ 8,600,000

Intrinsic value of option exercised

$ 15,500,000

18,400,000

11,100,000

Granted

900,000

Minimum eligible percentage to receive target number of shares of company's common stock

Maximum eligible percentage to receive target number of shares of company's common stock

200%

Cliff vesting period from grant date

3 years

Stock-based compensation expense

$ 82,300,000

79,600,000

66,700,000

Percentage of award vested upon meeting defined market based criteria

33.33%

November 15, 2023

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Repurchase of common stock (in shares)

1,400,000

5,600,000

September 12, 2024 share repurchase program

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Authorized value of common shares to be repurchased

$ 1,500,000,000

Period available for common stock to be repurchased

5 years

Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased

1,500,000,000

Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of forfeiture rates

Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of forfeiture rates

Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense

$ 14,000,000

14,200,000

12,000,000

Unrecognized compensation expense

$ 10,000,000

Weighted average period of unrecognized stock-based compensation, years

2 years 2 months 12 days

Stock Options | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation, period of vest term granted to employees, years

4 years

Percentage of vesting for stock options granted to employees

25%

RSUs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation, period of vest term granted to employees, years

3 years

Percentage of vesting for RSUs granted to employees

33%

Stock-based compensation expense

$ 61,100,000

58,500,000

48,200,000

Unrecognized compensation expense

$ 45,000,000

Weighted average period of unrecognized stock-based compensation, years

1 year 8 months 12 days

Fair value of RSUs vested

$ 51,500,000

$ 48,400,000

$ 43,800,000

Restricted Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted

700,000

Performance Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted

100,000

Vested, weighted average grant date fair value (in usd per share)

$ 71.94

$ 74.35

$ 71.16

PSU Free Cash Flow [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted

100,000

Minimum eligible percentage to receive target number of shares of company's common stock

Maximum eligible percentage to receive target number of shares of company's common stock

200%

PSU Free Cash Flow [Member] | 2023 Award

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation, period of vest term granted to employees, years

3 years

PSU Free Cash Flow [Member] | 2021 Award

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation, period of vest term granted to employees, years

1 year

Market Based Stock Units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation, period of vest term granted to employees, years

3 years

Granted

100,000

Minimum eligible percentage to receive target number of shares of company's common stock

Maximum eligible percentage to receive target number of shares of company's common stock

200%

Vested, weighted average grant date fair value (in usd per share)

$ 88.06

$ 97.91

$ 75.43

Cliff vesting period from grant date

3 years

2008 Equity Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of additional shares authorized

6,500,000

Common stock, shares authorized

38,000,000

Shares available for grant

7,500,000

2012 Employee Stock Purchase Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares that may be issued under Employee Stock Purchase Plan

8,500,000

Percentage of common stock price for ESPP

85%

Stock-based compensation expense

$ 7,200,000

$ 6,900,000

$ 6,500,000

Subsequent Event

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Authorized value of common shares to be repurchased

$ 250,000,000

Repurchase of common stock (in shares)

2,500,000

Percentage of share repurchase program

80%

Treasury stock, acquired

$ 250,000,000

Stockholders' Equity and Stoc_4

Stockholders' Equity and Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statement of Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 82.3	$ 79.6	$ 66.7
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	10.7	10.5	9.1
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	10.3	10.5	8.8
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	13.4	12	10.5
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	47.8	46.6	38.3
Restructuring Charges
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0.1	$ 0	$ 0

Stockholders' Equity and Stoc_5

Stockholders' Equity and Stock-Based Compensation - Information Pertaining to Stock Options Granted and Related Assumptions (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Share-Based Payment Arrangement [Abstract]
Options granted (in shares)	0.6	0.5	0.7
Weighted-average exercise price	$ 72.34	$ 74.66	$ 71.07
Weighted average grant date fair value (in usd per share)	$ 25.07	$ 25.95	$ 21.01
Assumptions:
Risk-free interest rates	4.40%	4.30%	1.10%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days
Expected volatility	33.40%	33.90%	34.20%
Dividend yield	$ 0	$ 0	$ 0

Stockholders' Equity and Stoc_6

Stockholders' Equity and Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Number of Shares (in millions)
Options outstanding at September 30, 2023	4.2
Granted	0.6	0.5	0.7
Canceled/ forfeited	(0.1)
Exercised	(0.4)
Options outstanding at September 28, 2024	4.3	4.2
Options exercisable at September 28, 2024	3.1
Options vested and expected to vest at September 28, 2024	4.2
Weighted- Average Exercise Price
Options outstanding at September 30, 2023	$ 51.63
Granted	72.34	$ 74.66	$ 71.07
Canceled/ forfeited	73.09
Exercised	39.89
Options outstanding at September 29, 2018	55.32	$ 51.63
Options exercisable at September 28, 2024	48.57
Options vested and expected to vest at September 28, 2024	$ 55.21
Weighted- Average Remaining Contractual Life (in Years)
Options outstanding at September 30, 2023	5 years 3 months 18 days	5 years 7 months 6 days
Options exercisable at September 28, 2024	4 years 2 months 12 days
Options vested and expected to vest at September 28, 2024	5 years 3 months 18 days
Options outstanding at September 28, 2024	5 years 3 months 18 days	5 years 7 months 6 days
Aggregate Intrinsic Value (in millions)
Options outstanding at September 30, 2023	$ 77.6
Exercised	15.5	$ 18.4	$ 11.1
Options outstanding at September 28, 2024	108.8	$ 77.6
Options exercisable at September 28, 2024	98.5
Options vested and expected to vest at September 28, 2024	$ 108.6

Stockholders' Equity and Stoc_7

Stockholders' Equity and Stock-Based Compensation - Restricted Stock Unit Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Number of Shares (in millions)
Non-vested at September 30, 2023	1,600
Granted	900
Vested	(700)
Forfeited	(100)
Non-vested at September 28, 2024	1,700	1,600
Weighted-Average Grant-Date Fair Value
Non-vested at September 30, 2023	$ 73.33
Granted	73.10
Vested	70.87
Forfeited	72.42
Non-vested at September 28, 2024	$ 73.84	$ 73.33
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	900
Stock-based compensation, period of vest term granted to employees, years	3 years
PSU Free Cash Flow [Member]
Number of Shares (in millions)
Granted	100	100	100
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	100	100	100
Performance Shares
Number of Shares (in millions)
Granted	100	100	100
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	100	100	100
Vested, weighted average grant date fair value (in usd per share)	$ 71.94	$ 74.35	$ 71.16
Market Based Stock Units
Number of Shares (in millions)
Granted	100	100	100
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	100	100	100
Vested, weighted average grant date fair value (in usd per share)	$ 88.06	$ 97.91	$ 75.43
Stock-based compensation, period of vest term granted to employees, years	3 years

Stockholders' Equity and Stoc_8

Stockholders' Equity and Stock-Based Compensation - Assumptions to Value Stock Options (Details) - USD ($)	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Assumptions:
Risk-free interest rates	4.40%	4.30%	1.10%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days
Expected volatility	33.40%	33.90%	34.20%
Dividend yield	$ 0	$ 0	$ 0
ESPP
Assumptions:
Risk-free interest rates	5.29%	4.10%	0.96%
Expected life (in years)	6 months	6 months	6 months
Expected volatility	33.40%	34%	34%
Dividend yield	$ 0	$ 0	$ 0

401(k) Plan (Details)

401(k) Plan (Details) - USD ($) $ in Millions	12 Months Ended
401(k) Plan (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Retirement Benefits [Abstract]
Contributions made by company	$ 23.3	$ 23.9	$ 21.8

Deferred Compensation Plan (Det

Deferred Compensation Plan (Details) - USD ($)	12 Months Ended
Deferred Compensation Plan (Details) - USD ($)	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred Compensation Liability, Current and Noncurrent	$ 82,400,000	$ 65,400,000
Nonqualified Deferred Compensation Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Maximum employee contributions from base salary, percentage	75%
Maximum employee contributions from annual bonus, percentage	100%
Employee contributions vested, percentage	100%
Compensation expense for the DCP discretionary contributions	$ 3,500,000	3,900,000	$ 4,000,000
Investment in group life insurance contracts	$ 71,000,000	$ 56,100,000
Percent vested annually	33.33%
Nonqualified Deferred Compensation Plan \| One Third Annually
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Contributions, vesting period, years	3 years

Non-cancelable Purchase Commi_3

Non-cancelable Purchase Commitments (Details) $ in Millions	Sep. 28, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal 2025	$ 475.9
Fiscal 2026	7.3
Fiscal 2027	3.4
Fiscal 2028	0.9
Fiscal 2029	0.5
Thereafter	0.7
Total	$ 488.7

Litigation and Related Matters

Litigation and Related Matters (Details)	Nov. 04, 2022 plaintiff claim
Commitments and Contingencies Disclosure [Abstract]
Number of plaintiffs \| plaintiff	100
Pending claims, number \| claim	1

Business Segments and Geograp_3

Business Segments and Geographic Information - Additional Information (Details)	12 Months Ended
	Sep. 28, 2024 USD ($) Segment	Sep. 30, 2023 USD ($) Segment	Sep. 24, 2022 USD ($)
Segment Reporting Disclosure [Line Items]
Total revenues:	$ 4,030,300,000	$ 4,030,400,000	$ 4,862,800,000
Intersegment
Segment Reporting Disclosure [Line Items]
Number of reportable segments \| Segment	4	4
Total revenues:	$ 0	$ 0	$ 0

Business Segments and Geograp_4

Business Segments and Geographic Information - Segment Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Segment Reporting Information [Line Items]
Total revenues:	$ 4,030.3	$ 4,030.4	$ 4,862.8
Operating income (loss):	882.6	668.4	1,640.2
Depreciation and amortization:	309	323.4	430.1
Capital expenditures:	130.2	150.2	127.2
Identifiable assets:	9,156	9,139.3	9,071.2
Diagnostics
Segment Reporting Information [Line Items]
Total revenues:	1,782	1,880.1	3,018.5
Operating income (loss):	303.1	193.9	1,359.4
Depreciation and amortization:	218.8	224.7	274
Capital expenditures:	80.2	85.2	96.8
Identifiable assets:	2,431.3	2,596.4	2,881.7
Breast Health
Segment Reporting Information [Line Items]
Total revenues:	1,522.9	1,432.7	1,227.8
Operating income (loss):	394.5	273	183.2
Depreciation and amortization:	41.6	50	58.8
Capital expenditures:	30.9	41.1	14.6
Identifiable assets:	1,588.9	1,170.1	1,245.8
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues:	641.3	604.2	522.9
Operating income (loss):	185.5	188.9	104.9
Depreciation and amortization:	48.1	48	96.6
Capital expenditures:	16.6	17	12.8
Identifiable assets:	1,419.9	1,455.4	1,461.5
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues:	84.1	113.4	93.6
Operating income (loss):	(0.5)	12.6	(7.3)
Depreciation and amortization:	0.5	0.7	0.7
Capital expenditures:	1.4	0.8	0.3
Identifiable assets:	48.3	33.7	27.5
Corporate and Other
Segment Reporting Information [Line Items]
Capital expenditures:	1.1	6.1	2.7
Identifiable assets:	$ 3,667.6	$ 3,883.7	$ 3,454.7

Business Segments and Geograp_5

Business Segments and Geographic Information - Revenues by Geography (Details)	12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Schedule Of Geographical Segments [Line Items]
Revenues	100%	100%	100%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	75%	75.90%	71.30%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	13.20%	12.90%	18.30%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	6.50%	6.30%	7.40%
Rest of world
Schedule Of Geographical Segments [Line Items]
Revenues	5.30%	4.90%	3%

Business Segments and Geograp_6

Business Segments and Geographic Information - Schedule of Geographically Located Property and Equipment, Net (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023	Sep. 24, 2022
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	$ 537.8	$ 517	$ 481.6
United States
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	379.7	367.6	332.4
Europe
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	70.6	67	72.1
Costa Rica
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	40	36	32.1
United Kingdom
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	32	32.4	31.7
Rest of world
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	$ 15.5	$ 14	$ 13.3

Accrued Expenses and Other Lo_3

Accrued Expenses and Other Long-Term Liabilities - Schedule of Accrued Expenses (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Accrued Expenses
Compensation and employee benefits	$ 289	$ 280.1
Income and other taxes	69.4	62.3
Operating lease liabilities (current)	24	20.4
Other	197.3	171.8
Total	$ 579.7	$ 534.6

Accrued Expenses and Other Lo_4

Accrued Expenses and Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023
Other Long-Term Liabilities
Reserve for income tax uncertainties	$ 311.8	$ 274.3
Operating lease liabilities (non-current)	83.9	47.1
Other	10.6	13.2
Other long-term liabilities	$ 406.3	$ 334.6